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Fokalkontakte dienen der Zelle als Verankerungen zwischen der 
extrazellulären Matrix mit dem Aktin Zytoskelett. Ein dynamisches 
Gleichgewicht von Abbau im vorderen Teil der Zelle und Aufbau von 
Fokalkontakten im hinteren Bereich der Zelle ist eine Grundvoraussetzung 
während der Zellwanderung. Trotz zahlreicher Studien, die den 
Regulierungsmechanismus der Fokalkontakte untersuchen, bleibt der Auf/Abbau 
von Fokalkontakten ungelöst. 
In der vorliegenden Arbeit untersuche ich die Verbindung zwischen 
Vesikel Transport und Fokalkontaktumbau mithilfe eines siRNA-Microarrays. 
Identifizierte Gene konnten dem Vesikeltransport und Fokalkontaktumbau 
zugeordnet werden. Ebenso, wurden bisher noch nicht charakterisierte Gene 
gefunden. Weiterführende Analysen werden wertvolle Informationen über den 
Einfluss von Vesikeltransport auf Fokalkontaktumbau liefern. 
Das Adaptor Protein Paxillin ist für die Rekrutierung von Struktur und 
Signalkomponenten zu Fokalkontakten nötig. Hier zeige ich, dass eine dominant 
negative Paxillin Mutante in einer Subpopulation von Clathrinvesikel 
akkumuliert und damit nahelegt, dass Paxillin im Clathrinvesikel-Weg und im 
Fokalkontaktumbau eine Rolle spielt. Darüberhinaus zeige ich dass, ein weiteres 










Focal adhesions are sites of a cell attachment to the underlying substrate. The 
dynamic turnover of focal adhesions is central to the process of cell migration and 
includes coordinated assembly of the new adhesions at the leading edge of the cell 
and disassembly of old ones at the cell rear. Despite intensive studies the exact 
mechanism involved in focal adhesion turnover has not been resolved. During the 
last twenty years a role of the vesicular trafficking machinery in this process has 
emerged, but the identity of the involved vesicular pathway remains elusive. 
In the presented study I examined a link between vesicular trafficking and 
focal adhesion turnover using an siRNA screening approach and investigated the role 
of vesicular transport in the recycling of the focal adhesion scaffold protein paxillin. 
With the help of an established siRNA microarray screening platform I 
identified several factors affecting vesicular trafficking and focal adhesion 
organization simultaneously.  These factors included uncharacterized molecules (for 
example KIF19, CCDC51, TM4SF19) and well-known vesicular components (COPI 
complex) that confirmed the putative link between vesicular trafficking and focal 
adhesions. The results of this screen provide a foundation for the further 
characterization of molecules putatively linking vesicular transport and focal 
adhesion dynamics.  
The adaptor protein paxillin is responsible for recruiting structural and 
signaling components to focal adhesions and thereby is involved in focal adhesion 
turnover and cell protrusion. Previous studies indicated that paxillin localization to 
focal adhesions is dependent on the vesicular trafficking pathway; however its nature 
was still unclear. In my work I demonstrated that in the absence of a functional focal 
adhesion targeting domain, paxillin accumulated in a subpopulation of clathrin 
vesicles. It led me to the conclusion that a specific part of the clathrin pathway might 
play a role in paxillin recycling and therefore in focal adhesion organization. Using 
the siRNA knockdown approach I confirmed that a subpopulation of clathrin vesicles 
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The recognition and acknowledgment of anomalies result in 
crises that are a necessary precondition for the emergence of 
novel theories and for paradigm change. 
Thomas Kuhn “The structure of scientific revolutions” 
Cell migration 
Cell migration has a central function in various biological processes in 
multicellular organisms such as embryonic development, response of the immune 
system to an inflammatory stimuli and wound healing during tissue repair. When 
cell migration becomes uncontrolled it leads to the development of different 
pathological changes including tumor metastasis, reduced immune defense and 
birth defects. Therefore to understand how cells migrate is an important issue in 
current research.  
Cell migration requires tight coordination of actin and microtubule 
cytoskeleton dynamics with the formation and disassembly of the cell-
extracellular matrix contacts so called adhesions (Figure 1). The steps of the cell 
migration include protrusion of the leading edge, formation of substrate 
adhesions at the front, translocation of the cell body, disassembly of the old 
adhesions and contraction at the rear. The structure that drives protrusion at the 
leading edge is called the lamellipodium. It contains a dense network of actin 
filaments; its coordinated polymerization at the front pushes the cell membrane 
forward and promotes lamellipodium extension. During cell protrusion initial 
contacts (called focal complexes) with the extracellular matrix (ECM) are 
established, some of them later develop into strong adhesions (called focal 
adhesions) (Ballestrem, Hinz et al. 2001; Kaverina, Krylyshkina et al. 2002; 
Zaidel-Bar, Ballestrem et al. 2003). Focal adhesions connect the ECM with 
bundles of actin filaments and serve as traction points for the forces that move the 
cell body forward through retraction of the cell rear (Geiger, Bershadsky et al. 
2001). Retraction forces are generated by means of actomyosin contractility. 
Formation of the nascent focal complexes is dependent on the small GTPase Rac, 
whereas focal adhesion assembly requires activation of the RhoA GTPase (Nobes 
and Hall 1995; Rottner, Hall et al. 1999). Disassembly of focal adhesions at the 
rear of the cell is an essential prerequisite for translocation of the cell in the 
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direction of movement. Assembly of the new focal adhesions at the protruding 
edge of the cell and their subsequent disassembly under the cell body and at the 
retracting edge is referred to as focal adhesion turnover.  
The role of microtubules in cell migration is less clear. An intact 
microtubule network is indispensable for directed migration of different cell types 
(Vasiliev, Gelfand et al. 1970; Xu, Wang et al. 2005). It has been proposed that 
microtubules deliver factors regulating focal adhesion turnover by direct targeting 
of focal adhesions (Kaverina, Rottner et al. 1998; Kaverina, Krylyshkina et al. 
1999). Additionally microtubules were suggested to be involved in the 
maintenance of the level of RhoA activity (Ren, Kiosses et al. 1999). 
The regulation of actin and microtubule networks during cell migration 
have been discussed in detail in several reviews (Kaverina, Krylyshkina et al. 
2002; Palazzo and Gundersen 2002; Small, Geiger et al. 2002; Wehrle-Haller and 
Imhof 2003). In my introduction I will concentrate on the mechanism of focal 
adhesion turnover.  
Figure 1| Schematic drawing of a migrating cell. | Protrusion of the leading edge is driven by 
lamellipodium containing a network of actin filaments. New focal complexes form at the leading 
edge of the cell; some of them later develop into strong focal adhesions connected with actin stress 
fibers. Retraction of the cell rear depends on the forces generated by actomyosin contractility, and 






Focal adhesions were first identified by interference reflection microscopy 
as specialized relatively immobile foci providing attachment of the cell to the 
substrate (Abercrombie and Dunn 1975; Izzard and Lochner 1980). The cell to 
substrate distance at focal adhesions appeared to be 10-15 nm. Since then it 
became well established that focal adhesions represent molecular complexes 
which link extracellular matrix via transmembrane receptors to the actin 
cytoskeleton (Zamir and Geiger 2001). More than 50 focal adhesion proteins 
were identified and their number still continues to grow. The components of focal 
adhesions can be divided into three groups according to their location: 
extracellular, transmembrane and cytoplasmic (Table 1).  
The major transmembrane receptors of focal adhesions are integrins. 
Integrins are heterodimeric receptors generated by selective pairing between 18α 
and 8β subunits. There are 24 distinct integrin receptors that possess different 
binding affinity to various ECM ligands (Hynes 1992). The type of integrins 
found within a given focal adhesions depends on the ECM to which cells are 
attached. The most studied adhesions to fibronectin contain α5β1-integrin as a 
major receptor. In addition to integrins there are a number of other 
transmembrane proteins involved in the organization of focal adhesions such as 
tetraspanins, proteoglycans (syndecan 4), growth factor receptors and matrix 
metalloproteases (Miranti and Brugge 2002). 
Integrins do not bind actin directly and do not have any enzymatic 
activity; instead they recruit a number of proteins that form a focal adhesion 
plaque providing connection to the actin cytoskeleton and performing signaling 
functions. Focal adhesion plaque proteins can be subdivided into several 
categories: structural proteins, adaptor or scaffolding proteins and enzymes (Lo 
2006; Allison L. Berrier 2007). Structural proteins, including talin, tensin, filamin 
and others, usually interact with integrins’ cytoplasmic tails or with actin directly 
and serve as the focal adhesion backbone. Adaptors (for example paxillin, 
PINCH, zyxin) link integrin-associated proteins with actin or signaling 
molecules. Finally, enzymes including tyrosine kinases (FAK, Src), phosphatases 
(PTP-1B) and modulators of small GTPases (GITs, ASAP1) transform and 
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transport signals from integrins to the actin cytoskeleton and other cellular 
compartments, and regulate focal adhesion turnover.  Among focal adhesion 
components there are also modulators of actin polymerization (VASP, profilin), 
indicating a role of focal adhesions in the control of actin polymerization. 
Despite extensive studies the mechanism of focal adhesion targeting 
remains poorly understood even for some well-known components. For example 
the identity of the focal adhesion docking molecules for the important scaffolding 
proteins paxillin and zyxin still has not been recognized.  
 
Focal adhesion assembly 
The cornerstone of the assembly of focal adhesions is the clustering of integrins 
that is mediated from outside of the cell by binding to the ECM ligands, and from 
the inside by intracellular tension generated by actin filaments (Burridge and 
Chrzanowska-Wodnicka 1996). Figure 2 demonstrates the model of contraction-
induced focal adhesion formation. First integrins bind to ECM, become activated 
and attach to the actin filaments. This process is accompanied by RhoA activation 
that in turn leads to the activation of myosin II and the stimulation of actomyosin 
Table 1 | Known focal adhesion components. Adapted from Lo, 2006. 
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contractility. The resulting tension bundles actin filaments into stress fibers and 
clusters the attached integrins. Clustering of the integrins induces further 
recruitment of early signaling and scaffolding molecules such as FAK, paxillin, 
talin and subsequently later ones such as zyxin and tensin (Miyamoto, Teramoto 
et al. 1995; Zaidel-Bar, Ballestrem et al. 2003). Whether proteins are recruited to 




In contrast to focal adhesion assembly there is no accepted model of focal 
adhesion disassembly. In my laboratory it has been suggested several years ago 
that focal adhesion disassembly requires delivery of so called “relaxing” factors 
that is dependent on microtubules (Kaverina, Krylyshkina et al. 1999; Kaverina, 
Krylyshkina et al. 2002). Those “relaxing” factors were expected to inhibit RhoA 






Figure 2 | Model for contruction-induced 
assembly of focal adhesions. | (A) Integrins are 
dispersed over the cell surface and do not attach 
to actin filaments. (B) Binding of integrins to 
ECM ligands leads to their attachment to actin 
filaments. (C) Rho activation stimulates 
actomyosin contractility that bundles actin 
filaments into stress fibers and clusters the 
integrins.  In turn, the integrin clustering 
stimulates activation of the regulatory proteins 
such as FAK kinase and recruitment of other 







inducing their disassembly. Since activation of RhoA promotes assembly of focal 
adhesions, it was logical to believe that a reversal of the RhoA activation would 
lead to their disassembly. However it was recently demonstrated that focal 
adhesion disassembly can occur in cells with constitutively active RhoA (Ezratty, 
Partridge et al. 2005).  Moreover in mitotic cells the loss of focal adhesions is 
also accompanied by high levels of RhoA activity (Maddox and Burridge 2003).   
Ezratty and co-workers proposed a new model where focal adhesion 
disassembly was mediated by endocytosis (Ezratty, Partridge et al. 2005). They 
found that microtubule-induced focal adhesion disassembly was dependent on the 
large GTPase dynamin, a key player of the cellular endocytic machinery. The 
idea of focal adhesion disassembly by endocytosis is consistent with the studies 
demonstrating endocytic recycling of integrins. However it is difficult to imagine 




Vesicular trafficking is a fundamental process that controls the 
architecture of different intracellular compartments and the communication 
between the cell and its environment. A simplified model of vesicular trafficking 
includes two major transport routes: endocytosis and exocytosis (Figure 3). 
Endocytosis represents the formation and inward movement of plasma membrane 
vesicles. It can be subdivided into clathrin-dependent and clathrin independent 
endocytotic pathways. Clathrin-dependent endocytosis involves the assembly of 
vesicles coated with clathrin (Hirst and Robinson 1998; Kirchhausen 2000; 
Mousavi, MalerÃ¸d et al. 2004). Clathrin-independent endocytosis uses an 
alternative protein coat or does not require a protein coat for the formation of 
endocytic vesicles. For example caveolae-dependent endocytosis occurs through 
plasma membrane invaginations that are enriched in cholesterol and 
sphingolipids (Candice M. Thomas 2008). 
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 Exocytosis includes delivery of the newly synthesized or recycled proteins 
to the plasma membrane. The vesicles of the early exocytic pathway are formed 
with participation of coat protein complexes I and II (COPI and COPII) 
(McMahon and Mills 2004; Béthune, Wieland et al. 2006; Kirchhausen 2007). It 
has been recently shown that clathrin vesicles also take part in protein recycling 
(Deborde, Perret et al. 2008).  
 Specific coat proteins together with their adaptor proteins recruit different 
cargos and determine the intracellular destination of the endocytic or exocytic 
vesicles. The assembly of coats and vesicle formation, budding, transport, 
tethering and fusion are under control of the Arf and Rab GTPases and their 
effectors (Zerial and McBride 2001; D'Souza-Schorey and Chavrier 2006). 
Figure 3| Simplified model of vesicular trafficking in eukaryotic cells. | In the endocytic 
pathway molecules are internalized at the plasma membrane in a clathrin-dependent or –
independent manner and delivered to the early endosomes. Then they are recycled back to the 
membrane and undergo exocytosis or they are transported to late endosomes and lysosomes. 
Exocytosis is also involved in the delivery of newly synthesized molecules from the endoplasmic 
reticulum (ER) to the plasma membrane. Those molecules are transported first from the ER to the 
Golgi in COPII-coated vesicles, then from the cis-Golgi to the trans-Golgi cisterns involving 
COPI coat proteins, and finally to the plasma membrane likely in a clathrin-dependent manner. 
Adapted from Kirchhausen, 2000. 











Vesicular fusion events are in addition dependent on soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs), which establish a 
specific connection between the transported vesicle and targeted membrane 
(Duman and Forte 2003). 
It was long ago proposed that polarized vesicular trafficking toward the 
leading edge and subsequent exocytosis is an essential condition for directional 
cell movement (Figure 4) (Kupfer A, Kronebusch PJ et al. 1987; Bretscher 1996). 
Exocytosis at the protruding edge could provide a new membrane mass for the 
cell extension and deliver new cell-surface receptors together with adhesion and 
cytoskeletal components. There are a number of studies demonstrating polarized 
exocytosis of vesicles toward the leading edge including direct observation of 
recycling receptors in moving fibroblasts (Bretscher 1983; Hopkins, Gibson et al. 
1994; Schmoranzer, Kreitzer et al. 2003).  
 In conformity with exocytosis polarized toward the cell front, endocytosis 
was proposed to occur mainly at the cell rear, contributing to the cycling of bulk 
membrane or adhesion molecules (Bretscher 1996). It was indeed demonstrated 
that clathrin endocytic vesicles were distributed towards the trailing edge of 
moving T-lymphocytes (Samaniego, Sanchez-Martin et al. 2007). Surprisingly in 
migrating fibroblasts clathrin-mediated endocytosis on the contrary was 
concentrated towards the leading edge (Rappoport and Simon 2003). It is possible 
that endocytosis plays a different role during distinct types of cell migration 
(rapid amoeboid lymphocyte movement and slow fibroblast movement).  
 Despite numerous studies the exact mechanism whereby vesicular 
Figure 4| Schematic drawing of the vesicular trafficking route in a migrating cell. | In a 




trafficking contributes to cell migration remains obscure. However the 
importance of  vesicular trafficking for cell polarization and migration is widely 
accepted and highlighted by various experiments. For example Bershadsky and 
Futerman used brefeldinA treatment to disrupt the Golgi apparatus and inhibit 
vesicle transport and observed a reduction in lamellipodium activity and loss of 
cell polarization (Bershadsky and Futerman 1994). More recently overexpression 
of the dominant-mutants of Rab11 that blocked endocytic recycling was found to 
produce impaired cell polarity and disorganized motility (Prigozhina and 
Waterman-Storer 2006). 
One way by which vesicular trafficking could influence cell migration is 
through the regulation of focal adhesion turnover. As mentioned before, a block 
in cellular endocytosis inhibited focal adhesion disassembly. And from the other 
side, vesicular recycling could deliver focal adhesion components to the leading 
edge of cells.  A role of vesicular endocytosis and recycling was intensively 
studied and well-accepted for the membrane components of focal adhesions, 
integrins. It is less clear whether the delivery of other focal adhesion molecules 
including regulatory and scaffolding proteins is also dependent on a vesicular 
trafficking pathway. There are however some indications that the focal adhesion 
scaffolding protein paxillin might be transported through a vesicular route. 
Paxillin recycling will be discussed in detail in the separate introduction for the 
second part of this work.  
 
Integrin trafficking 
On the basis of biochemical assays it was almost 20 years ago shown that 
certain integrin receptors are internalized from the plasma membrane to the 
endosomal compartments and then transported back to the cell surface (Bretscher 
1992). The initial idea was that integrin receptors are internalized at the retracting 
end of the cell and transported toward the leading edge where they undergo 
exocytosis and serve for the establishment of new adhesions. Since then the 
molecular mechanism of the integrin recycling and its role in cell migration has 
been studied in detail. However, the identification of the molecular machinery 
responsible for integrin trafficking still remains incomplete.  
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Studies of integrin recycling are hampered by several factors. First, there 
is not one common trafficking route for the recycling of all integrin heterodimers. 
Different integrin heterodimers can apparently use different internalization and 
recycling pathways. Moreover it has been demonstrated that in the absence of one 
trafficking pathway integrin receptors can be switched to another trafficking route 
(J. Norman, ELSO2008 congress). The diversity of the integrin recycling 
pathways makes it difficult to reconcile the data available into one general model.  
Second, the data on integrin recycling came primary from biochemical 
experiments. The most common assay addressing integrin recycling involves 
monitoring the dynamics of integrins labeled at the cell surface with specific 
antibodies. However the use of antibodies recognizing different conformational 
states of the same integrin receptor (“active” or “inactive” conformations) has led 
to the accumulation of contradictory results regarding pathways involved in 
receptor trafficking (Liu, He et al. 2007; Nishimura and Kaibuchi 2007). In 
addition there exist no convincing observations of integrins recycling through 
vesicular pathway in live cells that could be explained in part by low maturation 
efficiency of the overexpressed integrins fused to fluorescent proteins.   
Recent research on the integrin trafficking machinery is comprehensively 
summarized in several reviews (Caswell and Norman 2006; Pellinen and Ivaska 
2006; Caswell and Norman 2008). Below I will specifically discuss evidence for 
a role of integrin internalization and integrin recycling in focal adhesion turnover.  
Integrin internalization 
It has been for some time considered that integrins appear to be 
internalized in a clathrin-independent manner by a protein kinase C alpha 
(PKCα)-dependent caveolae pathway (for review see(Caswell and Norman 
2006)). However new evidences indicate that β1-integrins internalization could 
be regulated by the endocytic clathrin-adaptor AP2 (Liu, He et al. 2007; 
Nishimura and Kaibuchi 2007). For example a recent study demonstrated that the 
cargo-specific adaptor Numb found in AP2-clathrin vesicles controls endocytosis 
of β1-integrins by direct binding (Nishimura and Kaibuchi 2007). Moreover the 
same studies showed that suppression of the clathrin trafficking pathway by 
means of siRNA led to a reduction of the endocytosis rate of β1- and β3-
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integrins. The latest hypothesis suggests that the same integrins could be recruited 
and internalized in both clathrin- and caveolae-vesicular structures depending on 
the circumstances and their location in the cell (Caswell and Norman 2008).  
Despite numerous studies on integrin endocytosis there were just a few 
straight forward experiments showing a connection between the rate of clathrin- 
or caveolin-dependent integrin internalization and focal adhesion turnover. For 
example a block in integrin endocytosis led to the enlargement of focal adhesions 
accompanied by their stabilization and reduced disassembly rate (Ezratty, 
Partridge et al. 2005). Ezratty and co-workers demonstrated that siRNA 
knockdown of dynamin, a GTPase responsible for both clathrin-dependent and –
independent endocytosis, caused an increase of β1-integrin containing focal 
adhesions and inhibited their microtubule-induced disassembly. Previously it has 
been shown that a dominant-negative mutant of dynamin blocks β1-integrin 
internalization (Ng, Shima D et al. 1999). Taken together these data lead to the 
conclusion that dynamin-dependent integrin internalization is an essential step in 
the focal adhesion disassembly process. 
Additionally, enlargement of focal adhesions was observed upon 
inhibition of Rab21 function (Pellinen, Arjonen et al. 2006). Rab21 is a small 
GTPase that was found to be a positive regulator of β1-integrin endocytosis. 
Therefore an increase in focal adhesion size is a general consequence of 
suppression of integrin internalization.  
Integrin recycling 
Integrin heterodimers internalize into early endosomes from which they 
are transported directly back to the plasma membrane in a Rab4-dependent 
manner (short loop) or they first proceed to the perinuclear recycling 
compartment (PNRC) and only then return to the membrane through a Rab11-
dependent pathway (long loop). The short and the long loop pathways were 
shown to transport different integrin heterodimers and to be dependent on the 
different regulatory signals. Recently it has been demonstrated that 
downregulation of α5β1 trafficking through the long loop led to the increase in 
αvβ3 integrin recycling dependent on the short loop (J.Norman, ELSO2008 
congress). That means that these two pathways are interdependent and likely can 
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substitute for each other. Therefore experiments where one of the two pathways 
is suppressed with the aim to reveal its role in integrin recycling and focal 
adhesion turnover should be interpreted with caution.  
The link between integrin recycling to plasma membrane and focal 
adhesion turnover was investigated directly only in a limited number of studies. 
Most of the studies examined the influence of blocking integrin recycling on cell 
migration or cell spreading and did not address changes in focal adhesion 
turnover. Logically blocking integrin transport to the plasma membrane should 
decrease the size of focal adhesions. Surprisingly, the interference with integrin 
recycling routes on the contrary produced enlargement of focal adhesions. 
Woods and colleagues showed that a block in Rab4-mediated recycling of 
αvβ3 integrins by suppression of protein kinase D 1 (PKD1) led to reduced 
incorporation of integrins in newly forming focal adhesions at the leading edge 
and the appearance of prominent adhesions uniformly distributed at the ventral 
cell surface (Woods, White et al. 2004). Similarly a block of Rab11-dependent 
recycling upon expression of a Rab11 dominant-negative mutant (Rab11-GDP) 
was found to induce the formation of densely packed focal adhesions not only in 
protruding lamellipodium but uniformly at the cell perimeter (Prigozhina and 
Waterman-Storer 2006). Though Prigozhina and colleges did not investigate the 
effect of Rab11-GDP overexpression on integrin recycling in the cells examined, 
the inhibition of β1-integrin trafficking upon expression of Rab11-GDP mutant 
was previously shown by another research group (Powelka, Sun et al. 2004).  
Recently, an enlargement of focal adhesions was correlated with the 
inhibition of β1-integrin recycling and was also observed upon siRNA 
knockdown of EHD1, a protein which regulates return of the endocytosed cargo 
to the plasma membrane from the PNRC (Jovic, Naslavsky et al. 2007). The 
increase in focal adhesion size was shown to be a consequence of impaired focal 
adhesion disassembly. Accordingly, it has been proposed that interference with 
EHD1-dependent trafficking affects recycling of not only integrin receptors but 
also some focal adhesion disassembly factors (Jovic, Naslavsky et al. 2007). 
Another group of endocytotic proteins that was found to be involved in 
integrin trafficking is the SNARE (soluble NSF attachment protein receptors, 
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where NSF stands for N-ethylmaleimide-sensitive factor) family of membrane 
proteins. The main function of SNAREs is membrane fusion. It has been 
demonstrated that inhibition of SNARE function impaired recycling of α5β1-
integrins and led to an increased number of large focal adhesions (Gonon, Skalski 
et al. 2005; Skalski and Coppolino 2005). Coppolino and co-workers 
hypothesized that SNARE-mediated transport is involved in the delivery of 
factors that regulate focal adhesion size downstream of RhoA activation.  
Therefore enlargement of focal adhesions is a general effect observed 
upon interference with integrin recycling pathways at different levels. There are 
several theoretical explanations of how decreased transport of integrins to the cell 
surface results in large focal adhesions, however the exact reason is not clear.  
Role of the integrin trafficking in focal adhesion turnover.                      
Future prospective. 
In summary, integrin internalization is required for the disassembly of 
focal adhesions. However further experiments to distinguish the function of 
clathrin-dependent and clathrin-independent endocytic routes in focal adhesion 
disassembly would be necessary.  The role of the integrin recycling in focal 
adhesion turnover has to be addressed more carefully. It seems clear that 
recycling of integrins is essential for the formation of new focal adhesions at the 
polarized edge of cells. To answer the question about the requirement of integrin 
recycling for focal adhesion assembly in general, it would be helpful to inspect 
the situation when both, short and long, integrin trafficking loops are inhibited. 
Since it is likely that vesicular recycling is also involved in the transport of focal 
adhesion regulators such as disassembly factors, a new experimental approach to 
inhibit not the entire pathway but specifically its interaction with given integrins 
should be established. Thus it is important to promote identification of the novel 
proteins which are involved exclusively in the trafficking of integrins as for 
example the cargo-adaptor Numb. 
In addition development of imaging techniques that would allow 
observation of integrin internalization and recycling in live cells is a next critical 
step in revealing the role of integrin trafficking in focal adhesion turnover. The 
latest advances in this field include for example the generation of 
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photoactivatable GFP-α5 integrin that makes it possible to analyze integrin 
dynamics in real-time  




According to the foregoing introduction focal adhesion turnover is an 
essential part of cell migration. Resolving the pathway involved in the regulation 
of focal adhesion assembly and disassembly will provide a deeper understanding 
of the mechanism of cell movement. Over the last twenty years numerous data 
highlighting a role of vesicular trafficking machinery in focal adhesion turnover 
have accumulated. It has been widely accepted that the rate of intracellular 
integrin recycling depends on vesicular transport and influences focal adhesion 
dynamics and cell migration. The likelihood exists that focal adhesion scaffold 
and regulatory proteins also undergo vesicular recycling. However the nature of 
the vesicular trafficking pathway involved in focal adhesion turnover has not 
been specified and the exact players of this pathway remain elusive. In the 
presented study I examined a link between vesicular trafficking and focal 
adhesion turnover using two different approaches. 
In the first part of my work I established a siRNA microarray screen for 
identification of the factors involved in focal adhesion turnover. This method 
allows fast analysis of the entire groups and families of proteins regarding their 
influence on focal adhesions. I took an advantage of microarray RNAi replicas 
and assayed for proteins affecting vesicular trafficking pathway and focal 
adhesion organization simultaneously. Despite a number of limitations that 
emerged during the siRNA screen, I identified several uncharacterized as well as 
known vesicular trafficking regulators as factors involved in focal adhesion 
organization. This work was done in collaboration with Rainer Pepperkok and Jez 
Simpson at the EMBL, Heidelberg, Germany. 
In the second part of my study I attempted to answer the question ща 
whether vesicular trafficking is involved in the recycling of the focal adhesion 
scaffold protein paxillin. Paxillin recycling to focal adhesions has earlier been 
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proposed to be dependent on the vesicular trafficking pathway. However the 
identity of the putative vesicular structures responsible for the paxillin transport 
was not determined. I demonstrated that in the absence of the functional focal 
adhesion targeting domain, paxillin accumulated in a subpopulation of clathrin 
vesicles. This and other findings (described in Part 2) led me to the conclusion 
that a specific part of the clathrin pathway plays a role in paxillin turnover and 





















RNA interference (RNAi) is a cellular response to double-stranded RNA 
(dsRNA) leading to sequence-specific inhibition of gene expression. This 
phenomenon is based on the degradation of mRNA which has a region 
complementary to the dsRNA nucleotide sequence. The RNAi silencing was first 
described and applied for gene silencing in invertebrates: Caenorabditis elegans 
and Drosophila melanogaster cells. With the discovery of small interfering 
RNAs containing only 20-23 nucleotides (siRNAs) it became possible to 
overcome the mammalian interferon response to dsRNAs and achieve efficient 
RNAi gene knockdown in mammalian cells (Caplen, Parrish et al. 2001; Elbashir, 
Lendeckel et al. 2001).  Currently the siRNA technique is one of the most 
common and convenient methods to study gene functions by analyzing 
knockdown phenotypes. 
 At the beginning RNAi was used for down-regulation of individual genes 
(for review, see (McManus and Sharp 2002)), however soon large-scale RNAi 
screening techniques were introduced since RNAi made possible silencing of 
almost any gene with a known sequence (for review, see (Friedman and Perrimon 
2004)). Development of an automated approach for siRNA delivery and for 
automated phenotype analysis was a necessary step toward establishment of 
efficient high-throughput RNAi screens. Initially for mammalian culture cells 
delivery of siRNAs was achieved by conventional lipid-based transfection in 96- 
or 384-well plates using liquid-handling robotics (Pelkmans and Zerial 2005). 
Nowadays transfection in multiwell format is nearly completely replaced by more 
cost and time efficient microarray “reverse transfection”. 
“Reverse transfection” was first exploited by Ziauddin and Sabatini for 
cDNA transfection (Ziauddin and Sabatini 2001), and afterward modified by 
several laboratories for siRNA delivery (Kumar, Conklin et al. 2003; Erfle, 
Simpson et al. 2004; Neumann, Held et al. 2006).   In the “reverse-transfection” 
protocol mammalian cells are cultured on a glass slide that has been previously 
printed with different synthesized siRNA oligonucleotides. Cells that overlay 
each printed spot take up the siRNA from the glass surface, which than causes 
sequence-specific inhibition of gene expression. Thus each siRNA spot defines 
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an area of cells with suppression of an individual gene. Microarray-based siRNA 
platforms make possible performance and subsequent analysis of hundreds or 
even thousands of gene knockdowns just on one microscopy slide that provides 
increased data acquisition speed by microscopy and reduced cost owing to the 
miniaturized amounts of reagents needed. Moreover siRNA transfection occurs in 
homogeneous cell population in a highly parallel manner that improves the 
accuracy of the screening data. In addition several microarray platforms may be 
simultaneously produced and stored, and subsequently used as directly 
comparable replicas in the same screen or for the different screens. 
Despite the appealing advantages of microarray siRNA platforms for 
high-throughput analysis of gene functions the number of published screens using 
this technique is limited. The main reasons for that include first of all a 
requirement of quite expensive and sophisticated robotic equipment, as well as 
costly libraries of synthesized siRNA oligonucleotides. Therefore only well-
funded institutions and laboratories with ambitious goals of performing wide-
genome screens have the possibility and motivation to establish siRNA 
microarray production. For example two wide-genome screens were recently 
initiated: Mitocheck screen for genes involved in mitosis sponsored by the 
European Commission and a screen for protein trafficking regulators in the 
Rainer Pepperkok laboratory in EMBL, Heidelberg. However during past three 
years only their assays for identification of desired genes have been published 
whereas the analysis of collected data remains uncompleted (Neumann, Held et 
al. 2006; Simpson, Cetin et al. 2007). This is explained by the issue that 
development of a robust trustable assay for siRNA screening together with 
automated data analysis programs is a challenging and time consuming process. 
The choice of the right assay may predetermine the outcome of the screen and its 
significance. Handling of the collected data and its accurate analysis with 
subsequent validation experiments also requires considerable time and effort. 
Despite improvements in techniques siRNA microarrays are still too expensive 
for application on a genome-wide scale. 
Alternative strategies have in consequence been employed involving 
smaller siRNA screens for analysis of a limited but still sizeable group of genes 
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using easily scored assays. Such screens could be performed by smaller 
laboratories in collaboration with the main centers or institutes where large-scale 
siRNA screening technology is well established. Furthermore the amount of 
synthesized oligonucleotides in siRNA libraries sold by the companies such as 
Ambion is sufficient for printing multiple microarray platforms than necessary 
for a single screen. Sharing of microarray resources among laboratories therefore 
leads to a more effective approach for discovering new gene functions via siRNA 
platforms. 
In my work I took advantage of the willing collaboration of Rainer 
Pepperkok’s group in EMBL, Heidelberg and used their established siRNA 
microarray facility and to look for genes involved in focal adhesion regulation in 
human cell culture. My primary aim was to systematically analyze distinct groups 
and families of proteins regarding their influence on focal adhesions rather than 
perform a wide-genome siRNA screen. The microarray siRNA screening 
technique had not been previously exploited for analysis of focal adhesion 
structures. In the first part of my thesis work I have demonstrated the capability 





1. Cell culture and treatment 
Hela cells (gift of Yuko Kiyosue, KaN Research Institute, Kyoto) were 
maintained in DMEM (Gibco #31885-023) supplemented with 10% Fetal Calf 
Serum (PAA Laboratories) and penicillin/streptomycin (Gibco #15140-122). 
HeLa cell line stably expressing EGFP-paxillin was maintained in complete HeLa 
medium supplemented with 800 ug/ml G418 (generated by N. Andreyeva).  
To assay an effect of Brefeldin A (Sigma) on focal adhesions it was diluted in 
the complete medium to a final concentration 10 ug/ml and cells were incubated 
overnight. 
2. Preparation of siRNA microarrays 
Chemically synthesized 21nt RNA duplexes were obtained from Ambion 
Europe, Ltd. Preparation and spotting of siRNA mixtures onto single-well 
chambered  LabTek glass coverslips (NagleNunc, Rochester, NY,USA) were 
performed as previously described (Erfle, Simpson et al. 2004; Neumann, Held et 
al. 2006). Each LabTek coverslip contained 348 spots in a 12x32 format with a 
spot diameter of 400 um and a spot-to-spot distance of 1125 um. Spotted arrays 
were stored in plastic boxes containing silica gel at room temperature.   
3. Immunostaining of cell arrays 
HeLa cells (1,0x105 cells) were plated to the dried microarrays in a total 
volume of 1.5 ml complete medium. siRNA reverse transfection did not require 
any further manipulation; cells were transfected with siRNA oligos simply by 
growing on the siRNA spots.  After 50 hours incubation (37°C, 5% CO2) cells 
were fixed in a mixture of 3% Triton X-100 and 3% PFA for 3 minutes followed 
by fixation in 3%PFA for 35 minutes. Subsequently arrays were washed with 
1xPBS for a few minutes and stained for 1 hour at room temperature with Paxillin 
monoclonal antibody (BD Biosciences). After 15 minutes wash (3 times 5 
minutes with 1XPBS) arrays were incubated for 1 hour with Alexa-488 anti-
mouse antibody (Molecular Probes) mixed with Alexa-568 Phalloidin (Molecular 
Probes).  Cell nuclei were stained with 1 ug/ml Hoechst 33342 dye (Sigma-
Aldrich). After washing (3 times 10 minutes with 1XPBS), arrays were stored in 
1xPBS at 4°C. 
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4. Image acquisition  
Cell arrays were imaged with a 25x air objective on a scan^R fluorescence 
microscope (Olympus Biosystems) equipped as described (Simpson, Cetin et al. 
2007). Acquisition started from the first siRNA spot labeled with indelible ink 
and continued automatically based on spot-to-spot distance.  All images were 
acquired with the help of scan^R software using gradual autofocus mode. 
5. Validation by “conventional” siRNA transfection 
HeLa cells were seeded in 12-well plates (1,0x105 cells per well) 24 hours 
before transfection. siRNAs oligonucleotides (Supplementary Table 1) including 
Silencer Negative Control #2 siRNA (catalog # 4613) were produced by Ambion 
and stored at -20°C as 50 uM working stocks. Mixtures of 6 ul Oligofectamine 
(Invitrogen) with 24 ul OPTIMEM (Gibco) and 3 ul siRNA with 100 ul 
OPTIMEM were prepared separately and incubated at room temperature for 7 
minutes. Solutions were combined by gentle pipetting up and down and left for 
20 minutes at room temperature. Culture medium was changed to the medium 
without antibiotics. Afterward transfection mix was carefully added to the center 
of each well. On the next day cells were split on coverslips coated with 
fibronectin (10 ug/ul, Roche). Fixation and immunostaining procedures were 
performed in the same way as for cell microarrays. Coverslips were mounted on 
the slides with Prolong Gold (Molecular Probes) and dried at room temperature at 
least over night. siRNA knockdown times varied from 50 to 55 hours.  
6. Validation by RT-qPCR 
HeLa cells were subjected to siRNA transfection in 12-well format, split the 
next day into 6-well dishes and incubated for 50-55 hours. Total RNA was 
extracted and purified using High Pure RNA isolation Kit (Roche). cDNA was 
produced by reverse transcription using SuperScript II Reverse Transcriptase 
(Invitrogen) and Random primers (Invitrogen) according to the manufacturer’s 
protocol.  SybrGreen method was chosen for real-time PCR with gene-specific 
primers including primers for housekeeping gene GAPDH (Supplementary table 
7). Real-time PCR reactions were carried out on iCycler (BioRad) by repeating 
the following amplification cycle 40 times: denaturating at 95°C for 15 s 
followed by annealing at 56°C for 30 s and extension at 72°C for 30 s.  Degree of 
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siRNA knockdown was calculated by comparing the amplification level of the 
gene of interest, normalized through the level of the housekeeper gene, between 
samples transfected with a specific siRNA and negative control samples. 
7. Nocodazole wash-out assay 
HeLa cells (1,0x105 cells) were plated to the dried microarrays in triplicate. 
After 50 hours incubation one microarray platform was fixed. The cells on the 
other microarrays were starved for 1 hour in DMEM (supplied with 0.2% BSA) 
and treated with 8uM nocodazole in DMEM with 0.2%BSA for 4 hours. 
Afterward one replica of the two was fixed. The last microarray was rinsed with 
DMEM several times, left for two hours in DMEM with 0.2%BSA and finally 
also fixed. Fixation and following paxillin and actin staining was performed 
according to the standard protocol described above. All microarray incubation 
steps during assay were performed at 37°C with 5% CO2. 
8. Monitoring of focal adhesion dynamics in siRNA-treated cells 
Hela cells with stable expression of EGFP-paxillin were split on fibronectin-
coated (10 ug/ml of fibronectin (Roche) in 1xPBS) coverslips and transfected 
with negative control (Silencer Negative Control #2 siRNA, Ambion) or beta-
COP siRNAs (GGAUCUUCAACAUCCUAAU; Simpson, Cetin et al., 2007). 
After 55 hours incubation time live-cell videos were acquired on a Zeiss Axiovert 
200M inverted microscope equipped with a rear-illuminated, cooled CCD camera 
(Micromax or Cascade, Roper), halogen lamp, and filter wheel and shutters 
controlled with Metamorph software. Images were collected in green fluorescent 
channel with 30 s between frames using 100x1.4 NA Plan-Apochroma objective. 
During imaging cells were maintained in an open heating chamber (Warner 










9. Cell spreading assay 
HeLa cells were transfected with negative control or beta-COP siRNAs and 
after 55 hours incubation time replated onto fibronectin-coated (50 ug/ml 
fibronectin, Roche) coverslips. Following two hours incubation cells were fixed 





To test if it is possible to use siRNA microarray method for detection of 
factors involved in focal adhesion turnover, I created microarray platforms 
containing siRNAs to down-regulate expression of genes known or expected to 
play a role in cell-substrate adhesion and cell migration. Based on a literature 
search I selected 125 genes coding diverse focal adhesion scaffold and regulatory 
proteins (Supplementary Table 2). I also wanted to include in the preliminary 
screen complete protein families and systematically characterize all their 
members regarding influence on focal adhesions. Two protein groups were 
selected: Rho family GTPases including their regulators and molecular motor 
families together with microtubule tip proteins. 
The three most extensively studied RhoGTPases - RhoA, CDC42 and 
Rac1 - have long been accepted as key players in the coordination of actin, 
microtubule and focal adhesion reorganization during cell migration (for review 
see (Ridley 2001)). Recent research indicates that some of the other members of 
this family as well as their regulators also affect cell cytoskeleton architecture 
(for review see (Wennerberg and Der 2004)). Regulators of RhoGTPases include 
three subgroups which control GTP hydrolysis reaction: RhoGAPs (GTPase 
Activating Proteins catalyzing GTP hydrolysis), RhoGEFs (GTPase Exchange 
Factors promoting exchange of GDP for GTP) and RhoGDIs (Guanine nucleotide 
Dissociation Inhibitors preventing GDP release in the cytosol) (Supplementary 
Table 3). 
In my laboratory it was previously shown that inhibition of the motor 
protein kinesin-1 caused dramatic enlargement of focal adhesions (Krylyshkina, 
Kaverina et al. 2002). It was therefore suggested that motor-dependent delivery 
of regulatory proteins along actin or microtubule tracks to adhesion sites may 
influence adhesion turnover. That is why I chose to perform siRNA knockdown 
of kinesin and myosin motor families and microtubule tip proteins with the aim to 
investigate their possible involvement in focal adhesion rearrangement 
(Supplementary Table 4). 
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In total I selected 386 genes for the primary siRNA microarray 
experiment. 
At least two different siRNAs for each gene were designed and produced 
by Ambion Europe, Ltd and spotted randomly on to four LabTeck slides together 
with negative control scrambled siRNA and positive control siRNA 
(Supplementary Table 5). HeLa cells were plated on top of the slides where they 
took up the arrayed siRNA oligonucleotides upon reverse transfection.  After 50 
hours cells were fixed and stained with Hoechst 33342, an antibody against focal 
adhesion protein paxillin and phalloidin to visualize nuclei, focal adhesions and 
actin cytoskeleton in blue, green and red channels respectively. A 50 hour 
incubation period was chosen as a compromise between time sufficient for 
3  nuclei actin Focal adhesions 
2  1C
1B1A 
Figure 1 | Main steps in a siRNA microarray screening. | 1) Transfection mixtures containing siRNA 
oligonucleotides together with transfection reagent are automatically printed on LabTek chamber slide 
(1A. schematic drawing of spotted LabTek slide, 1B. photograph of the contact printer, 1C. photograph 
of spotted LabTek chamber); 2) HeLa cells are seeded on to dried microarrays (schematic drawing); 3) 
After 50 hours incubation time cells are fixed and stained to visualize structures of interest (nuclei, focal 
adhesions and actin). Three images from blue, green and red fluorescent channels are acquired with the 
help of automated microscopy from each siRNA spot. 
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protein depletion upon siRNA knockdown and the growth of cell to an optimal 
cell density for subsequent phenotypic analysis. Images from three fluorescent 
channels were acquired from the central area of each microarray spot with the 
help of automated microscopy. With the 25x objective it was possible to image 
50-100 cells per spot and achieve a resolution high enough to analyze structures 
as small as focal adhesions (Figure 1). 
As a positive control we used siRNA oligonucleotide targeting INCENP, 
inner centromer protein involved in cytokinesis. This siRNA was previously 
shown to give a robust and clearly recognized phenotype that was characterized 
by appearance of multinucleated cells (Neumann, Held et al. 2006).  In each 
experiment we observed that at least 50% of all cells located on the INCENP 
siRNA spots contained two or more nuclei (Figure 2). This provided an internal 
control to show that printed siRNA platforms were functional and had a high 
transfection efficiency rate. Negative control scrambled siRNA that did not 
recognize any mammalian mRNAs showed no phenotypic defects. 
Automated quantitative image analysis is considered to be the most 
unbiased approach for the evaluation of siRNA knockdown phenotypes and 
scoring of hits. Therefore I tried to develop image analysis program that would be 
able to recognize focal adhesions and classify phenotypes according to their 
number, size and distribution. Unfortunately the programs I tested such as 
MatLab and image-analysis software Cellenger (Definiens) were very sensitive to 
focus alterations and even with slightly out-of-focus images could not correctly 
Figure 2 | Knockdown of INCENP results in appearance of multinucleated cells. | 
Images of cells acquired from microarray spots with printed INCENP siRNA were manually 
analyzed. Upon INCENP knockdown at least 50% of cells contained two or more nuclei 
which were visualized by Hoechst 33342 staining (marked by arrows) (B).Control cells 




detect focal adhesion structures. This turned out to be a considerable problem 
since the automated acquisition program could not always accurately focus on 
focal adhesions. At first I attempted in collaboration with mathematicians to 
develop more sophisticated recognition algorithms but finally decided to carry 
out visual phenotypic analysis by eye. Visual scoring of hits turned out to be 
reproducible approach to identify novel focal adhesion regulators in explored 
microscopy assay. 
I performed blind visual inspection of acquired images and assigned 
phenotypes diverging from the negative control to two categories based on the 
size of focal adhesions: 1) with enlarged focal adhesions and 2) with smaller 
focal adhesions. I chose the size of adhesions as the main feature for 
classification because first of all it could be relatively easily estimated by eye. 
Secondly, I assumed that defects in focal adhesion turnover were reflected in 
their dimensions:  deregulation of focal adhesion assembly would lead to the 
decrease in focal adhesion size, whereas defects in the process of disassembly 
would cause enlargement of adhesion structures. To make analysis more reliable I 
performed and analyzed three replicate experiments. A gene was assigned to one 
of the categories if it was similarly scored in at least two replicate arrays and if 
the identical defect was seen in at least 50% of the acquired cells. 
Knockdown of 10% of the screened genes (38 out of 386) showed visible 
changes in focal adhesion size.  Two thirds of the scored siRNAs (22 out of 38) 
lead to the reduction in focal adhesion size rather than enlargement (Table 1) and 
corresponded to putative positive regulators. In addition to the adhesion 
alterations I could see a broad spectrum of distinct defects in cellular morphology 
and actin cytoskeleton organization. To simplify classification of the phenotypes 
I concentrated only on the two opposite defects on actin distribution:  appearance 
of strong stress fibers and loss of organized actin  
41 
 
Table 1 | List of the scored genes with annotation of the siRNA knockdown phenotypes. |   
The “Focal adhesion” column shows the effect of gene knockdown on focal adhesion size. The “Actin” 
column shows the effect of gene knockdown on the organization of the actin cytoskeleton (SF – 
formation of prominent stress fibers, Disorganized – loss of organized actin filaments). “siRNAs” column 
indicates how many different siRNA oligonucleotides for each gene were spotted onto microarrays and 
how many of them gave similar defective phenotypes (for example 2 siRNA out of 4 spotted produced 
similar phenotype). The last three columns indicate how many gene knockdown phenotypes were 































































1 ARHN Bigger  1 out of 2    
2 ARHGAP5 Bigger SF 1 out of 4    
3 DLC1 Bigger  1 out of 6    
4 ABR Bigger SF 1 out of 4   
5 AKAP13 Bigger SF 1 out of 6   
6 TIAM1 Bigger  1 out of 2    








8 ANXA2 Bigger SF 1 out of 6    
9 TPM1 Bigger SF 1 out of 8   
10 FLNC Bigger SF 1 out of 2   
11 TM4SF6 Bigger  1 out of 2    
12 PAK2 Bigger SF 1 out of 2    
13 PAK4 Bigger SF 1 out of 12    
14 TLN1 Bigger SF 1 out of 2    







 16 CDC42 Smaller Disorganized 2 out of 4    
17 Rac1 Smaller Disorganized 2 out of 6    
18 RhoB Smaller Disorganized 1 out of 2    
19 ARHGAP4 Smaller Disorganized 1 out of 2    




s 21 KIF11 Smaller 1 out of 2   
22 KIF1A Smaller Disorganized 1 out of 2    









25 MACF1 Smaller Disorganized 1 out of 4   
26 MLPH Smaller Disorganized 1 out of 2    
27 AP1B1 Smaller  1 out of 2    
28 ITG5B Smaller 1 out of 2   
29 ILK Smaller 1 out of 6   
30 FYN Smaller  1 out of 6    
31 FBLP-1 Smaller  1 out of 6    
32 PTK2 Smaller  1 out of 4    
33 NF2 Smaller Disorganized 1 out of 8    
34 PIK3R1 Smaller  1 out of 5    
35 PRKCA Smaller  1 out of 2    
36 MYLIP Smaller Disorganized 1 out of 2    
37 NCK2 Smaller Disorganized 1 out of 6    




filaments (in Table 1 marked as Disorganized actin).  A clear correlation was 
observed between focal adhesion enlargement and formation of actin stress 
fibers, while smaller focal adhesions were in half of the cases accompanied by the 
loss of organized actin.  These observations were consistent with the 
demonstration that the level of actin-myosin contractility affects focal adhesion 
organization (Burridge and Chrzanowska-Wodnicka 1996). 
To test whether the microarray siRNA phenotypes were reproducible I 
randomly selected several genes from the hit list and repeated knockdown with 
exactly the same oligonucleotides but using “conventional” oligofectamine 
transfection.  13 out of 15 chosen oligonucleotides caused focal adhesions 
alterations identical to the ones seen on the microarray chips. Figure 3 represents 
comparison of the original microarray adhesion phenotypes that were scored with 
25x magnification and reproduced phenotypes that were acquired with 63x 
magnification. The difference between enlarged and diminished focal adhesions 
in comparison with the control phenotype became even more obvious when 
images were acquired with 63x magnification upon individual siRNA 
transfections.  The aforementioned correlation between focal adhesion size and 
actin organization was also reproduced (Figure 4).  Two oligonucleotides 
targeting PTK2 and MLPH genes caused the defects in cell morphology and focal 
adhesion pattern but focal adhesion size remained similar to control phenotype.  
For 6 siRNAs I measured the mRNA knockdown efficiency in transfected 
cells by quantitative reverse-transcriptase PCR (qRT-PCR). I found that 4 
siRNAs (Rac1, ITGB5, MACF1, MYH9) suppressed the mRNA level of the 
targeted gene by 70-80% (Figure 5). For Cdc42 the residual mRNA level was less 
than 50% and for RhoB - around 80%. Since the protein and mRNA levels should 
mirror each other I assumed that the observed siRNA knockdown phenotypes 
resulted from the loss of corresponding protein function. However the appearance 
of visible loss-of-function phenotype does not always correlate with mRNA level 
and depends on the properties of particular protein. In the case of CDC42 and 
RhoB for example even a small reduction in mRNA level was sufficient to induce 




Figure 3 | Defective focal adhesion phenotypes were reproduced by “conventional” siRNA 
transfection. | Left column shows selective images that were acquired during microarray screen at 25x 
magnification.  Right column represents images of the cells exposed to “conventional” transfection with 
identical siRNA oligonucleotides and acquired at 63x magnification. For example knockdown of beta5-
integrin (ITGB5) by “conventional” siRNA transfection confirmed reduction in focal adhesion size 
detected in the microarray screen. Knockdown of talin1 (TLN1) and PAK2 kinase lead to the reproduced 
enlargement of adhesions. Focal adhesions were visualized by immunostaining with anti-paxillin 
antibody. 
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Figure 4 | Reproduced siRNA phenotypes confirmed interconnection between focal adhesion size and actin 
cytoskeleton organization. | Two left columns show examples of enlarged focal adhesions accompanied by 
formation of strong actin stress fibers upon siRNA knockdown of AKAP13, PAK2 and PAK4 genes.  Two right 
columns demonstrate reduced focal adhesions correlated with disarrangement of actin filaments upon suppression 
of CDC42, MYH9 and ITGB5 genes. Focal adhesions were visualized by anti-paxillin antibody staining, actin 
was stained with phalloidin. siRNA knockdown was performed using “conventional” siRNA transfection. Images 
were acquired at 63x magnification. 








































































Enlarged focal adhesions 
45 
 
Figure 5 | RT-PCR analysis confirmed 
siRNA knock-down efficiency. | siRNA 
knockdown was performed by 
“conventional” transfection. Remaining 
mRNA expression levels were determined 
50 hours after transfection and are shown as 






















Among the identified 38 genes were 5 for which the effect of siRNA 
knockdown on focal adhesion size was previously studied by independent 
research groups. For example down-regulation of the main RhoGTPase Rac1 or 
class II nonmuscle myosin heavy chain MYH9 was shown to prevent formation 
of focal adhesions and lead to a significant reduction in focal adhesion size (Yip, 
El-Sibai et al. 2007; Li, Friedmann et al. 2008), and depletion of p21-associated 
kinase PAK2 caused RhoA activation and an increase in focal adhesion size 
(Coniglio, Zavarella et al. 2008). As the microarray phenotypes resembled the 
published ones I concluded that the established microarray siRNA platforms 
could be suitable to detect genes directly or indirectly affecting focal adhesion 
size.  While I was searching for the published data regarding influence of gene 
knockdowns on focal adhesion organization particular on focal adhesion size I 
noticed that very often researches limited their studies of siRNA gene 
knockdowns to general characterization of cell migration or cell spreading.  But 
the changes in focal adhesions and actin cytoskeleton, main cellular components 
involved in these processes, remained unexplored.  siRNA depletion of integrin-
linked kinase (ILK) was shown to impair spreading of HeLa cells on fibronectin 
as well as migration in a Transwell motility assay (Fukuda, Chen et al. 2003). 
One of the possible reasons for the described ILK-knockdown defects might be 
deregulation of focal adhesion turnover. And indeed the microarray screen 
detected a decrease in focal adhesion size upon ILK siRNA transfection. 
Therefore focal adhesion microarray data provides a basis to identify genes 
potentially involved in cell adhesion and migration. 
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Figure 6 | siRNA knockdown of 
dynamin 2 produces enlargement of 
focal adhesions. | Knockdown of 
dynamin 2 was performed by 
“conventional” siRNA transfection 
using siRNA oligonucleotide 
published by G. Gunderson laboratory 
(Ezratty et al., 2005).  Focal adhesions 
were visualized by anti-paxillin 
antibody staining, actin was stained 
with phalloidin. Images were acquired 






















While I was able to identify proteins affecting focal adhesion size, I 
expected to score more than 10% genes since the majority of chosen siRNAs 
targeted genes that were shown or predicted to play a role in cell migration, 
spreading or cytoskeleton architecture.  A representative example of the gene 
which was not scored in the primary screen but was expected to be scored is 
dynamin-2 (DNM2), a GTPase involved in endocytosis. In the laboratory of 
G.Gundersen it was demonstrated that siRNA depletion of dynamin-2 lead to a 
twofold enlargement of focal adhesions due to its apparent function in focal 
adhesion disassembly (Ezratty, Partridge et al. 2005). However when I performed 
dynamin-2 siRNA knockdown in HeLa cells by conventional transfection with 
previously published siRNA oligonucleotide, a significant increase in focal 
adhesion size was observed (Figure 6), confirming the Ezratty et al. data.  
One of the possible reasons why fewer genes than expected were scored 
might be the manual annotation of the hits. During visual image inspection only 
the most obvious phenotypes were considered, whereas less visible changes in 
focal adhesion size were ignored. In addition it was complicated to evaluate 
phenotypes of the siRNA spots with higher cell density where cells were closely 
packed; that could also be a source of mistakes during visual scoring.  
Another potential reason for low hit number could be a low efficiency of 
siRNA knockdowns due to suboptimal design of the siRNA oligonucleotides. I 
counted the number of different siRNA sequences targeting the same gene which 
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produced similar focal adhesion phenotypes (Table 1). For only 3 out of the 38 
scored genes were there two distinct siRNAs which caused identical knockdown 
defects. For the rest of the genes only one oligonucleotide gave a clear 
phenotype, despite the use of more than 4 siRNAs for 50% of the targets.  
Discounting mistakes of visual scoring I could conclude that only 30% of the 
designed oligonucleotides efficiently produced a loss of function phenotype.  
The siRNA knockdown efficiency and appearance of loss-of-function 
phenotype is also dependent on the protein’s half-life. Depletion of stable, long-
lived proteins could require prolonged incubation time upon siRNA transfection. 
In the established microarray screen cell density was the limiting factor and 
restricted the knockdown period to around 50 hours. Thereby some of the genes 
coding stable proteins that affect adhesion turnover could have escaped detection. 
In conclusion I demonstrated that the siRNA microarray technique could 
be applied for detection of proteins involved in focal adhesion organization. 
However the method allows only a superficial rather than detailed systematic 
analysis, at least with the experimental design employed here. Nevertheless it 





In my assay for focal adhesion regulators I assumed that the size of 
adhesions would reflect the defects either in their assembly or disassembly 
processes.  With the aim to more easily distinguish between focal adhesion 
assembly and disassembly regulators I investigated ways to amplify these two 
events separately in cells exposed to siRNA action.  
It was already shown some time ago discovered that disruption of 
microtubules in fibroblasts or epithelial cells by nocodazole typically causes 
amplification in focal adhesion size and formation of strong stress fibers owing to 
increased RhoGTPase activity (Bershadsky, Chausovsky et al. 1996; Enomoto 
1996). Gunderson and colleagues recently demonstrated that upon microtubule 
re-polymerization after nocodazole washout, focal adhesions undergo 
48 
 
4 hours incubation with 
Nocodazole (8 uM) 
1h serum starvation 
2 hours Nocodazole 
washout 
Cell fixation and immunostaining 
Figure 7 | Schematic representation of nocodazole assay. | HeLa cells were seeded onto three 
microarray replicas. After 50 hours incubation time only one replica was fixed. Two other replicas were 
exposed to 1 hour serum starvation following by 4 hours incubation with nocodazole (8 uM). Afterward 
one of the replicas was fixed and the second one was subjected to nocodazole wash-out, incubated for 2 
hours and also fixed. All microarrays were stained with anti-paxillin antibody, phalloidin and Hoechst 
33342 to visualize focal adhesions, actin and nuclei respectively. 
disassembly to their initial state (Ezratty, Partridge et al. 2005). Therefore 
monitoring changes in adhesion size upon nocodazole treatment and its 
subsequent wash-out can serve as an assay for identification of focal adhesion 
assembly and disassembly factors. 
 I adopted the nocodazole wash-out protocol from the Gunderson 
laboratory for the use with microarray siRNA platforms. HeLa cells were grown 
on the LabTeck slides in triplicate with spotted siRNA oligonucleotides. One of 
the three microarray replicas was fixed 50 hours after plating the cells. The two 
other replicas were treated with nocodazole after 1 hour serum starvation. One 
replica of the two was fixed following 4 hours incubation with nocodazole. The 
last slide was subjected to nocodazole wash-out for two hours and also fixed 
(Figure 7). All slides were stained with Hoechst 33342, an antibody against focal 
adhesion protein paxillin and phalloidin to label respectively nuclei, focal 
adhesions and the actin cytoskeleton, and images from each siRNA spot were 
automatically acquired. Parallel analysis of the three replicas facilitated 
comparison of the effect of the same siRNA gene knockdown on focal adhesion 
organization in standard conditions, on focal adhesion assembly stimulated by 
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nocodazole, and on focal adhesion disassembly induced by nocodazole washout.   
 Visual inspection of the images revealed that cells from microarray spots 
with negative control siRNAs indeed showed a significant increase in focal 
adhesion size upon nocodazole addition accompanied by formation of prominent 
actin stress fibers. Nocodazole washout leads to the reversion of focal adhesions 
to their initial state and disappearance of stress fibers (Figure 8).  
For the first screening round the nocodazole assay was repeated twice 
with two siRNA microarray platforms created in the previously described part of 
the project and containing siRNA oligonucleotides to knockdown 240 genes 
including RhoGTPases, their regulators and motor proteins (Supplementary 
tables 3, 4). A gene product was considered to be involved in focal adhesion 
assembly if upon knockdown nocodazole failed to produce enlargement of 
cellular adhesions. Conversely, a gene product was expected to participate in 
focal adhesion disassembly if its knockdown prevented reduction of focal 
adhesions to their initial size after nocodazole wash-out. A phenotype was scored 
if it was observed in both experiments. 
Knockdown of only 4 genes lead to a strong inhibition of focal adhesion 
growth upon nocodazole treatment. Those genes were MYH9 (non-muscle 
Myosin IIa heavy chain), RhoB, ARHGDI and SH3BP1 (Figure 9). Focal 
adhesion assembly defects were reproduced using conventional siRNA 
transfection to knockdown MYH9 and RhoB (Figure 10). It is interesting to 
mention that among 240 examined genes suppression of 8 genes including  
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Figure 8 | Assembly of focal adhesions upon nocodazole treatment and disassembly to the initial 
state after nocodazole wash-out. | Presented images were acquired from the same scrambled siRNA 
spot on the three microarray replicas. First replica was fixed before treatment, second replica was fixed 
after 1 h starvation and 4 h incubation with nocodazole, third replica was fixed after 2 h nocodazole 
wash-out. Assembly of focal adhesions was accompanied by stress fibers formation that was reversible 
upon nocodazole wash-out. Focal adhesions were visualized by anti-paxillin antibody staining (green), 
actin was stained with phalloidin (red). Images were acquired at 25x magnification. 











Figure 9 | Enlargment of focal adhesions upon nocodazole treatment was abrogated after siRNA 
knockdown of MYH9, RhoB, ARHGDI and SH3BP1. | Presented images were acquired from 
microarrays fixed after 4 h nocodazole treatment. Focal adhesions were visualized by anti-paxillin antibody 
staining (green), actin was stained with phalloidin (red). Images were acquired at 25x magnification. 
Scrambled siRNA MYH9 siRNA RhoB siRNA
ARHGDI siRNA SH3BP1 siRNA
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MYH9 and RhoB (Table 1) caused defects in focal adhesion formation in 
standard conditions. However upon nocodazole addition only MYH9 and RhoB 
genes appeared to be essential for stimulated assembly of focal adhesions 
whereas the other 6 genes were not necessary for this process. This means that 
microtubule depolymerization by nocodazole activates focal adhesion assembly 
by bypassing proteins involved in a normal focal adhesion formation under 
standard conditions. 
Interestingly ARHGDI and SH3BP1 were identified as regulators of focal 
adhesion assembly only after nocodazole treatment. Most likely these genes 
influence focal adhesion formation also in a standard situation but the effects of 
their depletion on focal adhesion size are compensated by other factors and 
therefore not detected. Stimulation of focal adhesion assembly by nocodazole 
apparently reduces the impact of other regulators and exposes the role of 
ARHGDI and SH3BP1 in this process. 
The process of focal adhesion disassembly upon nocodazole wash out was 
less efficient and therefore difficult to score. Also cell populations on siRNA 
spots did not react uniformly to microtubule re-polymerization upon nocodazole 
removal. Figure 11 illustrates an example of evenly enlarged focal adhesions in 
nocodazole treated cells and heterogeneity in focal adhesion dimensions after 
wash out of the drug. This fact might indicate that adhesion disassembly induced 
by nocodazole washout is a more complex process with increased dependence on 
intracellular and environmental conditions.  
In the course of nocodazole assay many cells were deattaching (cells 
marked with asterisks, Figure 11) probably due to a combination of several 
factors such as siRNA knockdown, serum starvation and microtubule 
depolymerization. The detached cells affected the performance of the autofocus 
program and led to the accumulation of out-of-focus images, adding on additional 
complication to this assay. 
Nevertheless I demonstrated that the nocodazole assay may be exploited 
to identify some proteins required for focal adhesion assembly that would be 
missed in the standard control situation. However the assay was not robust 
enough for identification of disassembly regulators during microtubule re-
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polymerization. Based on these conclusions the idea of performing a further 
large-scale siRNA screen on the basis of nocodazole assay was set aside. 
Figure 10 | Defects in focal adhesion assembly upon nocodazole addition were reproduced by 
“conventional” siRNA transfection. | Upon 50 h incubation after “conventional” siRNA 
transfection cells were fixed before and after 4 h treatment with nocodazole. Suppression of RhoB 
and MYH9 genes leads to the reduction in focal adhesion size already in the standard conditions and 
prevents focal adhesion assembly after nocodazole addition. Focal adhesions were stained with anti-



















Scrambled siRNA RhoB siRNA MYH9 siRNA
Figure 11 | Illustration of heterogeneity in focal adhesion disassembly upon nocodazole 
wash-out by example of Rac1 depleted cells. | Images were acquired from the Rac1 siRNA spot 
after 4 h nocodazole treatment and after 2 h upon nocodazole wash-out. The whole population of 
nocodazole-treated cells displays equally enlarged focal adhesions. However upon nocodazole 
wash-out cells exhibit different levels of focal adhesion disassembly. Yellow and red rectangles 
highlight group of cells with high and low adhesion disassembly rates. Asterisks mark cells that 
detached in the process of nocodazole assay. Focal adhesions were stained with anti-paxillin 
antibody. Images were acquired at 25x magnification. 













As already indicated the RNAi screen was carried out in close 
collaboration with Rainer Pepperkok’s group in EMBL, Heidelberg. They have 
developed and performed a genome-wide siRNA microarray screen to 
systematically study proteins affecting the vesicular trafficking machinery in 
HeLa cells (Simpson, Cetin et al. 2007). Their assay was based upon the transport 
of a temperature sensitive viral transmembrane protein (tsO45G) from the ER, 
through the Golgi, to the cell surface. Automated image analysis with subsequent 
single-cell quantification of the protein transport efficiency allowed identification 
of the factors that are essential for the trafficking to plasma membrane. In total 
they scored around 700 genes involved in that process. To investigate the link 
between focal adhesion turnover and vesicular trafficking to the plasma 
membrane I decided to monitor focal adhesion changes using the microarray 
slides (Supplementary Table 6) containing trafficking hits kindly provided by Jez 
Simpson and Rainer Pepperkok.  
The procedure of the screen was similar to the one described in the first 
chapter. Briefly, HeLa cells were plated onto siRNA microarrays, fixed after 50 
hours incubation and stained to visualize focal adhesions, actin and nuclei. 
Images were acquired with the help of automated microscopy and subjected to 
manual inspection. The screen was carried out in duplicate. I selected hits 
according to the defects in focal adhesion size dividing them into two groups – 
with enlarged and reduced focal adhesions. In addition I monitored changes in 
actin cytoskeleton, paying attention to the formation of prominent stress fibers 
and loss of organized actin structure. The gene was scored as a hit if a similar 
defective phenotype was seen in both experiments. 
I identified 87 genes whose knockdown caused a strong alteration in focal 
adhesion size (Table 2). Only 15% of phenotypes represented reduction in focal 
adhesion size whereas the majority of the phenotypes showed focal adhesion 




Table 2 | List of the genes whose knockdown caused vesicular trafficking and focal adhesion 
defects. | Genes were grouped according to known or predicted functions of corresponding proteins. The 
“Focal adhesion” column shows the effect of gene knockdown on focal adhesion size. The “Actin” 
column shows the effect of gene knockdown on the organization of the actin cytoskeleton (SF – 
formation of prominent stress fibers). “siRNAs” column indicates how many different siRNA 
oligonucleotides for each gene were spotted onto microarrays and how many of them gave similar 
defective phenotype (for example 2 siRNAs out of 2 spotted produced similar phenotype). The last 
column indicates (red boxes) about defects in Golgi apparatus organization revealed by staining with anti-
GM130 antibody. 
 
Group # Gene Focal Adhesions Actin siRNAs Golgi 
1 iqsec1 Bigger  2 out of 3  
2 kif19 Bigger SF 1 out of 1  
3 spnb2 Bigger  1 out of 1  










5 rap1gds1 Bigger  1 out of 3  
6 arcn1 Bigger  1 out of 1  
7 copb2 Bigger  1 out of 1  
8 copg Bigger  1 out of 1  
9 copb Bigger  1 out of 1  









11 skd3 Bigger  2 out of 2  
12 agtrap Bigger  1 out of 1  
13 flt3lg Bigger SF 1 out of 1  
14 glra1 Bigger  2 out of 3  
15 il1f5 Bigger SF 1 out of 1  
16 sez6l2 Bigger SF 1 out of 1  
17 eps15l2 Bigger  1 out of 1  
18 flt4 Bigger  2 out of 3  
19 fprl2 Bigger  1 out of 1  
20 grin2c Bigger SF 1 out of 1  
21 ms4a6a Bigger  1 out of 3  
22 or10a4 Bigger  2 out of 3  
23 or4p4 Bigger  1 out of 1  
24 tyrobp Bigger  2 out of 3  
25 sgcg Bigger SF 1 out of 1  
26 np_775772.1 Bigger  1 out of 1  
27 ccdc51 Bigger  1 out of 1  






















29 reg4 Bigger  1 out of 1  
30 cdk5r1 Bigger  1 out of 1  
31 khk Bigger  1 out of 3  
32 ppapdc1 Bigger SF 1 out of 3  







34 mast3 Bigger  1 out of 2  
35 nhp2l1 Bigger  1 out of 1  
36 znf10 Bigger SF 1 out of 1  
37 bcorl2 Bigger  2 out of 3  
38 dqx1 Bigger SF 2 out of 3  
39 hscarg Bigger SF 1 out of 2  
41 mxd4 Bigger  1 out of 3  
42 oa48-18 Bigger  1 out of 2  
43 pml Bigger SF 2 out of 3  
44 mcm7 Bigger  2 out of 2  
45 polr3f Bigger SF 1 out of 3  























47 ccdc124 Bigger  1 out of 1  
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Table 2 | List of the genes whose knockdown caused vesicular trafficking and focal adhesion 
defects. | Genes were grouped according to known or predicted functions of corresponding proteins. The 
“Focal adhesion” column shows the effect of gene knockdown on focal adhesion size. The “Actin” 
column shows the effect of gene knockdown on the organization of the actin cytoskeleton (SF – 
formation of prominent stress fibers). “siRNAs” column indicates how many different siRNA 
oligonucleotides for each gene were spotted onto microarrays and how many of them gave similar 
defective phenotype (for example 2 siRNAs out of 2 spotted produced similar phenotype). The last 
column indicates (red boxes) about defects in Golgi apparatus organization revealed by staining with anti-
GM130 antibody. 
 
Group # Gene Focal Adhesions Actin siRNAs Golgi 
48 iqcf1 Bigger  1 out of 2  
49 notch2nl Bigger  1 out of 1  
50 loc348180 Bigger  1 out of 1  
51 9430057o19rik Bigger  1 out of 1  
52 loc401565 Bigger  1 out of 1  
53 spryd4 Bigger  1 out of 1  
54 thap4 Bigger  1 out of 1  
55 loc649917 Bigger  1 out of 1  
56 znf167 Bigger  1 out of 3  
57 q8n507_human Bigger  1 out of 1  
58 q8n779_human Bigger  1 out of 1  
59 q8wuc7_human Bigger  1 out of 1  
60 q96nc1_human Bigger  1 out of 1  
61 xp_370634.2 Bigger  1 out of 1  
62 dkfzp434g072 Bigger SF 2 out of 2  
63 c19orf165 Bigger SF 2 out of 2  
64 c5orf17 Bigger  1 out of 2  













66 mgc20398 Bigger SF 2 out of 2  
67 rplp2 Bigger SF 1 out of 1  
68 adam20 Bigger  1 out of 1  
69 insl6 Bigger  1 out of 1  
70 ipo8 Bigger  1 out of 1  
71 npc1l1 Bigger  1 out of 1  
72 sst Bigger SF 1 out of 2  












74 ndnl2 Bigger  2 out of 3  
75 itgav Smaller  1 out of 1  
76 itgb5 Smaller  1 out of 1  C
yt
 
77 rhof Smaller  1 out of 3  
Tr
f 
78 c9orf19 Smaller  1 out of 3 
 
79 fgf19 Smaller  1 out of 1  
80 tva2_human Smaller  1 out of 1  Tm
r 
81 egfl6 Smaller  1 out of 3  
82 hoxc9 Smaller  1 out of 1  




84 kiaa0363 Smaller  1 out of 1  
U
f 85 o15421_human Smaller  1 out of 1 
 
D




For most of the genes there was only one siRNA oligonucleotide taken from the 
aforementioned genome-wide screen. For 34 genes additional oligonucleotides 
were designed by Ambion and Quiagen companies. For half of those genes (44%) 
two oligonucleotides with distinct sequences gave identical knockdown 
phenotype. However only 52% of the additionally synthesized siRNAs were 
efficient in gene depletion. 
All identified genes were annotated with the help of Bioinformatic 
Harvester database (http://harvester.fzk.de/harvester/) and assigned to various 
functional groups based on the known or predicted functions of corresponding 
proteins: cytoskeleton related proteins, vesicular trafficking related proteins, 
receptors and transmembrane proteins, transcription factors and other nuclea 
proteins, proteins with unknown functions and with known miscellaneous 
functions including ribosomal proteins (rplp2, npc1l1), signaling peptides (sst, 
npw, insl6), metalloproteinase (adam20). 
I decided to narrow the number of final hit-genes by performing an 
additional secondary screen. As a parameter for screening I chose the 
morphology of the Golgi apparatus, the central membrane structure in the 
secretory trafficking pathway. The Golgi complex in mammalian cells is 
organized in the form of continuous ribbon-like membrane structure positioned in 
the perinuclear area. An appropriate coordination of membrane traffic to and 
from the Golgi is essential to preserve its organization and function. Therefore an 
alteration in Golgi morphology could serve as a marker of trafficking defects. For 
example it was shown that siRNA knockdown of Golgi-localized protein 
golgin45 lead to the dispersal of Golgi ribbon into small vesicular fragments and 
at the same time caused an almost complete block in transport of VSVG protein 
(Short, Preisinger et al. 2001). Interference with the function of Golgi-localized 
serine/threonine kinase YSK1 by means of siRNA transfection also induced 
Golgi scattering. Notably blocking YSK1 function with a dominant-negative 
mutant abrogated cell migration into the wound (Preisinger, Short et al. 2004). 
Thereby there is a potential link not only between Golgi apparatus morphology 
and membrane trafficking, but also to cell migration and eventually focal 
adhesion turnover. However other cellular events can also influence Golgi 
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dispersal such as arrest in mitosis or defects in fatty acid and cholesterol 
biosynthesis (Bard, Casano et al. 2006), for this reason an interpretation of the 
results based on Golgi morphology should be made with care. 
To monitor changes in Golgi morphology cells split onto microarrays were 
fixed after 48 hours incubation time and stained with antibody against Golgi 
peripheral membrane protein GM130. Automatically acquired images were 
manually scored for defects in Golgi morphology, such as fragmentation of Golgi 
ribbons into smaller elements or Golgi aggregation and swelling (Figure 12). The 
secondary screen was repeated twice and those genes that showed the same 
phenotype were considered. I found that 33 out of 86 genes affecting vesicular 
transport to plasma membrane and focal adhesion size were also necessary for the 
maintenance of Golgi architecture (Table 2). 
Among the identified genes were several subunits of the coat protein 
complex COPI (copb, copb2, copg), their siRNA knockdown lead to a similar 
increase in focal adhesion size and aggregation of Golgi structure. COPI complex 
is an essential coat component of vesicles, participating in the anterograde 
transport within the Golgi and recycling to the ER. In the R. Pepperkokk 
laboratory siRNA oligonucleotides targeting beta-COP subunit (copb) has been 
previously validated and it has been shown that siRNA depletion of beta-COP 
severely reduced transport of the tsO45G protein to the cell surface (Erfle, 
Simpson et al. 2004). I decided to reproduce and investigate in more detail the 
influence of beta-COP knockdown on focal adhesion size and turnover. 
I performed “conventional” transfection of HeLa cells with beta-COP 
siRNA and observed first of all swelling of the Golgi apparatus labeled with 
GM130 antibodies (not shown) and secondly formation of enlarged paxillin-
stained adhesions at the cell periphery that mimicked the phenotype seen in the 
microarray screen (Figure 13). The focal adhesions were connected with 
prominent actin stress fibers aligned with the cell edge giving the cells a 
polygonal shape. The cell center of beta-COP depleted cells in contrast to cells 
transfected with scrambled siRNA was depleted of focal adhesions and actin  
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Figure 12| Defects in Golgi apparatus organization detected in microarray screen. | Left 
column represents examples of images acquired at 25x magnification during micro-array screen. 
Knockdown of ccdc124 and loc646643 genes caused fragmentation of the Golgi structure. 
Knockdown of beta-COP lead to the Golgi swelling. Images in the right column represent enlarged 










































Figure 13 | siRNA knockdown of beta-COP produces enlargment of 
focal adhesions and formation of peripheral actin stress fibers. | HeLa 
cells were transfected with Scrambled or beta-COP siRNAs for 55 hours, 
fixed and stained with anti-paxillin antibody (green), phalloidin (red) and 
Hoechst 33342 (blue).  
Scarmbled siRNA Beta-COP siRNA 
Figure 14 | Blocking of COPI- complex function with BrefeldinA lead to 
the enlargment of focal adhesions and formation of strong stress fibers.| 
HeLa cells were treated with 10 ug/ml BrefeldinA for 15 hours, fixed and 
stained with anti-paxillin antibody (green) and phalloidin (red).  
Control cells BrefeldinA treatment 
Figure 15 | beta-COP knockdown cells display increased focal adhesion turnover rate at the cell 
periphery. | HeLa cells with stable expression of GFP-Paxillin were transfected with negative control 
or beta-COP siRNAs for 55 hours and imaged for 120 minitues (1 frame per 30 sec). Arrows mark 
appearance of new focal adhesions at the cell edge of beta-COP depleted cells. Focal adhesions at the 
edge of negative control siRNA transfected cells remained mostly stable. Asterisks point to the 



























filaments. Other focal adhesion proteins vinculin and zyxin were likewise 
associated with the more prominent peripheral focal adhesions in cells with 
reduced beta-COP expression (not shown). 
It is interesting to mention that prolonged treatment of cells with Brefeldin 
A, a compound that inhibits COPI complex formation and disrupts Golgi 
structure, also leads to the enlargement of focal adhesions at the cell periphery, 
disassembly of inner focal adhesions and assembly of strong stress fibers (Figure 
14).  
An explanation for the enlarged peripheral focal adhesions in beta-COP 
depleted cells might be a change in the kinetics of focal adhesion turnover. To 
determine whether focal adhesion dynamics was impaired upon beta-COP 
knockdown I performed live imaging of cells stably transfected with fluorescent 
focal adhesion protein GFP-Paxillin and depleted of beta-COP. During 100 
minutes observation the formation and disassembly of focal adhesions at the cell 
periphery was markedly increased in beta-COP knockdown cells in comparison 
with negative control siRNA treated cells (Figure 15, Supplementary movie 1).  
I also examined spreading of beta-COP depleted cells on fibronectin. Upon 
beta-COP siRNA knockdown HeLa cells showed delay in spreading after the first 
two hours (Figure 16). Collectively, these data for the first time provided the 
evidence of the  involvement of beta-COP and thus the whole COPI complex in 
regulating focal adhesion organization and turnover as well as downstream 
processes such as cell spreading. Therefore the siRNA microarray method may be 
considered as a useful tool to identify a link between focal adhesion turnover and 
vesicular trafficking machinery.  
Next I performed detailed bioinformatics and database analysis of the final 
hits with a focus on their domain architecture, homologues in other species and 
expression profile. I excluded genes that might affect membrane trafficking as 
well as focal adhesion state indirectly through their roles in transcription 
regulation, protein translation or basic metabolism. I was interested in the 
evolutionary conserved genes with ubiquitous expression, preferably with 
predicted transmembrane domains. Finally I selected three genes with unknown 
function for the further characterization: KIF19, CCDC51 and TM4SF19. 
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CCDC51 (Coiled-coil Domain Containing 51) is a 46kDa highly conserved and 
ubiquitously expressed protein with two predicted transmembrane domains. 
Kinesin family member KIF19 belongs to a N-8 kinesin subfamily with N-
terminal motor domain and was shown to be expressed in brain, lung, ovary and 
testis (Miki, Okada et al. 2005). TM4SF19 is an uncharacterized ubiquitously 
expressed member of tetraspanin family with 4 transmembrane domains; the 
other members are involved in cell-substrate contact (Hemler 2005). Currently I 
am in the process of cloning the chosen genes with the further aim of determining 
their cellular localization and roles in vesicular transport and focal adhesion 
turnover. 
Figure 16 | beta-COP knockdown 
cells show delay in spreading on 
fibronectin. | HeLa cells were 
transfected with Scrambled or beta-
COP siRNAs for 55 hours, replated 
onto fibronectin-coated glass 
coverslips, incubated for 2 hours, 
fixed and stained with anti-paxillin 
antibody. Arrows mark beta-COP 
depleted cells that were unable to 




























I have adapted the siRNA microarray screening approach to find genes 
involved in focal adhesion organization and turnover. A special candidate-set of 
siRNA oligonucleotides targeting genes with known or predicted roles in cell 
adhesion or migration was created.  Using microarray platforms with spotted 
siRNAs from the candidate-set I have demonstrated that the microarray technique 
was suitable for detection of genes involved in focal adhesion turnover. However 
the number of identified genes was lower than I expected from the candidate set. 
Moreover an attempt to conduct systematical characterization of whole protein 
families (such as RhoGTPases or motor proteins) on the basis of their function in 
focal adhesion turnover was not successful. Below I will summarize and discuss 
the main caveats and limitations of the siRNA technique that could explain 
unsatisfactory efficiency of the performed screen. 
First of all siRNAs containing 21-23 nucleotides are less efficient triggers 
of RNAi-based gene suppression than long dsRNAs that can be used in 
invertebrates but not in mammalian cells due to the mammalian-specific antiviral 
response. siRNAs with different nucleotide sequences but targeting the same 
gene could have different efficiency of gene knockdown. Thus the right choice of 
siRNA sequence is a major determinant of the effective gene suppression. 
Especially proper design of siRNA sequences is important in large-scale 
experiments such as microarray screens when a degree of gene knockdown could 
not be estimated.  That is why most of the screens include multiple siRNAs 
targeting the same gene to increase the probability of obtaining efficient gene 
knockdown. Despite the use in my screen of 2 to 6 different siRNA sequences for 
each gene, only one of the siRNAs usually produced a knockdown phenotype and 
the proportion of the efficient siRNAs was only 30%. Therefore suboptimal 
siRNA oligonucleotide design might be one of the main reasons for low hit 
number. 
Secondly I monitored loss-of-function phenotypes only at single time 
point (50 hours after siRNA transfection) that was determined by optimal cell 
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density. However the appearance of the RNAi phenotypes is dependent on the 
protein half-life that may significantly vary from protein to protein. In some cases 
even a small residual amount of protein is sufficient to maintain its function 
therefore knockdown of stable proteins usually requires more time. This means 
that the phenotypes developing only after prolonged incubation after siRNA 
treatment were left undetected in my assay.  
Functional redundancy among proteins is the next issue that restricts 
identification of gene function by analysis of its knockdown phenotype (for 
review see (Thomas 1993)). For example only three motor proteins (two kinesins 
and one myosin) were identified in the screen; however more of them are 
expected to be involved in cytoskeleton and focal adhesion regulation. I suggest 
that in the absence of one particular motor protein other closely-related motors 
can transport its cargos. Combinatorial siRNA screen that would allow 
simultaneous knockdown of multiple motors in different combinations could be 
the next step toward uncovering motor proteins functions (for review see(Sahin, 
Loebke et al. 2007)). 
 A robust and unbiased assay is another important element that determines 
efficiency of the siRNA screen. Nocodazole wash-out assay is a valuable 
approach to dissect regulators of the focal adhesion disassembly (Ezratty, 
Partridge et al. 2005). But when applied to cells seeded onto microarray platforms 
it produced a highly variable response within a cell population and therefore was 
not considered as appropriate assay for large-scale experiments.  
For the primary focal adhesion turnover screen I chose a simple assay 
based on the visual changes in focal adhesion size upon siRNA knockdown that 
were monitored by eye. The manual scoring procedure can not provide precise 
quantitative measurements and reveals only the most obvious phenotypes leaving 
minor changes undetected. Thus the visual analysis method could also be one of 
the reasons for the low number of scored hits. Development of an automated 
processing program extracting quantitative data from the images could improve 
identification of the weak phenotypes but from the other side it could also 
increase the rate of false-positive hits. 
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It was interesting to compare the results of my candidate screen with the 
similar siRNA-based screen performed by K. Simpson and colleagues (Simpson, 
Selfors et al. 2008). Using candidate siRNA library targeted genes with known or 
predicted roles in cell migration and adhesion they were looking for genes 
involved in epithelial cell migration into the wound. There were 118 common 
genes between their and mine siRNA libraries. Among those genes they scored 9 
high confidence hits, 13 genes were picked up as hits in my screen, but only one 
gene was scored in both screens (Figure 17). The percentage of scored genes in 
Simpson’s and my screen were similar, 7.6% and 11% respectively. These two 
screens could not be directly compared because the assays used and cell types 
were different. However based on the fact that cellular movement is dependent on 
focal adhesion turnover a higher overlap between two screens would be expected.  
In my opinion the problems of the siRNA knockdown method together with assay 
limitations compromise the outcome of the screens making them unsuitable for 
complete systematic analysis of gene functions.  But on the other hand siRNA 
large-scale screens could be considered as one of the options for the fast 










Figure 17 | Schematic comparison of screen 
results. | Epithelial cell migration screen was 
performed by Simpson and colleges (Simpson, 
Selfors et al. 2008) to identify inhibitors and 
accelerators of MCF7-cell migration into the 
wound (blue circles). Focal adhesion turnover 
screen detected regulators of focal adhesion 
organization in HeLa cells (pink circles). For 
118 overlapped genes the hit-rates were around 
10% in both screens. Only one gene was 





With the aim to uncover a possible connection between vesicular 
trafficking and focal adhesion turnover I have performed a siRNA microarray 
screen looking for gene products whose knockdown affects cellular trafficking 
machinery and at the same time causes focal adhesion defects. For the screen I 
used a siRNA library against subset of genes identified in a genome- wide siRNA 
screen as regulators of constitutive protein trafficking to the plasma membrane 
(kindly provided by J. Simpson and R. Pepperkok). As an outcome of the screen 
33 genes important for the maintenance of focal adhesion organization as well as 
for the integrity of Golgi apparatus structure were detected. Disturbance of the 
Golgi structure was chosen as an indicator of vesicular trafficking alterations. 
Among final hits there were several subunits (copb, copb2, copg) of the 
well-characterized COPI complex that is essential for the Golgi to the 
endoplasmic reticulum (ER) and intra-Golgi membrane transport. A blockade of 
the Golgi-to-ER retrograde transport causes perturbations of Golgi organization 
and subsequently of anterograde trafficking pathway including secretory protein 
transport. Knockdown of a beta-COP subunit (copb) was shown to reduce 
transport of the viral glycoprotein ts-O45-G to the plasma membrane (Erfle, 
Simpson et al. 2004). I have demonstrated that siRNA-induced beta-COP 
suppression leads to the defects in focal adhesion turnover, actin cytoskeleton 
organization and cell spreading. Therefore functional vesicular trafficking 
machinery seems to play a role in the regulation of focal adhesion dynamics. 
However suppression of the COPI complex influences focal adhesion 
organization rather indirectly through the general perturbation of the vesicular 
trafficking system and does not provide insight into the specific vesicular 
membrane pathway involved in focal adhesion turnover.  
At the origin of the screen I hoped to identify genes that would highlight 
an element of the cellular transport machinery taking part in focal adhesion 
turnover. But the majority of the final hits turned out to be known or predicted 
transcription factors, DNA/RNA associated proteins, signaling peptides, receptors 
with rather general cell maintenance functions and unknown proteins. The role of 
some of those proteins especially transcription factors might be very important 
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for focal adhesion organization however their influence is not direct and they do 
not bring information about the core adhesion regulatory machinery. I chose three 
candidates (KIF19, TM4SF19, CCDC51) from the uncharacterized genes that are 
ubiquitously expressed, highly conserved and possess either motor or 
transmembrane domains. I intend in follow up studies to define their cellular 
localization and further characterize their roles in vesicular trafficking and focal 
adhesion turnover. 
The low number of specific vesicular trafficking genes identified in my 
screen may be explained by the nature of the exploited siRNA library created on 
the basis of the wide-genome screen performed in Pepperkok laboratory. It 
included siRNAs for genes found to be involved in the secretory transport of a 
viral ts-O45-G protein (Simpson, Cetin et al. 2007). First of all the trafficking 
pathway utilized by ts-O45-G could be different from the one involved in focal 
adhesion regulation. Secondly, the wide-genome screen had its own limitations 
that probably lead to the loss of some important vesicular trafficking genes and 
accumulation of false-positive genes affecting general house-keeping pathways. 
Notably the compiled siRNA library did not target major genes of the cellular 
vesicular system coding components of clathrin and caveolin vesicular pathways, 
and many important regulators of endocytic pathway such as Rab GTPases 
(Rab4, Rab5, Rab9) and their regulators. That is why a better approach would be 
to compose a specific set of siRNAs targeting genes with known or predicted 
function in vesicular trafficking (similar to the candidate siRNA library that was 
created for screening of adhesion and migration related genes). Such a library 
screened for focal adhesion dynamic defects may provide more information 









During the course of my work I noticed that a great part of loss-of-
function experiments including individual siRNA knockdown studies as well as 
siRNA large-scale screens (Kiger, Baum et al. 2003; Simpson, Selfors et al. 
2008) concentrated on the characterization of gene functions in very general 
processes such as cell migration or cell morphology. However identified defects 
in cell migration do not provide information about the particular cellular pathway 
in which a gene of interest is involved. I think that it would be very important in 
the future to dissect the roles of genes on a deeper level and look at the separate 
pathways of cell migration such as focal adhesion turnover. 
The screen that I initiated here represents a first step toward identification 
of cellular pathways regulating focal adhesion assembly and disassembly. An 
improvement of siRNA oligonucleotide design as well as development of 
appropriate automated phenotype analysis software will help to increase 
efficiency of the screen and expand it to a genome-wide scale. 
I have also demonstrated that vesicular trafficking pathway (likely 
different from ts-O45-G secretory route) is involved in focal adhesion turnover. 
In the future a siRNA screen with a candidate set of oligonucleotides may help to 






















As discussed earlier it has been suggested that the turnover of the main 
focal adhesion receptors integrins is dependent on a vesicular endocytotic 
pathway. I have demonstrated in the first part of my work that suppression of 
retrograde vesicular trafficking by knockdown of COPI complex or BrefeldinA 
treatment led to the alteration of focal adhesion organization and dynamics. 
However it is unclear whether the vesicular trafficking machinery is involved 
only in the transport of focal adhesion membrane components or also plays a role 
in the delivery of the adhesion’s cytoplasmic scaffolding and regulatory proteins. 
Several research groups have published evidence for a possible 
involvement of vesicular transport in the turnover of the focal adhesion protein 
paxillin. Moreover analysis of numerous paxillin immunolabelings during my 
siRNA screening project revealed an occasional appearance of distinct 
perinuclear vesicular structures. Therefore I focused on the role of vesicular 
transport in paxillin turnover. 
Paxillin is a 68kDa protein that was first purified in 1990 and 
characterized as a direct binding partner of another focal adhesion protein 
vinculin (Turner, Glenney et al. 1990). The C-terminal part of paxillin contains 
four LIM domains with double zinc-finger motifs. The N-terminal half includes 
five leucine- and aspartate-rich LD modules with the conservative consensus 
Figure 1 | Paxillin binding partners. | Paxillin contains multiple protein binding domains, 
including five N-terminal LD motifs and four C-terminal LIM domains. Represented binding 
partners were identified on the basis of various GST-pull down, coprecipitation and yeast two-hybrid 
experiments.  Adapted from Brown&Turner, 2004. 
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sequence LDxLLxx. Both types of paxillin domains were shown to be implicated 
in protein-protein interactions (Figure 1). The LIM domains serve as binding sites 
for tubulin and PTP-PEST tyrosine phosphatase; the LD motifs bind vinculin, 
FAK and ILK kinases, actopaxin and GIT1/GIT2 RhoGTPase activating proteins 
(for review see (Brown and Turner 2004)). Consistent with its multidomain 
structure paxillin is a scaffolding molecule that mediates a signal cross-talk 
between regulatory and structural proteins at focal adhesions. A recent review by 
Deakin and Turner comprehensively summarizes paxillin functions in the 
regulation of Rho GTPase signaling in the proximity of adhesion sites 
highlighting its role as a key element in cell polarization and migration (Deakin 
and Turner 2008). The critical role of paxillin was confirmed by the early 
embryonic lethality in mice upon gene disruption (Hagel, George et al. 2002). 
Cultured paxillin-null fibroblasts displayed abnormal focal adhesions and defects 
in cell migration. This suggests that paxillin is not essential for the formation of 
focal adhesions but is important for their maintenance or turnover (Hagel, George 
et al. 2002). Similar defects in cell motility were observed in paxillin-null 
embryonic stem cells (Wade, Bohl et al. 2002). 
Localization of paxillin to focal adhesions was shown to be dependent on 
the integrity of LIM2 and LIM3 domains (Brown, Perrotta et al. 1996), but the 
identity of the docking component at focal adhesion sites has not been 
determined. Paxillin was found to be one of the earliest proteins targeting to 
nascent adhesions at the cell edge that suggests its participation in the assembly 
of adhesions (Zaidel-Bar, Ballestrem et al. 2003; Digman, Brown et al. 2008). 
Conversely paxillin has also been demonstrated to contribute to focal adhesion 
disassembly. For example, overexpression of paxillin with mutations preventing 
its tyrosine phosphorylation at positions 31 and 118 impairs the disassembly of 
focal adhesions in migrating cells (Webb, Donais et al. 2004), implicating that a 
switch in paxillin phosphorylation is an important determinant of paxillin’s 
influence on focal adhesion dynamics. Thus paxillin targeting to focal adhesions 
is a prerequisite of their efficient turnover and apparently requires fine temporal 
and spatial regulation. 
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The pathway involved in paxillin targeting to focal adhesions remains to 
be clarified. In 1998 Mazaki and colleges showed that overexpressed paxillin 
localized not only to focal adhesion plaques but also to perinuclear vesicular-like 
structures located in the Golgi area (Figure 2) (Mazaki, Uchida et al. 1998). 
Several years later the same authors published immunoelectron microscopy 
images confirming localization of a significant fraction of paxillin to Golgi-like 
structures and unidentified membrane structures in the perinuclear region of 3Y1 
cells (Mazaki, Hashimoto et al. 2001). Based on these findings it was suggested 
for the first time that vesicular membrane trafficking was a possible mechanism 
of paxillin delivery to focal adhesions. 
In parallel it was discovered that microinjection of a constitutively active 
form of ARF1, a GTPase involved in the assembly of coated vesicles at the Golgi 
and thereby in vesicular trafficking, induced redistribution of paxillin from the 
cytoplasmic fraction to focal adhesion structures (Norman, Jones et al. 1998). 
Moreover microinjection of a dominant-negative mutant of ARF1 (∆17ARF1) 
was found to prevent LPA-induced assembly of paxillin-containing focal 
adhesions. These data provided the first strong evidences of a role of ARF1 
GTPase and hence the vesicular transport machinery in the recruitment of paxillin 
to focal adhesion structures. 
Additional support for the involvement of vesicular trafficking in paxillin 
localization came from studies of G-protein-coupled receptor kinase interacting 
proteins (GIT1 and GIT2), which possess ArfGTPase-activating protein 
(ArfGAP) domains and control the activity of several ARF GTPases including 
ARF1 (for review see (Hoefen and Berk 2006)). GIT2 (ubiquitously expressed) 
Figure 2 | Co-localization of paxillin with Golgi marker at the perinuclear area. | NIH3T3 cells 
were transfected with EGFP-paxillin (alpha-isoform) (red). Golgi was visualized by immunostaining 
with antibody recognizing 58kDa Golgi protein (green). Arrow highlight the area where EGFP-
paxillin co-localize with Golgi marker. Adapted from Mazaki et al., 1998. 
EGFP-paxillinGolgi 58kDa protein merge 
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and the closely related GIT1 (expressed in specific cell types) were shown to 
interact directly with the paxillin LD4 motif (Turner, Brown et al. 1999; Zhao, 
Manser et al. 2000; West, Zhang et al. 2001). GIT proteins are also involved in 
the formation of a molecular complex that contains PAK-interacting exchange 
factors (α- and β-PIX) and p21-activated kinase (PAK).  PIX proteins are 
guanine-nucleotide exchange factors (GEF) responsible for Rac1 and CDC42 
activation (for review see (Rosenberger and Kutsche 2006)). PAK kinase is 
activated by Rac1 or Cdc42 and catalyzes disassembly of stress fibers through 
phosphorylation of LIM kinase and myosin-light-chain kinase (for review see 
(Bokoch 2003)). Localization of the GIT-PIX-PAK complex to focal adhesion 
sites is dependent on GIT binding to paxillin and essential for coordination of 
Rac1 signaling during cell spreading and migration (West, Zhang et al. 2001; 
Brown, Cary et al. 2005). Expression of a paxillin mutant without the LD4 
sequence that is unable to recruit GIT-PIX-PAK complex leads to defects in focal 
adhesion turnover (Webb, Donais et al. 2004). 
GIT1 protein was found not only at focal adhesion sites but also at the 
cytoplasmic vesicular-like structures that were motile and moved toward the cell 
periphery or toward the cell body in retracting regions of the cells (Manabe, 
Kovalenko et al. 2002). GIT1 cytoplasmic structures contained paxillin (Figure 3) 
as well as other proteins of the GIT-PIX-PAK signaling complex and thereby 
were proposed to play role in the delivery of components to and from focal 
adhesions. However Manabe and colleges did not consider those vesicular 
structures important for paxillin turnover. 
Other experiments based on the overexpression of GIT proteins and their 
Figure 3 | GIT1 cytoplasmic complexes contain paxillin. | CHOK1 cells were transfected with 
EGFP-GIT1 (A) or stained with anti-GIT1 antibodies (C). Paxillin was visualized by 
immunostaining with anti-paxillin (B.D). Arrow highlight the cytoplasmic complexes where GIT1 
and paxililn co-localize. Adapted from Manabe et al., 2002. 
A B C D
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ArfGAP domain-mutants also demonstrated their ability to sequester paxillin 
from focal adhesions and recruit it to a vesicular-like cytoplasmic compartment 
(Di Cesare, Paris et al. 2000; Zhao, Manser et al. 2000; Mazaki, Hashimoto et al. 
2001; Paris, Za et al. 2002). However the nature of the observed vesicular-like 
compartment remained ambiguous: de Curtis and co-workers identified it as 
Rab11-positive recycling endosomes (Matafora, Paris et al. 2001; Paris, Za et al. 
2002), whereas Manabe and colleagues excluded the membrane nature of GIT1 
and paxillin containing structures (Manabe, Kovalenko et al. 2002). Finally a 
hypothetical model was proposed according to which direct interaction of the 
GIT-complex with paxillin induces its re-localization away from focal adhesions 
and regulates its recycling back through a vesicular endocytic compartment to the 
cell periphery to newly formed focal adhesions (Figure 4, (Matafora, Paris et al. 
2001)). 
 In addition, overexpression or downregulation of other ArfGAP family 
members (PAG3, ACAP1, ASAP1) also leads to the redistribution of paxillin 
from focal adhesions (Kondo, Hashimoto et al. 2000; Liu, Loijens et al. 2002; 
Liu, Yerushalmi et al. 2005). In summary, the role of ArfGAP proteins in paxillin 
localization highlights a possible connection between ARF-dependent vesicular 
trafficking and paxillin transport to focal adhesions. 
Figure 4 | Schematic model of paxillin vesicular recycling. | Paxillin interaction with GIT-PIX-
PAK complex induces its re-localization away from focal adhesions. GIT and PIX proteins are 
responcible for the localization of paxillin to the recycling endocytic compartment. ARF-GAP 
domain of GIT is important for the regulation of paxillin vesicular transport back to the cell surface. 
Active form of Rac can be an important determinate of the translocation of paxillin and GIT 







However the aforementioned data provide rather indirect evidences of 
paxillin vesicular recycling and do not reveal the exact mechanism. Further 
progress towards elucidating the paxillin trafficking process was considerably 
hampered by the inability to visualize paxillin-containing vesicular structures in 
living or fixed cells in standard conditions by conventional microscopy. Since the 
first report 10 years ago the existence of paxillin vesicular structures has not been 
confirmed. 
 I supposed that a block in paxillin targeting to focal adhesions might lead 
to its enhanced accumulation in putative vesicular structures which then might 
become visible by means of conventional microscopy. Therefore I created a 
series of paxillin mutants defective in focal adhesion targeting and demonstrated 
that those mutants indeed redistributed to the cytoplasmic vesicular-like 
structures which were clearly observed in live cells. Moreover I determined that 
the vesicular-like structures containing paxillin mutants belonged to the clathrin 
trafficking pathway. I also showed that wild type paxillin could localize to a 
subset of clathrin vesicles and interact with their components. As a conclusion 
from the performed experiments I suggest that accumulation of paxillin mutants 
defective in focal adhesion binding in the clathrin vesicles reflects the existence 
of a clathrin-dependent trafficking pathway involved in paxillin recycling and 
therefore in focal adhesion turnover. Using the RNAi approach I confirmed a role 




1. Antibodies and reagents 
The following antibodies were used: mouse monoclonal antibody to mRFP 
(kindly provided by Dr. Jan Faix, Hannover Medical School, Germany), paxillin 
and clathrin heavy chain (BD Transduction Laboratories #P13520, #C43820); 
polyclonal rabbit antibody to GIT1 (Cell Signaling #2919) and EpsinR 
(ProteinTech Group, Chicago, #10470-1-AP). The secondary antibodies Alexa 
Fluor 568, Alexa Fluor 488, Alexa Fluor 350 were purchased from Molecular 
Probes, Invitrogen. 
2. DNA Constructs 
Human EGFP-Paxillin was provided by Ravi Salgia (Salgia, Li et al. 1995), 
EGFP-Clathrin Light Chain A was kindly provided by C. Rottner (HZI, 
Braunschweig), EGFP-fused Rab GTPases (Rab 1A, Rab 2A, Rab21, Rab 5A, 
Rab 11A, Rab 8A, Rab 9A, Rab7) were kindly provided by J. Simpson (EMBL, 
Heidelberg, Germany).  
3. Plasmid Construction and Site-directed Mutagenesis 
Coding sequence of the human paxillin was amplified from EGFP-Paxillin 
using primers incorporating EcoRI and KpnI restriction sites (Forward:GGA 
ATT CGG ATG GAC GAC CTC GAC GCC CTG; Reverse: GG GGT ACC 
CTA GCA GAA GAG CTT GAG GAA GCA) and ligated into mRFP-C3 vector 
(provided by R. Tsien, University of California, USA). The site-directed 
mutagenesis was performed according to the instruction manual using 
QuikChange Site-Directed Mutagenesis Kit (Stratagene). Primers are indicated in 
the Table1.  
To generate paxillin construct with deletion of the LIM3 domain (mRFP-
Paxillin-∆LIM3), the entire mRFP-Paxillin plasmid excluding only LIM3 
sequence was amplified with primers containing SalI restriction site 
(Forward∆LIM3: CAT GTC GAC TGT GAG GTG CAC TAC; Reverse∆LIM3: 
GTA GTC GAC CTT GGG TGC GAA CAT). Amplification product was 
digested with SalI and re-ligated back into circular plasmid. Similar procedure 
with specific primers containing BcuI restriction site was performed to create 
paxillin constructs with deletion of the LD4 domain (Forward∆LD4: CAG ACT 
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AGT ACA GGG AGC AGC TCA C; Reverse∆LD4: GTC ACT AGT CCT GGT 
GGC AGA GGA G). 
To construct a prokaryotic expression vector encoding the GST-GFP fusion 
protein, the sequence of the EGFP protein was amplified from EGFP-C3 vector 
(BD Bioscience) with primers containing EcoRI and XhoI sites (Forward: C 
GAA TTC TTT AGT GAA CCG TCA GATC; Reverse: CTT GAG CTC GAG 
ATC TGA GTA CTT G). The amplification product was introduced into pGEX-
4T-1 vector (GE Healthcare) using EcoRI and XhoI restriction enzymes. 
Afterward sequence of the paxillin or paxillin-2C/A mutant was amplified using 
primers with EcoR1 and NheI restriction sites and introduced into the  previously 
created GST-GFP-vector between GST and GFP sequences (Forward: A GAA 
TTC ATT CGG GGG ATG GAC G; Reverse: GGC TAG CGA GCA GAA GAG 
CTT GAG). 
4. Cell culture and transfection 
Hela cells (gift of Yuko Kiyosue, KaN Research Institute, Kyoto) were 
maintained in DMEM (Gibco #31885-023) supplemented with 10% Fetal Calf 
Serum (PAA Laboratories) and penicillin/streptomycin (Gibco #15140-122). RPE 
cells (hTERT RPE-1) were cultured in DMEM F12 (Sigma), 10% Fetal Bovine 
Serum (Sigma), 7.5% Sodium bicarbonate, L-glutamine and 
penicillin/streptomycin. HT1080 (gift of Dr. J. Schwarzbauer, Princeton 
University) were cultured in DMEM supplemented with 10% FBS (Hyclone), L-
 Forward primer 
C465A GGC ATC CTG AGG CCT TTG TGT GCC GGG AAT 
C468A CCT GAG GCC TTT GTG GCC CGG GAA TGC TTC ACG 
C445A C AAG TGT GGC GGC GCA GCC CGG GCC ATC CTG 
C489A GAC GGG CAG CCC TAC GCT GAG GTG CAC TAC C 
?LIM3 CAT GTC GAC TGT GAG GTG CAC TAC 
?LD4 CAG ACT AGT ACA GGG AGC AGC TCA C 
 Reverse primer 
C465A CAT TCC CGG CAC ACA AAG GCC TCA GGA TG 
C468A CGT GAA GCA TTC CCG GGC CAC AAA GGC CTC AGG 
C445A CAG GAT GGC CCG GGC TGC GCC GCC ACA CTT G 
C489A G GTA GTG CAC CTC AGC GTA GGG CTG CCC GTC 
?LIM3 GTA GTC GAC CTT GGG TGC GAA CAT 
?LD4 GTC ACT AGT CCT GGT GGC AGA GGA G 
Table 1 | Primers for site-directed mutagenesis 
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glutamine and penicillin/streptomycin. HeLa cells were transfected using 
Superfect (Quiagen) according to the manufacture protocol. RPE and HT1080 
cells were transfected with FuGENE6 (Roche) according to the manufacture 
protocol. 
5. Immunostaining 
For immunostaining cells were split on coverslips coated with fibronectin ( 10 
ug/ml, Roche). Cells were fixed in 4% PFA for 20 minutes. For the staining cells 
were permeabilized with 0.05% Triton X-100 in 1xPBS for 5 minutes. After 15 
minutes wash (3 times 5 minutes with 1XPBS) coverslips were incubated for 1 
hour with primary antibody, washed with 1xPBS (3 times 10 minutes with 
1XPBS) and incubated for 1 hour with secondary antibody. Cell nuclei were 
stained with 1 ug/ml Hoechst 33342 (Sigma-Aldrich) in 1xPBS for 10 minutes. 
For immunostaining of focal adhesions and actin cytoskeleton cells were fixed in 
a mixture of 3% Triton X-100 and 3% PFA for 3 minutes followed by fixation in 
3%PFA for 35 minutes and standard incubation with antibodies. Actin was 
labeled with Alexa Fluor 568-Phalloidin (Molecular Probes, Invitrogen). 
Coverslips were subjected to immunostaining or upon transfection were directly 
mounted on the slides with Prolong Gold (Molecular Probes) and dried at room 
temperature over night. 
6. siRNA transfection 
HeLa cells were seeded in 12-well plates (1,0x105 cells per well) 24 hours 
before transfection. siRNA oligonucleotides targeting human clathrin heavy chain 
(UAAUCCAAUUCGAAGACCAAU, Motley, Bright et al., 2003), human 
EpsinR (AAUACAGAUAUGGUCCAGAAA, Hirst, Miller et al., 2004) and also 
Silencer Negative Control #2 siRNA (catalog # 4613) were produced by Ambion 
and stored at -20°C as 50 uM working stocks. Mixtures of 6 ul Oligofectamine 
(Invitrogen) with 24 ul OPTIMEM (Gibco) and 3 ul siRNA with 100 ul 
OPTIMEM were prepared separately and incubated at room temperature for 7 
minutes. Solutions were combined by gentle pipetting up and down and left for 
20 minutes at room temperature. Culture medium was changed to the medium 
without antibiotics. The transfection mix was carefully added to the center of 
each well. On the next day cells were split on coverslips coated with fibronectin 
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(10 ug/ml, Roche). Fixation and immunostaining procedures were performed as 
described. siRNA knockdown of EpsinR was examined after 72 hours. For 
Clathrin Heavy Chain siRNA two transfections were performed two days apart, 
and experiments were carried out 2 days after the second knockdown.  
7. Transferrin Uptake assay 
Cells were starved for 45 minutes in DMEM with 0.2% BSA, incubated with 
25 ug/ml Alexa Fluor 568 transferrin (Molecular Probes, Invitrogen) in the same 
medium for 15 minutes at 37°C, washed with 1xPBS and fixed as described for 
immunostaining. 
8. Transwell migration assay 
The Transwell cell migration assay was performed using transwell 12-well 
plates with the membrane pores of 8 um in diameter (Greiner). Cells were starved 
in serum-free medium with addition of 0.2% BSA overnight. Afterward 3-4x105 
cells were plated in the serum-free medium to the upper well. The lower 
compartment was filled with medium containing 10% FCS, and cells were 
allowed to migrate overnight. Inserts were transferred into fresh 12-well plates 
filled with Trypsin-EDTA and incubated for 10 minutes at 37°C. Cells were 
deattached from the membrane by gentle shaking of the plate, the inserts were 
removed and cells left in the wells were counted with hemocytometer. 
9. Immunoprecipitation 
Confluent cells from a 10 cm culture dish were harvested by trypsination and 
lysed on ice for 20 minutes in 250 ul of lysis buffer LBII (50 mM Tris-HCl pH 
7.4, 2 mM EDTA, 75 mM NaCl, 1% Triton X100, 10% Glycerol, 0.05 mM DTT 
supplemented with complete protease inhibitors (Roche)). The lysate was cleared 
by centrifugation (at 13000xg for 15 minutes at 4°C). Protein G-Sepharose beads 
(40 ul, GE Healthcare) were pre-coupled with anti-mRFP antibody (4 ug) in 
500ul 0.01% TritonX-100 in 1xPBS during 1 hour at 4°C. The beads were 
washed twice with 1 ml of IP buffer (50 mM Tris-HCl pH 7.4, 5 mM EDTA, 150 
mM NaCl, 0.1% Triton X100 supplemented with protease cocktail inhibitors 
tablets (Roche)). Thereafter beads were incubated for 2 hours at 4°C with 250 ul 
of crude lysate or 250 ul of particle fraction adjusted to 500 ul with IP buffer. 
Subsequently the beads were washed three times with IP buffer (30 minutes) and 
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resuspended in 50 ul of 2xSDS protein loading buffer, boiled for 10 minutes and 
centrifuged for 3 minutes at 10000xg. Proteins were detected by immunoblotting 
using appropriate antibodies. For mass spectrometry analysis immunoprecipitates 
were eluted with 0.1 M Glycine-HCl buffer pH 2.5. Beads were incubated twice 
with 50 ul of the buffer for 5 minutes, eluates were combined and immediately 
adjusted to a physiological pH by addition of 1.0 M Tris pH 7.5 (10 ul for 100 ul 
of eluate volume). 
10. Cell fractionation 
Protocol was adopted from Guillemin et al., 2005. Confluent cells from a 10 
cm culture dish were harvested by trypsination and resuspended for 5 minutes on 
ice in 500 ul CLB buffer ( 10 mM HEPES, 10mM NaCl, 1 mM KH2PO4, 5 mM 
NaHCO3, 5mM EDTA, 1 mM CaCl2, 0.5 mM MgCl2). Homogenization was 
performed by applying 12 strokes with a syringe (26G needle). Then 50 ul of 2.5 
M sucrose was added to restore isotonic conditions. The first round of 
centrifugation was performed at 6300xg for 12 minutes in a tabletop centrifuge. 
Supernatant was centrifuged at 107000xgfor 30 minutes using S100AT 4-463 
rotor (Sorvall, RC-M150 GX ultracentrifuge). The resulting pellet representing 
the particle fraction with vesicular membranes was resuspended in 100 ul or 250 
ul of the LBII buffer.  
11. GST-Pull down assay 
Cellular lysates were prepared as described for immunoprecipitation. 
Gluthatione-Sepharose 4B beads (GE Healthcare) were incubated first for 1 hour 
at 4°C with 10 ug of the recombinant GST-proteins in 500 ul of 0.01% Triton 
X100 in 1xPBS. Beads were washed twice with 1 ml of the IP buffer and 
incubated with 250 ul of the cell lysate adjusted to a final volume of 500 ul with 
IP buffer. Thereafter beads were washed three times for 30 minutes, boiled in 50 
ul of 2xSDS protein loading buffer for 10 minutes and centrifuged for 3 minutes 
at 10000xg. Proteins were detected by immunoblotting with specific antibodies. 
12. Purification of GST-Paxillin-GFP fusion proteins 
GST-GFP and wild type and mutant GST-Paxillin-GFP were expressed in 
Escherichia coli BL21 and affinity purified from the crude lysates with 
Gluthatione-Sepharose 4B according to the specifications of the manufacture (GE 
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Healthcare). Briefly, 500 ml exponentially growing cultures were induced with 
0.1 mM IPTG at 16°C overnight. Cells were harvested by centrifugation and 
sonicated in 25 ml of 1xPBS on ice in short bursts. Triton-X100 was added to the 
lysate to a final concentration of 1% and incubated for 30 minutes at 4°C. After 
centrifugation (10 minutes 12000xg) the supernatant was incubated with 500 ul 
50% Gluthatione-Sepharose 4B slurry for 30 minutes at room temperature. The 
GST-fusion proteins were eluted with the help of disposable columns using 250 
ul of elution buffer (50 mM Tris-HCl, 10 mM reduced gluthatione (Sigma) pH 
8.0). Four eluate fractions were collected and combined. The integrity of the 
purified proteins was controlled by SDS-PAGE electrophoresis and Coomassie 
Blue staining. Eluted proteins were extensively dialyzed against Microinjection 
buffer (2mM Tris-acetate pH 7.0, 50 mM KCl, 0.1 mM DTT) using Slida-A-lyzer 
Dialysis Cassette (Pierce).  Recombinant proteins were concentrated with 
Vivaspin columns (Sartorius stedim biotech). Concentration of the proteins was 
adjusted to 1.6 mg/ml with microinjection buffer. 
13.  Live microscopy and microinjection 
Live-cell videos were acquired on a Zeiss Axiovert 200M inverted microscope 
equipped with a rear-illuminated, cooled CCD camera (Micromax or Cascade, 
Roper), halogen lamp, and filter wheel and shutters controlled with Metamorph 
software. Images were collected in one or two fluorescent channels with 
100x1.46 NA Plan-Apochroma objective (designed for TIRF). During imaging 
cells were maintained in an open heating chamber (Warner instruments) at 37°C 
in the complete medium supplemented with 15 mM HEPES. 
Injections were performed with sterile Femtotips (Eppendorf) held in a 
micromanipulator with a pressure supply from an Eppendorf Microinjector 5242. 
Cells were injected with a continuous outflow mode from the needle under a 






The domain structure of the paxillin molecule is shown in Figure 1. The 
LIM domains of paxillin are unique cysteine-rich motifs that form a double zinc 
finger structure with the consensus sequence CX2CX16-23(C/H)X2CX2CX2CX16-
21CXX(D/H/C) and are found in a variety of proteins including transcription 
factors and other focal adhesion components (Hic5, Zyxin) (Michelsen, 
Schmeichel et al. 1993; Schmeichel and Beckerle 1994; Konrat, Weiskirchen et 
al. 1997). Each zinc finger is stabilized through the chelation of one molecule of 
zinc by a combination of four cysteine, hystidine, or aspartate amino acid 
residues. In 1996 Brown and colleagues demonstrated that point mutations of 
zinc chelating cysteins affecting the formation of the first and second zinc-fingers 
of LIM3 as well as deletion of the entire LIM3 domain eliminated paxillin 
targeting to focal adhesions (Brown, Perrotta et al. 1996). Based on the studies of 
the similar mutations the LIM2 domain was suggested to influence the efficiency 
of the paxillin binding to adhesions. Recently Kaverina and co-workers 
demonstrated that separate GST-fused LIM2 or LIM3 domains injected into cells 
localized only weakly to focal adhesions, whereas a GST-LIM2-LIM3 construct 
was localized strongly (Efimov, Schiefermeier et al. 2008). Therefore 
cooperativity between LIM2 and LIM3 domains is essential and sufficient for 
effective localization of paxillin to focal adhesions. 
Figure 1 | Schematic representaion of mRFP-Paxillin molecule with detailed sructure of LIM3 
domain . | Paxillin LIM3 domain forms a double zinc-finger structure. Each zinc finger is stabilized 
through the chelation of one molecule of zinc by a combination of four cysteine residues. 
82 
 
I proposed that paxillin defective in focal adhesion binding might 
accumulate in putative vesicular structures involved in its recycling. In order to 
check my hypothesis I generated a paxillin mutant with amino-acid substitutions 
of two chelating cysteins in the LIM3 domain and fused it to mRFP (monomeric 
red fluorescent protein) at the C-terminal end (mRFP-Paxillin-C465A/C468A 
later named as mRFP-Paxillin-2C/A).  Upon transfection into different cell lines 
(HeLa, RPE, HT1080) this paxillin mutant localized only residually to focal 
adhesions compared to the mRFP-Paxillin-Wild Type (WT) construct and 
concentrated instead in numerous cytoplasmic vesicular-like structures (Figure 
2). Similar vesicular-like structures were observed upon overexpression of the 
identical mutant fused to EGFP that excluded the possibility of unspecific protein 
aggregation caused by the mRFP-tag (data not shown).  Upon prolonged 
overexpression Paxillin-2C/A induced the appearance of abnormally large 
“vesicles”, therefore all subsequent experiments were performed after 10-12 
hours upon transfection (Figure 2, D). 
Upon live imaging, stable as well as fast moving mRFP-Paxillin-2C/A-
containing structures were detected. The movement of the vesicular-like 
structures was abolished by nocodazole and was thus dependent on an intact 
microtubule network (Figure 3, Supplementary movie 2). In addition, the mRFP-
Paxillin-2C/A punctate structures underwent apparent fusion and budding events.  
On the basis of the described observations I concluded that mRFP-Paxillin-2C/A 






Figure 2 |Localization of mRFP-Paxillin-2C/A mutant to intracellular vesicular-like structures. | 
mRFP-Paxillin-Wild Type (WT) efficiently localized to focal adhesions upon transfection in HeLa cells 
(A). mRFP-Paxillin-2C/A concentrated at the cytoplasmic vesicular-like structures upon transfection in 
HeLa (B) and RPE cells (C). Prolonged overexpression time of mRFP-Paxillin-2C/A led to the formation 
of abnormal large vesicular-like structures marked by arrows (D, RPE cell). Cells were subjected to 







Figure 3 | Movement of mRFP-Paxillin-2C/A structures is dependent on intact microtubule 
network. | HT1080 cells were transfected with mRFP-Paxilin-2C/A  and imaged at 3 s interval before 
and after Nocodazole addition (A, B, Supplementary movie 2). Overlays of the frames (1,4,7 frames in 
green, 2,5,8 – in red; 3,6,9 – in blue) demonstrate complete inhibition of vesicular movement upon 
nocodazole treatment. The arrow indicates example of fast moving mRFP-Paxillin-2C/A vesicle, the 




Paxillin  accumulation  in  the  vesicular­like  structures  is  reversely 
dependent on the focal adhesion binding efficiency  
To exclude the possibility that mutations of the two particular cysteines 
(C465A and C468A, Figure 1) caused unspecific binding of paxillin to vesicular-
like structures, additional paxillin mutants with alternative mutations in the LIM3 
domain were created:  mRFP-Paxillin-C445A with disruption of only the first 
zinc-finger, mRFP-Paxillin-C489A with disruption of only the second zinc-
finger, and mRFP-Paxillin-∆LIM3 with deletion of the entire LIM3 domain. 
Upon transfection into HeLa cells all paxillin mutants showed enhanced 
accumulation in the similar vesicular-like structures (data not shown). However 
within the same cell population each of the paxillin mutants was observed not 
only in the vesicular-like structures, but also in focal adhesions or diffusively 
distributed in the cytoplasm (Figure 4). Cytoplasmic labeling appeared particulate 
in nature but the vesicular structures could not be clearly resolved (Figure 4C, 
enlarged rectangle). In the majority of ells the paxillin constructs displayed 
predominant localization either in the vesicular-like structures or in focal 
adhesions. Other cells showed simultaneous localization of the paxillin mutants 
in vesicular-like structures and focal adhesions (Figure 4D). In this case focal 
adhesion binding was less efficient as suggested by a weaker intensity of 
adhesion labeling.  
 I calculated the percentage of cells exhibiting predominant vesicular, 
focal adhesion or cytoplasmic localization of each transfected mutant or wild type 
paxillin. The histogram (Figure 4E) shows that wild type paxillin localized to 
focal adhesion sites in more than 90% of cells examined. Notably a fraction of 
the wild type paxillin was also found in the cytoplasm with concentration in the 
perinuclear area consistent with the previous studies demonstrating existence of 
the paxillin pool in the perinuclear Golgi region (as discussed in the Introduction, 
(Mazaki, Uchida et al. 1998), 1998, Figure 4A). The paxillin cytoplasmic fraction 
seemed to have a vesicular nature (Figure 4A, enlarged rectangle). 
The integrity of the first but not the second LIM3 zinc finger was more 
important for paxillin binding to focal adhesions, as reflected by the smaller 
percentage of cells with focal adhesion localization of mRFP-Paxillin-C445A in 
comparison with mRFP-Paxillin-C489A (16% and 31% respectively). Disruption 
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of both zinc-fingers in the LIM3 domain (mRFP-Paxillin-2C/A) almost 
completely eliminated paxillin binding to focal adhesions and led to its 
accumulation in vesicular-like structures in 50% of the cells. 
 Surprisingly, deletion of the entire LIM3 domain did not have such a 
crucial impact on paxillin adhesion localization and mRFP-Paxillin-∆LIM3 was 
found at focal adhesions in 32% of cells. This data is in contrast with the original 
studies of Brown and colleagues demonstrating that deletion of the LIM3 domain 
abrogated paxillin targeting to focal adhesions completely (Brown, Perrotta et al. 
1996). However they expressed chicken paxillin in hamster CHO.K1 cells and 
analyzed paxillin localization by immunostaining with polyclonal antiserum 
specifically recognizing the chicken isoform of paxillin. Their method was likely 
not sensitive enough to detect residual binding of paxillin mutants to focal 
adhesions or to paxillin-containing vesicular structures. In my experiments I 
utilized a more direct method and observed living cells or cells fixed without any 
further manipulations. 
First, as a conclusion from the localization analysis of different LIM3 
mutants I suggest that paxillin targeting to focal adhesions does not depend 
exclusively on the LIM3 domain. In the absence of the intact LIM3 domain it 
may be mediated by another motif, likely the LIM2 domain as supported by the 
previous studies (Brown, Perrotta et al. 1996; Efimov, Schiefermeier et al. 2008). 
Secondly paxillin redistribution to vesicular-like structures is not a consequence 
of specific mutations but is observed for each paxillin mutant that failed to 
localize efficiently to focal adhesions. Moreover wild-type paxillin is also likely 
localized to the vesicular-like structures in the perinuclear area but they can not 
be clearly resolved by conventional microscopy. 
And finally there is an inverse correlation between the ability of paxillin 
to target to focal adhesions or vesicular structures. Accordingly I hypothesize that 
the presence of paxillin mutants in vesicular structures reflects the existence of 
trafficking vesicles involved in paxillin transport that can’t be resolved by 
conventional fluorescent microscopy under standard conditions. When paxillin is 
defective in focal adhesion binding it is retained at the putative transporting 
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vesicles and leads to their stabilization and enlargement and thereby makes them 
distinctly visible. 
Figure 4 | Heterogeneous localization of expressed paxillin mutants. | Upon expression in HeLa cells 
paxillin mutants showed focal adhesion (A), vesicular (B) or diffuse cytoplasmic (C) localization in 
different cells of the same population. Enlarged rectangular regions at the left demonstrate putative 
particle nature of the cytoplasmic staining. (D) In some cells paxillin mutants were located at the 
vesicular-like structures and at focal adhesions simultaneously (mRFP-Paxillin-C489A expression, 
arrows mark weak focal adhesion labeling). Histogram shows percentage of cells exhibiting adhesion, 
vesicular or cytoplasmic localization of the expressed mutant (E). The blue curve highlights the efficiency 
of focal adhesion binding of different mutants. The green curve highlights the efficiency of their vesicular 
localization. HeLa cells were transfected with the following constructs: mRFP-Paxillin-WT, mRFP-
Paxillin-C489A, mRFP-Paxillin-∆LIM3, mRFP-Paxillin-C445A, mRFP-Paxillin-2C/A. More than 200 





































To determine the nature of the vesicular-like structures containing paxillin 
defective in focal adhesion targeting I examined their co-localization with various 
GFP-tagged Rab GTPases – molecules involved in vesicular membrane fusion 
and budding. Different Rab proteins function in distinct parts of the trafficking 
pathway and provide convenient markers of certain vesicular compartments. The 
tested Rab GTPases included Rab1A and Rab2A which are specifically involved 
in ER-to-Golgi trafficking, Rab21 and Rab5A which are markers of early 
endosomes, Rab11A and Rab8A - markers of recycling endosomes and Rab9A 
and Rab7 - markers of late endosomes (for the review see (Zerial and McBride 
2001). However none of the aforementioned RabGTPases showed significant co-
localization with mRFP-containing vesicular structures (Figure 5).  
In addition the paxillin mutant did not co-localize with vesicles containing 
internalized fluorescent transferrin (Figure 6). Transferrin is a ligand of the 
transferrin receptor that is constitutively internalized from the cell surface in 
clathrin-coated vesicles, delivered to the sorting or recycling endosomes and 
transported back to the plasma membrane. Transferrin recycling was shown to be 
dependent on Rab5, Rab4 and Rab11 GTPases. Therefore the absence of the 
overlap between paxillin mutant and transferrin signals was in agreement with the 
lack of its co-localization with Rab5 and Rab11 in the previous experiment.  
Since I was unable to co-localize paxillin mutant-containing structures 
with any of the available vesicular pathway markers I adopted a biochemical 
approach. I purified the cellular particle fraction enriched in vesicular membrane 
components using standard ultracentrifugation. The amount of the expressed 
mRFP-Paxillin-2C/A found in the particle fraction was significantly higher in 
comparison with mRFP-Paxillin-WT, whereas their expression levels in crude 
lysates were similar (Figure 7A). Afterwards I performed immunoprecipitation of 
the mutant and wild-type paxillin proteins from the particle fraction using an anti-
mRFP antibody followed by mass spectrometry analysis of the 
immunoprecipitates. As demonstrated in Figure 7B the recovery of the mutant 
protein from the particle fraction was more efficient than recovery of the wild- 
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Figure 5 | mRFP-Paxillin-2C/A structures did not contain any of the tested RabGTPases. | HeLa cells were 
co-transfected with mRFP-Paxilin-2C/A (in red) and one of the following GFP-tagged RabGTPases (in green): 
Rab1A and Rab2A (markers of ER-to-Golgi trafficking pathway), Rab21 and Rab5A (markers of early 
endosomes), Rab11A and Rab8A (markers of recycling endosomes), Rab9A and Rab7 (markers of late 
endosomes). There is no significant overlap between green- and red-colored structures on the merge images. 
Cells were fixed and subjected to fluorescent microscopy. 
Figure 6| GFP-Paxillin-2C/A vesicular-like 
structures do not co-localize with endocytotic 
vesicles containing transferrin. | Hela cells 
transfected with GFP-Paxillin-2C/A (in green) 
were incubated for 30 minutes at 37°C with 
Alexa568-labeled transferrin (in red). The cells 
were than washed and fixed.   
Figure 7 | Immunoprecipitation of expressed paxillin proteins from cellular particle fraction. | (A) 
Immunoblot  showing enrichment of mRFP-Paxillin-2C/A in particle fraction in comparison with mRFP-
Paxillin-WT. (B) Immunoblot showing mRFP-Paxillin-2C/A and mRFP-Paxillin-WT precipitated from 
the particle fraction using anti-mRFP antibody. Particle fraction was purified according to the protocol 












type paxillin. The low level of the wild type paxillin in the immunoprecipitate did 
not allow its identification by mass spectrometry analysis. Mass spectrometry 
analysis of the mRFP-Paxillin-2C/A precipitate detected paxillin itself and 
number of its binding partners presented in Table 1. Mass spectrometry analysis 
was repeated twice for two independent experiments and proteins found in the 
negative control immunoprecipitate from untransfected cells were excluded from 
the final results.  
As shown in Table 1 mass spectrometry analysis identified the well-
known paxillin binding partners - GIT1, GIT2 and beta-PIX proteins as well as 
tubulin.  GIT1 and GIT2 proteins were demonstrated to bind both paxillin and 
beta-PIX directly, forming a signaling complex involved in the regulation of cell 
protrusion and migration (as discussed in the Introduction). Tubulin was 
identified as a direct paxillin binding partner in a yeast two-hybrid screen 
(Herreros, Rodriguez-Fernandez et al. 2000) and  later on confirmed by GST-pull 
down experiments to bind to the LIM2 and LIM3 domains of paxillin (Brown and 
Turner 2002). Paxillin binding to tubulin was shown to play a role in the 
regulation of microtubule dynamics, particularly catastrophe events at focal 
adhesion sites (Efimov, Schiefermeier et al. 2008). Detection of tubulin and 
components of the GIT-signaling complex confirmed that I was able to isolate 
paxillin-binding partners combining immunoprecipitation from the enriched 
particle fraction with mass spectrometry analysis. 
 Notably several components of clathrin vesicles emerged as binding 
Table 1 | Binding partners of 
mRFP-Paxillin-2C/A detected 
by mass spectrometry 
analysis. | Identified binding 
partners of mRFP-Paxillin-
2C/A included components of 
the well-known GIT-PIX 
signaling complex as well as 




GIT1 ARF-GTPase activating protein GIT1
GIT2 ARF-GTPase activating protein GIT2
ARHGEF7 Rho-guanine nucleotide exchange factor beta-PIX
CLTC clathrin heavy chain 1
CLTA Clathrin light chainA
CLTB Clathrin light chain B
CLINT1 Clathrin interacting protein, Epsin R
PIK3C2A Phosphoinositide 3 kinase, class 2, alpha
TUBB1 Tubulin beta-1 chain

























































partners of mRFP-Paxillin-2C/A (Table 1): clathrin heavy chain, two clathrin 
light chains, the clathrin adaptor protein EpsinR and phosphoinositide 3-kinase 
C2alpha (PIK3C2A). Clathrin heavy chain and light chains form the lattice-like 
coat of the vesicles that are endocytosed from the plasma membrane or bud from 
the intracellular trans-Golgi network (TGN). When coating membranes, clathrin 
does not bind to the membrane directly but does so via adaptor proteins. One of 
those adaptor proteins is EpsinR that simultaneously binds to clathrin and 
phosphoinositides at the membrane (preferentially PtdIns(4)P) and has been 
localized to the TGN and to the endosomal structures (Kalthoff, Groos et al. 
2002; Wasiak, Legendre-Guillemin et al. 2002; Hirst, Motley et al. 2003; Mills, 
Praefcke et al. 2003; Saint-Pol, Yélamos et al. 2004). Phosphoinositide 3-kinase 
C2alpha (PIK3C2A) was detected in a subset of clathrin-coated vesicles at the 
plasma membrane and also at the intracellular vesicular structures in the TGN 
(Gaidarov, Smith et al. 2001). It has been shown to interact specifically with the 
terminal domain of the clathrin heavy chain (Gaidarov, Zhao et al. 2005). 
PIK3C2A was suggested to participate in the production of PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 that accumulates at the leading edge of motile cells (Rickert, 
Weiner et al. 2000). 
The identification of the clathrin chains, EpsinR and PIK3C2A in the 
mRFP-Paxillin-2C/A immunoprecipitate suggests that the vesicular-like 
structures observed upon overexpression of paxillin mutants defective in focal 
adhesion targeting are clathrin vesicles. Indeed mRFP-Paxillin-2C/A was 
localized to a subset of clathrin vesicles labeled with anti-clathrin antibody (not 
shown) or GFP-Clathrin Light Chain A (Figure 8) in HeLa cells. The fact that 
only a distinct population of clathrin vesicles contained the paxillin mutant 
indicated the presence of a specific factor determining paxillin mutant binding to 
clathrin structures. I therefore conclude that the paxillin mutants most likely bind 
clathrin heavy and light chains indirectly or in cooperation with an additional 
adaptor protein. The other three paxillin mutants defective in focal adhesion 
targeting (mRFP-Paxillin-C445A, mRFP-Paxillin-C489A, mRFP-Paxillin-




I confirmed the interaction of paxillin mutants as well as wild type protein 
with clathrin heavy chain and EspinR using immunoprecipitation from both the 
particle fraction (data not shown) and crude lysates by Western-blot analysis 
(Figure 9). Interestingly paxillin wild type protein was able to bind both clathrin 
heavy chain and EpsinR in immunoprecipitation experiments but upon co-
transfection of mRFP-Paxillin-WT with GFP-Clathrin Light Chain A these two 
proteins localized to focal adhesions and vesicular structures respectively and no 
co-localization was observed (Figure 10).  However when GFP-Paxillin-WT was 
expressed together with mRFP-Paxillin-2C/A, the wild type protein localized 
together with the mutant protein in vesicular structures, in addition to focal 
adhesions (Figure 11). Those structures were identified as clathrin vesicles by 
immunostaining with clathrin heavy chain antibodies (Figure 12). 
Immunoprecipitation did not reveal an interaction between expressed mRFP-
Paxillin-2C/A and endogenous wild type paxillin and therefore excluded the role 
of oligomerization in the wild type paxillin localization to the vesicular structures 
induced by the mutant (data not shown). Accumulation of the wild type paxillin 
in clathrin vesicles induced by overexpression of its mutant is consistent with the 





Figure 9| Binding of paxillin wild type and mutant 
proteins to Clathrin Heavy Chain and EpsinR as 
confirmed by immunoprecipitation. | Immuno-
precipitation was performed with anti-mRFP antibody 
from crude lysates of HeLa cells transfected with one of 
the paxillin constructs (RFP-Paxillin-WT, RFP-Paxillin-
2C/A, RFP-Paxillin-C445A, RFP-Paxillin-C489A, RFP-
Paxillin-∆LIM3). Blots were probed with anti-paxillin, 
anti-CHC and anti-EpsinR antibodies. Negative control 
immunoprecepitation from untransfected cells did not 








Figure 8| mRFP-Paxillin-2C/A localizes to a subset 
of clathrin vesicles. | Hela cells were co-transfected 
with mRFP-Paxillin-2C/A (in red) and GFP-Clathrin 
light chain A (in green) (B), fixed and imaged by 
fluorescent microscopy. Enlarged rectangular area 
from (B) represents examples of clathrin vesicles 
containing mRFP-Paxillin-2C/A (marked with arrow) 
and without it (marked by asterisk) (A).  
Figure 10| mRFP-Paxillin-WT was not detected at clathrin vesicles. | Hela cells were co-transfected 
with mRFP-Paxillin-WT (in red) and GFP-Clathrin light chain A (in green), fixed and imaged by 
fluorescent microscopy. Enlarged rectangular area demonstrates paxillin localization to focal adhesions 





Figure 11| Wild type paxillin is redistributed to the 
vesicles induced by paxillin mutant defective in focal 
adhesion targeting. | Hela cells were co-transfected 
with GFP-Paxillin-WT (in green) and mRFP-Paxillin-
2C/A (in red), fixed and imaged by fluorescent 
microscopy. Enlarged rectangular area demonstrates 
localization of wild type paxillin to focal adhesions and 




Figure 12| Wild type paxillin co-localizes with paxillin-LIM3-
mutant in clathrin vesicles. | Hela cells were co-transfected with 
mRFP-Paxillin-2C/A (in red) and GFP-Paxillin-WT (in green), 
fixed and stained with antibody recognizing clathrin heavy chain 
(in blue). Enlarged rectangular area demonstrates localization of the 
wild type paxillin together with the mRFP-Paxillin-2C/A in clathrin 
vesicles (examples of the vesicles are marked with arrows). 





The standard approach for observation of protein localization and 
dynamics in live cells is overexpression of a protein of interest fused to a 
fluorescent molecule. However protein overexpression is a gradual process taking 
at least several hours after introduction of a coding plasmid into the cells. During 
this time increasing intracellular concentration of the expressed protein can lead 
to the readjustment of the cellular processes as well as to the protein 
accumulation in unspecific compartments such as lysosomes. Microinjection of 
the fluorescently-labeled protein into live cells is an alternative to the 
overexpression method and allows immediate analysis of protein intracellular 
dynamics and localization. 
With the aim to study paxillin dynamics upon microinjection I created 
constructs coding wild type paxillin and paxillin-2C/A-mutant proteins fused to 
the glutathione S-transferase (GST) at the C-terminus and to the EGFP protein at 
the N-terminus. The GST moiety allows affinity purification of the proteins upon 
bacterial expression; the EGFP tag enables visualization of the hybrid proteins 
directly after injection into cultured cells. In addition EGFP is useful for 
monitoring and optimizing recombinant protein expression in bacteria. Fusion of 
the EGFP to the recombinant proteins was also suggested to enhance their 
stability and solubility (Rücker, Schneider et al. 2001). The GST-Paxillin-WT-
GFP, GST-Paxillin-2C/A-GFP and GST-GFP hybrid proteins were efficiently 
expressed in Escherichia coli BL21 and affinity-purified using Gluthatione-
Sepharose 4B. SDS-PAGE analysis revealed major bands of approximately 117 
kDa for recombinant paxillin proteins and 56 kDa for GST-GFP hybrid that were 
recognized by anti-GFP antibodies (Figure 14 B, A). 
Dynamics of GST-GFP hybrid paxillin proteins as well as control GST-
GFP molecule were monitored by time-lapse microscopy directly after injection 
into HeLa cells, followed by cell fixation and subsequent fluorescent microscopy 
analysis. Injection of the control GST-GFP protein produced a homogeneous 
cytoplasmic signal observed by live microscopy and imaging of fixed cells 
(Figure 13, Supplementary movie 3). Recombinant Paxillin-WT started to 
concentrate at focal adhesion sites already 30 seconds after injection (time 
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required to switch from a manual microinjection mode to image acquisition). 
Figure 15 demonstrates the dynamics of paxillin accumulation in two focal 
adhesion regions in one of the injected HeLa cells (Supplementary movie 4, small 
rectangular area). Analysis of similar regions adjacent to focal adhesions did not 
show an increase in paxillin signal intensity. Therefore it was concluded that 
targeting of recombinant paxillin to focal adhesions was specific.  
Interestingly appearance of small vesicular structures was clearly 
observed upon injection of the wild type paxillin in some of the cells (Figure 15 
D, Supplementary movie 4, large rectangular area). Those structures exhibited 
fast movement in the perinuclear area as well as around focal adhesions. 
However the speed of the time-lapse microscopy imaging did not allow detailed 
analysis of their dynamics.  
Imaging of the fixed cells confirmed GST-Paxillin-WT-GFP localization 
to the focal adhesions and to the vesicular structures (Figure 13). Paxillin 
vesicular structures contained clathrin in the perinuclear region of the cells as was 
shown by co-localization with mRFP-Clathrin Light Chain and by 
immunostaining with anti-CHC antibody (Figure 17). 
Surprisingly distribution of the injected recombinant paxillin was not 
uniform within focal adhesions. Paxillin was found to localize in distinct clusters 
that were often concentrated only at the focal adhesion periphery (Figure 16).  
GFP-fused Paxillin-2C/A mutant did not localize to focal adhesion sites 
upon microinjection consistent with its previously shown defect in focal adhesion 
binding. Imaging of the injected cells after fixation revealed labeling of numerous 
small vesicles concentrating at the perinuclear area distinct from the diffuse 
cytoplasmic localization of the control GST-GFP protein (Figure 13). Time-lapse 
microscopy failed to resolve the same vesicular structures in live cells probably 
due to their tiny size and fast movement. In several cells blurred perinuclear 
motility of the vesicular-like structures was observed whereas the majority of the 
cells displayed cytoplasmic signal (Figure 18A, Supplementary movie 5). 
 The size of the vesicles labeled by recombinant mRFP-Paxillin-2C/A was 
smaller and more uniform compared with vesicles induced by overexpression of 
the same paxillin mutant. However injected GST-Paxillin-2C/A-GFP co-localized 
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with expressed mRFP-Paxillin-2C/A in the enlarged vesicular structures (Figure 
18 B, Supplementary movie 6), indicating that small vesicles visualized by GST-
Paxillin-2C/A-GFP and bigger vesicles observed upon mRFP-Paxillin-2C/A 
overexpression belong to the same vesicular compartment. This fact further 
supports the previously proposed idea that paxillin mutant redistribution from 
focal adhesions to the vesicles leads to their stabilization and increase in size. The 
time after microinjection was too short to induce changes in the vesicles 
dimensions upon Paxillin-2C/A binding. Therefore it is likely that small vesicular 
structures labeled by recombinant GST-Paxillin-2C/A-GFP (Figure 13) 
demonstrate physiological size of the putative vesicles related to paxillin 
trafficking.  
 I also confirmed the ability of GST-Paxillin-WT-GFP and GST-Paxillin-
2C/A-GFP to bind clathrin heavy chain and EpsinR in vitro by GST-pull downs 
from cellular particle fractions (Figure 14). Both proteins also showed an 
interaction with the known paxillin-binding partner GIT1 providing 





Figure 13 | Localization of the recombinant GFP-tagged wild type and mutant paxillin proteins upon 
microinjection. | Hela cells were injected with GST-Paxillin-WT-GFP, GST-Paxillin-2C/A-GFP or GST-
GFP as a control, fixed and imaged by fluorescent microscopy. Enlarged rectangular areas demonstrate 
localization of the wild type paxillin to the focal adhesions and vesicular structures, of the mutant paxillin 
defective in focal adhesion targeting to the population of small numerous vesicles. Injected GST-GFP 
produced diffused cytoplasmic staining. 
GST-Paxillin-2C/A-GFP GST-GFPGST-Paxillin-WT-GFP 
Figure 14 | Recombinant wild type and mutant paxillin proteins interact with clathrin, EpsinR and 
GIT1. | (A) GST-Paxillin-WT-GFP, GST-Paxillin-2C/A-GFP and GST-GFP recombinant proteins were 
coupled to Gluthatione-Sepharose 4B and used in pull-down assay from a particle fraction of HeLa cells. 
Control experiment contained only Gluthatione-Sepharose. Bound proteins were analyzed by Western Blot 
with antibodies against Clathrin Heavy Chain, EpsinR, GIT1 and GFP. Anti-GFP antibody recognized 
recombinant GST-GFP (56 kDa) and paxillin proteins (117 kDa). (B) Coomassie staining of the purified 





































































































































Figure 15 | Recombinant wild type paxillin localized to focal adhesions and vesicular structures upon 
injection into cultured cells. | (A) The Hela cell shown was injected with GST-Paxillin-WT-GFP and directly 
imaged by time-lapse microscopy for 5 minutes with 1 sec interval. White rectangles highlight regions analyzed in 
(C) and (D) (Supplementary movie 4). (B, C) Dynamics of paxillin accumulation was analyzed in two focal 
adhesion regions (A1 and A2) and compared with similar control regions nearby (B1 and B2). Montage of the time-
lapse frames (C) and graphs (B) demonstrate a gradual increase in the intensity of the paxillin signal at the focal 
adhesion sites and slight decrease at the adjacent cytoplasmic regions. (D) Frames of the time-lapse movie 
representing paxillin vesicles (marked by arrows) observed in the perinuclear area and around focal adhesions. 
Adhesion region 1 (A1) 
Adhesion region 2 (A2) 
Background region 1 (B1)



























Figure 16 | Recombinant wild type 
paxillin formed clusters at the focal 
adhesions. | Hela cells were injected with 
GST-Paxillin-WT-GFP, fixed and imaged 
by fluorescent microscopy. Arrows mark 
focal adhesions where paxillin distinctly 
concentrated in clusters at the periphery. 
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Figure 17| Recombinant wild type paxillin localized to clathrin 
vesicles in the perinuclear area. | Hela cells  expressing mRFP-
Clathrin Light Chain were injected with GST-Paxillin-WT-GFP, 
fixed and imaged by fluorescent microscopy. Arrows mark 
examples of vesicles containing both clathrin and paxillin. Image 
















Figure 18| Live observations of the recombinant paxillin defective in focal adhesion targeting upon 
injection into cultured cells. | (A) Hela cell was injected with GST-Paxillin-2C/A-GFP and directly imaged by 
time-lapse microscopy for 5 minutes with 1 sec interval. Several frames of the time-lapse movie show blurred 
vesicular-like structures in the perinuclear area (Supplementary movie 5). (B) HeLa cell was transfected with 
mRFP-Paxillin-2C/A, incubated overnight, injected with GST-Paxillin-2C/A-GFP and directly imaged by time-
lapse microscopy (Supplementary movie 6).  Upon injection GST-Paxillin-2C/A-GFP redistributed to the 
enlarged vesicles containing mRFP-Paxillin-2C/A at first in the proximity of the injection site (labeled by 

















GST-Paxillin-2C/A-GFP merge mRFP-Paxillin-2C/A 






C. Turner and colleagues previously reported binding of the clathrin 
heavy chain to the recombinant LD4 domain of paxillin (Turner, Brown et al. 
1999). However neither clathrin interaction with endogenous paxillin nor the role 
of the LD4 motif in this interaction was under investigation. In the same study 
direct interaction between paxillin LD4 domain and GIT1 protein was identified. 
Deletion of the LD4 domain was shown to abrogate GIT1 binding to paxillin and 
subsequent recruitment of GIT-PIX-PAK complex to focal adhesion sites 
(Turner, Brown et al. 1999; West, Zhang et al. 2001). 
 I aimed to examine a role of the LD4 motif in the paxillin interaction with 
clathrin using localization of the Paxillin-2C/A mutant to clathrin vesicles as a 
model. I generated constructs coding mRFP-Paxillin-WT, mRFP-Paxillin-2C/A 
and mRFP-Paxillin-∆LIM3 with additional deletion of the LD4 domain and 
analyzed their localization upon transfection in cultured cells. The percentage of 
cells exhibiting distinct vesicular, focal adhesion or diffused cytoplasmic labeling 
upon transfection of the each construct was calculated (Figure 19C). Deletion of 
the LD4 domain did not influence the ability of the wild type paxillin to localize 
to focal adhesion sites, consistent with previously reported data (West, Zhang et 
al. 2001) (Figure 19 A, C). Paxillin-2C/A-∆LD4 mutant exhibited predominant 
diffuse cytoplasmic localization however in 15% of the transfected cells it was 
still detected in vesicular structures containing clathrin (Figure 19 A, B, C). 
Before deletion of the LD4 domain mRFP-Paxillin-2C/A mutant localized to the 
clathrin vesicles in 45% of the transfected cells, therefore the LD4 motif probably 
determines the efficiency of the paxillin accumulation in the clathrin vesicles. 
Inline with this hypothesis, deletion of the LD4 motif in the Paxillin-∆LIM3 
construct completely eliminated appearance of the visible paxillin-containing 
vesicles. 
Immunoprecipitation analysis demonstrated that deletion of the LD4 
domain abrogated paxillin biding to GIT1 but not to clathrin heavy chain and 
EpsinR (Figure 19D). This fact together with mRFP-Paxillin-2C/A-∆LD4 
localization to the clathrin vesicles suggests that paxillin binding to clathrin is not 
dependent on its LD4 domain and interaction with GIT1. Identification of the 
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clathrin-binding sites within paxillin molecule will bring valuable insights into 
connection between clathrin trafficking and paxillin recycling. 
Figure 19 | Role of the LD4 motif in paxillin binding to clathrin. | (A) Upon transfection into HeLa cells 
mRFP-Paxillin-WT and mRFP-Paxillin-2C/A lacking LD4 motif localized to focal adhesions and to 
vesicular-like structures respectively. (B) mRFP-Paxillin-2C/A-∆LD4 (in red) localized to a subset of 
clathrin vesicles labeled by GFP-Clathrin Light Chain A (in green). (C) Histogram shows percentage of the 
cells exhibiting adhesion, vesicular or diffused localization of the paxillin proteins before and after deletion 
of LD4 domain. HeLa cells were transfected with the following constructs: mRFP-Paxillin-WT, mRFP-
Paxillin-2C/A, mRFP-Paxillin-∆LIM3 with or without LD4 domain. Number of analyzed transfected cells 
was higher than 200 for each case. (D) Deletion of LD4 domain abrogates interaction of paxillin constructs 
with GIT1 but not with Clathrin Heavy Chain (CHC) or EpsinR. Immunoprecipitation was performed with 
anti-mRFP antibody from crude lysates of HeLa cells transfected with one of the paxillin constructs (RFP-
Paxillin-WT, RFP-Paxillin-2C/A, RFP-Paxillin-∆LIM3 with or without LD4 domain). Blots were probed 
with anti-paxillin, anti-GIT1, anti-CHC and anti-EpsinR antibodies. The negative control with lysates from 
untransfected cells did not show any signal (not shown). Additional image at the right demonstrates weak 

































































Clathrin-coated vesicles take part in the diverse trafficking pathways 
including endocytosis from the plasma membrane and retrograde trafficking from 
the TGN membranes and endosomes.  As already mentioned EpsinR is a clathrin 
adaptor protein that was found in a distinct subset of clathrin vesicles and shown 
to play a role in cargo-selection and vesicle budding from the TGN/endosomes 
rather than from the plasma membrane (Hirst, Motley et al. 2003). EpsinR has a 
specific function in the clathrin trafficking pathway that is distinct from the other 
clathrin adaptors. For example EpsinR mediates retrograde transport of Shiga 
toxin from endosomes to TGN whereas another abundant clathrin adaptor AP1 is 
not required for this process (Saint-Pol, Yélamos et al. 2004).  Depletion of 
EpsinR by means of RNAi does not cause such a dramatic effect as clathrin 
knockdown which produces complete loss of clathrin-coated membranes and 
aggregation of the post-Golgi compartments (Motley, Bright et al. 2003). EpsinR 
depleted cells have a normal post-Golgi morphology with clathrin-coated 
budding membranes though their amount is reduced (Hirst, Miller et al. 2004). 
Identification of EpsinR as an interaction partner of paxillin in the 
previous experiments led to the hypothesis that it may be a specific adaptor 
connecting paxillin to a subpopulation of clathrin vesicles. Therefore I 
investigated more closely the influence of EpsinR on paxillin turnover and focal 
adhesion organization. In order to analyze EpsinR function in focal adhesion 
dynamics I applied an RNAi approach. Hirst and colleagues have already 
successfully exploited siRNA knockdown of EpsinR to study its cellular 
functions in HeLa cells (Hirst, Miller et al. 2004). Therefore I used a siRNA 
oligonucleotide from their studies that was proven to be effective and specific for 
EpsinR depletion. To compare the consequences of the EpsinR knockdown with 
suppression of the entire clathrin machinery I performed in parallel knockdown 
of clathrin heavy chain (CHC). 
 Using siRNA transfection I effectively reduced levels of EpsinR and 
CHC at least by 70-80% (Figure 20 D). First I examined transferrin 
internalization rate and showed that it was affected by knockdown of CHC but 
not EpsinR (Figure 20 B). Inhibition of the transferrin uptake upon clathrin 
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suppression has been earlier described and therefore proved the efficiency of the 
clathrin knockdown (Hinrichsen, Harborth et al. 2003; Motley, Bright et al. 
2003). Depletion of EpsinR caused re-distribution of the internalized transferrin 
vesicles from the perinuclear area to the cell periphery as compared with control 
cells. The different effects of EpsinR and CHC siRNA knockdowns on transferrin 
internalization confirmed a specific role of EpsinR in the clathrin trafficking 
pathway.  
Secondly siRNA depletion of EpsinR and CHC induced an increase in 
size of focal adhesions containing paxillin and the formation of prominent actin 
stress fibers at the cell periphery (Figure 20A). Enlargement of focal adhesions 
upon EpsinR knockdown was more significant than upon CHC siRNA depletion. 
Moreover CHC and EpsinR siRNA-treated cells showed a 60% and 50% 
reduction in cell migration rate respectively in a Transwell migration assay. The 
observed changes in focal adhesion dimensions together with migration defects 
would be inline with an imbalance in focal adhesion turnover.  
In summary, the obtained data revealed a role of the clathrin trafficking 
pathway, specifically its EpsinR-dependent part in focal adhesion organization 
and cell migration.  
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Figure 20| siRNA knockdown of EpsinR leads to the enlargement of focal adhesions and reduced cell 
migration. | (A) HeLa cells treated with Scrambled, EpsinR or Clathrin Heavy Chain (CHC) siRNAs were 
immunostained with phalloidin 568 to visualize actin (in red) and anti-paxillin antibody labeling focal adhesions 
(in green). (B) HeLa cells treated with Scrambled, EpsinR or CHC siRNAs were incubated for 15 minutes at 
37°C with Alexa568-Transferin, fixed and the efficiency of Transferrin endocytotic uptake judged by intensity 
of the intracellular vesicular labeling. Asterisk marks a cell that was not transfected with CHC siRNA and 
showed unaffected transferrin endocytosis similar to the control cells treated with Scrambled siRNA. (C) HeLa 
cells treated with Scrambled, CHC and EpsinR siRNAs were incubated for 48 hours and subjected to a 
Transwell-migration assay overnight. Relative number of migrated cells in each case was calculated. (D) 
Efficiency of the EpsinR and CHC siRNA knockdowns was confirmed by immunobloting of crude cellular 
lysates with anti-EpsinR and anti-CHC antibodies and anti-tubulin antibody as a control for equal protein 
















































































 The existence of a vesicular trafficking pathway involved in the recycling 
of focal adhesion protein paxillin has been proposed previously. However the 
nature of this putative vesicular pathway remained elusive. From the studies of 
the paxillin mutants defective in focal adhesion binding I conclude that clathrin 




Paxillin localization to focal adhesions was shown to be dependent on the 
double zinc finger LIM3 domain (Brown, Perrotta et al. 1996). In contrast to 
previous data I found that deletion or structural alterations of LIM3 did not 
eliminate focal adhesion localization of paxillin completely but rather reduced its 
efficiency, suggesting that other motifs are also involved in paxillin binding to 
adhesions. Recent microinjection experiments of Kaverina and co-workers 
supported my findings and demonstrated that a LIM3 domain alone was not able 
to localize to focal adhesions as opposed to the combination of the LIM3 with 
LIM2 domains (Efimov, Schiefermeier et al. 2008). Interestingly focal adhesion 
localization of another LIM domain-protein zyxin was also found to be dependent 
on multiple LIM domains. None of the recombinant proteins harboring only one 
of the three zyxin LIM domains was accumulated in focal adhesions in contrast to 
the constructs combining at least two domains (LIM1 and LIM2 or LIM2 and 
LIM3) (Nix, Fradelizi et al. 2001). Therefore stable focal adhesion association of 
paxillin by analogy with zyxin might require tandem LIM domains (most likely 
LIM2 and LIM3). 
I also showed that interference with the structure of the first LIM3 zinc 
finger affected paxillin localization to focal adhesions stronger than disruption of 
the second zinc finger, and disruption of both zinc fingers had a greater effect 
than deletion of the entire domain. Probably the altered structure of the LIM3 
zinc fingers prevents binding of the adjacent LIM2 domain to focal adhesions. 
Accordingly disruption of the first LIM3 zinc finger is more crucial than of the 
108 
 
second one since it is located closer to LIM2. And deletion of LIM3 does not 




I demonstrated that the efficiency of paxillin binding to focal adhesions is 
inversely correlated with its accumulation in cytoplasmic vesicular-like 
structures. I suggest when paxillin is not able to bind to focal adhesions it is 
retained in the putative recycling vesicles that leads to their stabilization and 
enlargement and makes them readily observed by conventional microscopy. 
Under standard conditions vesicles containing wild type paxillin cannot be 
detected, probably due to their small size or transient nature. Therefore the 
observed vesicles containing paxillin defective in focal adhesion binding provide 
only indirect evidence for the existence of the paxillin vesicular recycling 
pathway. 
It is interesting to compare my findings with studies of the paxillin yeast 
ortholog Pxl1p (Paxillin-like protein-1). Pxl1p contains two LIM domains (highly 
similar to the LIM3 and LIM4 domains of mammalian paxillin) that are 
responsible for protein targeting to the sites of polarized growth, at the tip of the 
bud and bud neck. At those sites the active reorganization of actin cytoskeleton 
occurs in response to localized RhoGTPase signaling, thereby they might be 
considered as analogs of mammalian focal adhesion sites. It was shown that 
deletion of the LIM domains led to the Pxl1p relocalization to the intracellular 
vesicular-like structures similar to the Golgi compartment (Mackin, Sousou et al. 
2004). Therefore the LIM domains likely share evolutionary conserved function 
of protein targeting to specific cellular compartments such as mammalian focal 
adhesions or yeast bud tips. I suggest that the putative vesicular trafficking route 
involved in paxillin recycling may be also evolutionary conserved since both 
mammalian and yeast paxillin proteins accumulate in vesicular structures upon 
disruption of the LIM domains. 
Additionally the mammalian paxillin homologue Hic-5 was also found 
redistributed to vesicular-like structures from focal adhesion plaques upon 
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structural alterations in the LIM3 domain (Nishiya, Iwabuchi et al. 1999). 
Unfortunately Nishiya and colleges did not comment on possible implications of 
Hic-5 accumulation in vesicular structures. However their findings suggest that 
vesicular trafficking could be a common mechanism for the recycling of all 
paxillin family members. 
Enhanced binding of the paxillin-LIM3-mutants to the recycling 
vesicular-like structures allowed identification of their components using mRFP-
Paxillin-2C/A protein as a bait. The identified components included clathrin 
heavy chain, two light chains, clathrin-interacting protein EpsinR and PIK3C2A. 
Therefore I assigned those vesicular structures to the clathrin-trafficking pathway. 
Subsequent immunoprecipitation and co-localization experiments confirmed 
interaction of the paxillin mutants defective in focal adhesion binding with 
Clathrin Heavy Chain, clathrin adaptor EpsinR and their localization to a 
subpopulation of fast moving clathrin vesicles. 
 
Localization of the wild type paxillin to the clathrin vesicles. 
Accumulation of the paxillin-LIM3-mutants in clathrin vesicles suggest 
the existence of the clathrin trafficking route involved in paxillin recycling. 
Therefore I examined localization of the wild type paxillin to clathrin vesicles. 
The first indication that paxillin interacts with clathrin came from studies 
of Turner and colleges when they discovered that the LD4 domain of paxillin 
binds Clathrin Heavy Chain (CHC) in GST pulldown experiments in vitro 
(Turner, Brown et al. 1999). However significance of this finding was not further 
investigated.  
At first I demonstrated that wild type paxillin binds CHC and EpsinR in 
the immunoprecepitation and GST-pull down experiments. However despite the 
detected interactions, overexpressed wild type paxillin did not localize to distinct 
clathrin vesicles. Therefore I undertook a different approach for localizing 
paxillin using microinjection of recombinant wild type paxillin fused to the GFP 
molecule. Recombinant paxillin demonstrated more distinct vesicular localization 
with reduced cytoplasmic background as compared with overexpression, 
probably due to the lower concentration of the introduced protein. In the 
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perinuclear area of the injected cells vesicular structures containing recombinant 
wild type paxillin co-localized with clathrin.  
Additionally upon co-transfection of the wild type paxillin with one of the 
paxillin-LIM3-mutants both co-localized in the enlarged clathrin vesicles. This 
confirmed the ability of the wild type protein to localize to the clathrin structures.  
In summary, wild type paxillin was demonstrated not only to bind to 
clathrin vesicle components but also to localize to clathrin vesicles.  However 
paxillin localization to the clathrin vesicles could not be detected under standard 
conditions by conventional fluorescence microscopy because of the reasons 
suggested above (small size and transient nature of the structures). The size of 
clathrin vesicles can be as small as 60 nm in diameter and the speed of movement 
can reach 5-20 um/s under certain conditions (Zhao, Gaidarov et al. 2007), that 
would be beyond the detection of standard time-lapse microscopy resolution. I 
believe that this was the reason why the putative paxillin recycling vesicles still 
have not been observed in live cells. Therefore further studies of clathrin-
dependent paxillin recycling may require the development of high resolution 
microscopy techniques. Attempts to perform super-resolution imaging of paxillin 
in focal adhesions of live cells using photoactivated localization microscopy 
(PALM) has been recently presented (Shroff, Galbraith et al. 2008). PALM 
allows the collection of images at spatial resolution close to 60 nm but with low 
frame rates (~25s/frame). Interestingly, that PALM revealed nano-particles of 
paxillin inside focal adhesions that form a diffuse background when viewed by 
conventional diffraction-limited microscopy. Notably, I also observed clusters of 
the paxillin inside focal adhesions upon injection of the recombinant wild type 
paxillin but not after overexpression. Unfortunately, temporal resolution of the 
PALM technique is not sufficient yet to examine the fast dynamics of paxillin 
particles in respect of clathrin trafficking pathway. I suggest that the combination 
of microinjection with low amounts of labeled paxillin with fast time-lapse 
microscopy could provide an alternative approach to observe paxillin dynamics 







siRNA knockdown of clathrin heavy chain (CHC) and EpsinR caused 
dramatic enlargement of focal adhesions, formation of strong peripheral actin 
stress fibers and led to reduction in cell migration rate. Therefore clathrin 
trafficking pathway and specifically its EpsinR-dependent part likely play a role 
in focal adhesion turnover and cell migration. 
As discussed before EpsinR is a clathrin adaptor, which is enriched in the 
TGN and endosomal compartments and does not overlap with AP2, the main 
endocytic clathrin adaptor at the plasma membrane. Therefore EpsinR is 
suggested to be responsible for intracellular trafficking rather than for 
endocytosis (Kalthoff, Groos et al. 2002; Wasiak, Legendre-Guillemin et al. 
2002; Hirst, Motley et al. 2003; Mills, Praefcke et al. 2003; Saint-Pol, Yélamos et 
al. 2004). I have also demonstrated that EpsinR is actually not required for 
transferrin uptake. Therefore in respect of focal adhesion turnover, EpsinR might 
regulate rather recycling of focal adhesion components toward plasma membrane 
then internalization.  
 On the basis of the identified interaction between paxillin, clathrin and 
EpsinR it is tempting to speculate that the EpsinR-dependent clathrin trafficking 
pathway might be involved in paxillin recycling to focal adhesions. Enlargement 
of focal adhesions upon EpsinR knockdown could be explained by defects in 
paxillin turnover. However at this stage I cannot exclude possible the 
involvement of EpsinR in the trafficking of other focal adhesion components 
such as integrins. 
As discussed in the main introduction it has been recently shown that 
integrins undergo clathrin-dependent internalization (Nishimura and Kaibuchi 
2007). At present there are no direct studies demonstrating involvement of the 
clathrin-dependent recycling in the integrin delivery to the plasma membrane. 
However a GTPase-activating protein ACAP1 was found to regulate recycling of 
β1-integrin (Li, Ballif et al. 2005) and recruitment of clathrin to the recycling 
endosomes (Li, Peters et al. 2007). This indicates that clathrin is involved not 
only in the internalization but also in the recycling of certain integrins.  
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Therefore it will be important to determine a role of the EpsinR-dependent 
clathrin trafficking in the recycling of not only paxillin but also other focal 
adhesion proteins including integrins. In addition it will be interesting to define 
the contribution of the paxillin recycling to the focal adhesion turnover separately 
from integrin recycling. For this purpose siRNA-mediated depletion of EpsinR 
and especially CHC would not be suitable because it blocks the entire recycling 
pathway. To dissect the specific impact of paxillin recycling on focal adhesion 
turnover it would be necessary to identify the mechanism of paxillin recruitment 























Taken together the studies described above bring new insights into 
understanding of the link between vesicular trafficking and focal adhesion 
turnover.  
 I have demonstrated that paxillin defective in focal adhesion binding 
accumulates in a subpopulation of clathrin vesicles. This finding led me to a 
proposal that paxillin recycling might occur through clathrin-dependent 
trafficking pathway. As indirect evidence I show that the part of the clathrin-
dependent pathway associated with the adaptor protein EpsinR is indeed involved 
in the regulation of focal adhesions.  Further experiments toward understanding 
of how paxillin binds to clathrin vesicles and what factors regulate its turnover 
are required.    
Theoretically, the clathrin machinery is a good candidate for the polarized 
transport of paxillin and other adhesion components including integrins. First of 
all, clathrin vesicles are quite small (up to 60 nm in diameter), can move as fast as 
5-20 um/s under certain conditions (Zhao, Gaidarov et al. 2007), their movement 
is dependent on the microtubule tracks (Rappoport, Bushra et al. 2003; Zhao, 
Gaidarov et al. 2007) and their assembly is tightly regulated by a number of 
specific clathrin-adaptor proteins. Therefore clathrin vesicles can provide a fast 
but controlled delivery of the necessary components towards polarized cell edge 
along microtubule tracks. Secondly clathrin trafficking pathway was found to 
contribute to the polarized delivery of basolateral membrane proteins in epithelial 
cells (Deborde, Perret et al. 2008) in a possibly analogous process.  
The involvement of the microtubules in vesicular trafficking of cell 
adhesion components remains an open question. On the one hand migrating cells 
form array of stable microtubules oriented toward the leading edge which might 
determine polarization of the vesicular transport (Gundersen and Bulinski 1988). 
On the other hand cells have been shown to be able to spread and form focal 
adhesions even in the absence of a microtubule network. My preliminary 
experiments also demonstrated that upon microinjection recombinant paxillin 
redistributed to focal adhesions even after microtubule disassembly. However in 
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the absence of microtubules paxillin bound first to focal adhesions close to the 
microinjection site, whereas in a control situation it evenly accumulated in all 
focal adhesions. I suggest that vesicular trafficking is dispensable for the 
localization of focal adhesion components, which than may be distributed by 
means of cytoplasmic diffusion. However polarized vesicular transport of focal 
adhesion components along microtubules becomes essential during directional 
cell migration.  
Interestingly the formation of tight junctions was also found to be 
dependent on regulated membrane traffic (see review (Yu and Turner 2008)). The 
tight junctions form intercellular connections between epithelial cells and similar 
to focal adhesions consist of transmembrane proteins, plaque proteins and 
cytoskeletal components including actin. Therefore vesicular transport is likely a 
common mechanism underlying the polarized and controlled delivery of the 
components to different cellular plasma membrane structures. Notably tight 
junction components were shown to pre-assemble at the vesicular membranes 
prior to recycling to the plasma membrane (see review (Yu and Turner 2008)). 
Whether focal adhesion molecules are also transported as a pre-formed complex 
remains to be established. In the future it will be interesting to determine whether 
the clathrin trafficking pathway plays a role only in paxillin recycling or also 
influence turnover of the integrins and other focal adhesion proteins.  
 In conclusion, Figure 1 demonstrates a model of the possible involvement 
of clathrin trafficking pathway in the turnover of focal adhesion components 
(integrins and paxillin) in a migrating cell. Clathrin machinery and specifically 
endocytic clathrin-adaptor AP2 plays a role in the integrin internalization 
(Nishimura and Kaibuchi 2007). Upon internalization integrins are directed to a 
recycling endosomal compartment in the perinuclear area. I suggest that paxillin 
is transported to the recycling compartment in complex with integrins or 
alternatively, recruited there directly from the cytoplasm via unknown factor. 
Trafficking of paxillin and integrins from recycling compartment to the cellular 
leading edge depends on the clathrin vesicles containing adaptor EpsinR and on 
the polarized array of microtubules. 
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I think that the future application of evolving high resolution microscopy 
techniques in combination with selective dissection of the clathrin pathway 
should shed more light on the involvement of vesicular trafficking in cytoskeletal 
dynamics and cell motility. 
Figure 1 | Scheme demonstrating a role of the clathrin trafficking pathway in the turnover of focal 
adhesion components.  | Integrins are internalized via a mechanism that is dependent on clathrin and its 
adaptor AP2 (Nishimura and Kaibuchi 2007). Paxillin might be transported to the recycling compartment 
(RC) in a complex with integrins. Alternatively paxillin might be recruited to the RC directly from the 
cytoplasm via unknown component. Delivery of paxillin (jointly or apart from the integrins) to the 
leading edge of the cell from the RC involves clathrin vesicles containing the EpsinR adaptor. Transport 
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Movie 1. Dynamics of focal adhesions in control (at the bottom) and beta-COP 
depleted (on the top) HeLa cells with stable expression of EGFP-Paxillin. Time-
lapse movie with 1 minute interval between frames. 
Movie 2. Dynamics of the vesicular structures containing mRFP-Paxillin-2C/A in 
HT1080 cell. Movement of the vesicles is inhibited upon microtubule 
disassembly after nocodazole addition. Time-lapse movie with 3 sec between 
frames. 
Movie 3. Cytoplasmic labeling upon microinjection of the recombinant GST-
GFP protein into HeLa cell. Time-lapse movie with 1 second interval between 
frames. The movie was acquired starting 30 seconds after injection. 
Movie 4. Microinjection of the GST-Paxillin-WT-GFP protein into HeLa cell. 
The injected protein localized to focal adhesions (as observed in the small 
rectangle) and to vesicular structures (as observed in the big rectangle). Time-
lapse movie with 1 second interval between frames. The movie was acquired 
starting 30 seconds after injection. 
Movie 5. Dynamics of blurred vesicular-like structures in the perinuclear area 
upon injection of the GST-Paxillin-2C/A-GFP protein into HeLa cell. Time-lapse 
movie with 1 second interval between frames. The movie was acquired starting 
30 seconds after injection. 
Movie 6. Microinjected GST-Paxillin-2C/A-GFP protein (acquired in the green 
channel) localized to the vesicular-like structures containing overexpressed 
mRFP-Paxillin-2C/A (acquired in the red channel) in HeLa cell. Time-lapse 
movie with 3.5 seconds between frames. The movie was acquired starting 30 








siRNA sense sequence 5´-3´  siRNA antisense sequence 5´-3´  
AKAP13 136052 CCAACAAAGAUGCCUAUACtt GUAUAGGCAUCUUUGUUGGtg
TM4SF6 138892 GCCAUGCAGUAGACAAGAUtt AUCUUGUCUACUGCAUGGCtt
PAK2 110776 GGAUCUGUUAAGCUCACUGtt CAGUGAGCUUAACAGAUCCtt
PAK4 288585 CCACUGCCUGAAGAACCAGtt CUGGUUCUUCAGGCAGUGGtt
TLN1 5467 GGAGGAAAUAACAGGGACCtt GGUCCCUGUUAUUUCCUCCtt
CDC42 10418 GGAUUAUGACAGAUUACGAtt UCGUAAUCUGUCAUAAUCCtc
Rac1 120600 CCUUUGUACGCUUUGCUCAtt UGAGCAAAGCGUACAAAGGtt
RhoB 41889 GAACUAUGUGGCCGACAUUtt AAUGUCGGCCACAUAGUUCtc
KIF1A 14392 GGGAUACAACGUGUGCAUCtt GAUGCACACGUUGUAUCCCtc
MYH9 11605 GGUGAAGGUGAACAAGGAUtt AUCCUUGUUCACCUUCACCtt
MACF1 258846 CCAAAGUGACUUGAAGGAUtt AUCCUUCAAGUCACUUUGGtt
AP1B1 9431 GGAGAAGAAGAAGGAGGCAtt UGCCUCCUUCUUCUUCUCCtt
ITGB5 11108 GGUCUCAACAUAUGCACUAtt UAGUGCAUAUGUUGAGACCtg
MLPH 42410 GAUGAGUCCUGCUCAGAGAtt UCUCUGAGCAGGACUCAUCtg
PTK2 103596 GGGAGAAGUAUGAGCUUGCtt GCAAGCUCAUACUUCUCCCtc





Gene RefSeq Gene RefSeq Gene RefSeq 
ITGB1 NM_002211 NCK2 NM_003581 GIT1 NM_014030 
ITGB3 NM_000212 BCAR1  NM_014567 GIT2 NM_057169 
ITGB4 NM_000213 PAX  NM_002859 ANXA2 NM_001002858 
ITGB5 NM_002213 LIMS1 NM_004987 CFL1 NM_005507 
ITGB6  NM_000888 SORBS1 NM_006434 EVL NM_016337 
CD151 NM_004357 PPFIA1 NM_177423 GSN NM_000177 
CD81 NM_004356 GNB2L1 NM_006098 DIAPH1 NM_005219 
TM4SF6 NM_003270 NUDT16L1 NM_032349 DIAPH2 NM_007309 
TM4SF7 NM_001025237 SDCBP NM_005625 DIAPH3 NM_030932 
TRPM7 NM_017672 SORBS3 NM_005775 NEXN  NM_144573  
LRP1  NM_002332 ABL1 NM_007313 PFN1 NM_005022  
PTPNS1 NM_080792 ABL2 NM_005158 PFN2 NM_053024 
CALR NM_004343 CSK  NM_004383 PARVA NM_018222 
CANX NM_001746  PTK2 NM_153831 PARVB NM_001003828 
CIB NM_006384 FYN NM_002037 TNS NM_022648  
ITGB3BP NM_014288 SRC NM_005417 TENC1 NM_015319 
ICAP1 NM_004763 YES1 NM_005433 TPM1 NM_001018004 
ACTB NM_001101  MAPK3 NM_002746 TPM2 NM_003289 
K-alpha-1 NM_006082  MAPK1 NM_002745 TPM3 NM_152263 
TUBB  NM_178014 ILK NM_004517 TPM4 NM_003290 
VIM NM_003380 LIMK1 NM_002314 VASP NM_003370 
ACTN1  NM_001102   LIMK2 NM_001031801 PPIA NM_021130 
ACTN4 NM_004924 MAP3K1 NM_005921 GAPDH NM_002046 
VIL2 NM_003379 MYLK NM_053025
FLNA NM_001456   PAK1 NM_002576
FLNB NM_001457  PAK2 NM_002577
FLNC NM_001458  PAK4 NM_005884 
NF2 NM_000268 PKCA  NM_002737 
PLEKHC1 NM_006832 PKCE NM_005400
MIGFILIN NM_017556 PRKCM NM_002742
MSN NM_002444 ROCK1 NM_005406
MYLIP NM_013262 ROCK2 NM_004850
PALLD NM_016081  PIK3CA NM_006218
RDX NM_002906 PIK3CB NM_006219 
TLN1 NM_006289  PI3KCG NM_002649 
TLN2 NM_015059  PIK3R1  NM_181523 
TES NM_015641  PIP5K1C NM_012398
VCL  NM_014000  PTEN  NM_000314 
ZYX NM_003461 PTPN1 NM_002827 
CAV1 NM_001753 PTPN12 NM_002835
CAV2 NM_001233 PTPRF NM_002840
CBL NM_005188 PTPN11 NM_002834 
CRK NM_005206 PTPRA NM_002836
CRKL NM_005207 CAPN1  NM_005186 
CSRP1 NM_004078 CAPN2 NM_001748
GRB2 NM_002086 CAPNS1 NM_001749
GRB7 NM_005310 RNF5 NM_006913 
TGFB1I1 NM_015927 ARF1 NM_001024227
LASP1 NM_006148 DDEF1 NM_018482
LIMS2 NM_017980 DNM1 NM_004408
NCK1 NM_006153 DNM2 NM_001005360
 
 
Table 2 | Cell migration-related proteins (including focal adhesion scaffold and 




Gene RefSeq Gene RefSeq Gene RefSeq
RhoGTPAses ARHGEF10 NM_014629 GDIs 
ARHA NM_001664  ARHGEF10L NM_018125 ARHGDIA NM_004309 
ARHB NM_004040  ARHGEF17 NM_014786 ARHGDIB NM_001175 
ARHC NM_175744   ABR NM_021962 ARHGDIG NM_001176 
RAC1 NM_006908 BCR NM_004327 RhoGAPs 
RAC2 NM_002872   ALSIN NM_020919 ARHGAP23 XM_290799
RAC3 NM_005052  VAV2 NM_003371 ARHGAP10 NM_024605 
ARHG NM_001665  VAV3 NM_006113 Chimerin 1 NM_001822 
CDC42 NM_001791 VAV1 NM_005428 Chimerin 2 NM_004067
ARHQ NM_012249  OBSCN NM_052843 ARHGAP5 NM_001030055
ARHJ NM_020663 ARFGEF6 NM_004840 GRLF1 NM 004491
WRCH1 NM_021205  ARHGEF7 NM_003899 OPHN1 NM_002547 
RHOV NM_133639 PREX1 NM_022835 GRAF NM_015071 
RND1 NM_014470   ARHGEF4 NM_020820 ARHGAP11A NM_014783
ARHN NM_005440  ARHGEF9 NM_015320 STARD8 NM_014725 
ARHE NM_005168  SPATA13 NM_153023  STARD13 NM_178006
ARHD NM_014578 TIAM2 NM_012454 DLC1 NM_182643
RHOF NM_019034 TIAM1 NM_003253 ARHGAP6 NM_013427 
RHOH NM_004310 PLEKHG4 NM_015432 ARHGAP19 NM_032900
RHOBTB1 NM_004310 HAPIP NM_001024660 ARHGAP28 NM_001010000 
RHOBTB2 NM_004310 TRIO NM_007118 ARHGAP18 NM_033515  
RhoGEFs (Dbl family) FLJ32854 AK057416 ARHGAP20 NM_020809 
ARHGEF19 NM_014448  GEFT NM_182947 ARHGAP8 NM_001017526 
SGEF NM_015595 MCF2L2 NM_015078 ARHGAP1 NM_004308  
ARHGEF15 NM_173728 MCF2 NM_005369 ARHGAP4 NM_001666 
ARHGEF5 NM_005435 MCF2L NM_024979 SRGAP3 NM_014850
NGEF NM_019850 FLJ20184 NM_017700 SRGAP1 NM_020762 
ARHGEF2 NM_004723 DNMBP NM_015221 FNBP2 NM_015326
AKAP13 NM_006738  SOS1 NM_005633 SH3BP1 NM_018957
ARHGEF18 NM_015318  SOS2 NM_006939 RICH2  NM_014859 
RGNEF NM_001080479 ECT2 NM_018098  RICH1 NM_001006634  
ARHGEF12 NM_015313 PLEKHG5 NM_020631 GMIP NM_016573 
ARHGEF11 NM_014784 PLEKHG6 NM_018173  ARHGAP29 NM_004815
ARHGEF1 NM_199002 RhoGEFs (Dock family) HA1 NM_012292 
ITSN1 NM_003024 DOCK1 NM_001380 PIK3R1 NM_181523
ITSN2 NM_006277 DOCK2 NM_004946 PIK3R2 NM_005027
Net1 NM_005863   DOCK5 NM_024940 OCRL1 NM_000276 
ARHGEF3 NM_019555  DOCK3 NM_004947 C5ORF5 NM_016603
FARP1 NM_005766  DOCK4 NM_014705 KIAA1688 NM_025251
FARP2 NM_014808 DOCK6 NM_020812 ARHGAP24 NM_001025616
FGD6 NM_018351 DOCK7 NM_033407 ARHGAP25 NM_001007231
FGD2 NM_173558 DOCK8 NM_203447 MYO9B NM_004145 
FGD4 NM_139241  Zizimin1 NM_015296 MYO9A NM_006901 
FGD1 NM_004463 DOCK10 NM_014689 SYDE1 NM_033025
FGD3 NM_033086 DOCK11 NM_144658 CENTD2 NM_139181
RasGRF1 NM_002891  CENTD1 NM_015230
RasGRF2 NM_006909 CENTD3 NM_022481
 




Gene RefSeq Gene RefSeq Gene RefSeq 
RhoGAPs 
CDGAP NM_020754  
SNX26 NM_052948  
RACGAP1 NM_013277  
RALBP1 NM_006788 
BCR NM_004327 















Gene RefSeq Gene RefSeq Gene RefSeq
Kinesin family Myosin family Microtubule Tip Proteins
KIF1A NM_004321 MYO1A NM_005379 CLIP170 NM_002956
KIF1B NM_015074   MYO1B NM_012223 CLIP115 NM_003388
KIF1C NM_006612  MYO1C NM_033375 Dynactin1 NM_004082
KIF2A NM_004520 MYO1D NM_015194 EB1 NM_012325
KIF2B NM_032559  MYO1E NM_004998 EB2 NM_014268
KIF2C NM_006845 MYO1F NM_012335 EB3 NM_012326
KIF3A NM_007054 MYO1G NM_033054 CLASP1 NM_015282  
KIF3B NM_004798 MYH1 NM_005963 CLASP2 NM_015097 
KIF3C NM_002254 MYH2 NM_017534 LIS1 NM_000430
KIF4A AF071592  MYH3 NM_002470 APC NM_000038 
KIF4B AF241316 MYH4 NM_017533 APC2  NM_005883 
KIF5A NM_004984 MYH6 NM_002471 ACF7 NM_012090
KIF5B NM_004521 MYH7 NM_000257 XMAP215 NM_001008938
KIF5C NM_004522 MYH8 NM_002472 melanophilin NM_024101
KIF6 NM_145027 MYH9 NM_002473
KIF7 NM_198525 MYH10 NM_005964 
KIF9 NM_022342 MYH11 NM_002474
KIF10 NM_001813  MYH13 NM_003802
KIF11 NM_004523 KIAA1512 AB040945
KIF12 NM_138424 KIAA1000 AB023217
KIF13A NM_022113 MYO3A NM_017433
KIF13B NM_015254  MYO3B NM_138995
KIF14 NM_014875 MYO5A NM_000259
KIF15 NM_020242 MYO5B AY274809 
KIF16A AK122666 MYO5C NM_018728
KIF16B BX647572 MYO6 NM_004999
KIF17 NM_020816  MYO7A NM_000260 
KIF18A NM_031217  MYO7B XM_291001 
KIF18B XM_085634 MYO9A NM_006901 
KIF19A NM_153209 MYO9B NM_004145
KIF20A NM005733 MYO10 NM_012334 
KIF20B NM_016195 MYO15A NM_016239 
KIF21A NM_017641  MYO15B BC027875 
KIF21B BC078676 MYO16 AB020672
KIF22 NM_007317   MYO18A NM_203318
KIF23  NM_004856 MYO18B NM_032608 
KIF24 NM_018278 Dynein family
KIF25 NM_005355 DYNC1H1 NM_001376
KIF26A XM_050278  DYNC1I1 NM_004411 
KIF26B BC035896 DYNC1I2 NM_001378 
KIF27 NM_017576 DYNC1LI1 NM_016141
KIF28 XM_497745  DYNC1LI2 NM_006141
KIFC1 NM_002263 DYNLT1 NM_006519
KIFC2 NM_145754  DYNLT3 NM_006520
KIFC3 NM_005550 DYNLRB1 NM_014183
KAP3 NM_014970 DYNLRB2 NM_130897
beta1- NM_145730  DYNLL1 NM_003746
JIP-1 NM_005456 DYNLL2 NM_080677
JIP-2 NM_139124 DYNC2H1 HSU53531
JIP-3 NM_033392  DYNC2LI1 NM_015522  
 
 





001--28431--INCENP 052--empty--empty 103--147798--ARHGAP22 154--empty--empty 
002--219541--CDGAP 053--empty--empty 104--288549--ABR 155--empty--empty 
003--18693--RALBP1 054--empty--empty 105--empty--empty 156--empty--empty 
004--empty--empty 055--242584--GSN 106--empty--empty 157--empty--empty 
005--empty--empty 056--33026--DIAPH3 107--empty--empty 158--empty--empty 
006--empty--empty 057--118353--TPM1 108--empty--empty 159--35874--GIT2 
007--132552--ARHGAP15 058--empty--empty 109--empty--empty 160--147287--ANXA2 
008--29772--ABR 059--empty--empty 110--empty--empty 161--143784--PFN2 
009--empty--empty 060--empty--empty 111--22840--CENTD1 162--empty--empty 
010--empty--empty 061--empty--empty 112--35730--SNX26 163--empty--empty 
011--empty--empty 062--empty--empty 113--empty--empty 164--empty--empty 
012--empty--empty 063--scramble--scramble 114--empty--empty 165--43886--TPM3 
013--empty--empty 064--35700--GIT2 115--empty--empty 166--112126--PPIA 
014--empty--empty 065--45010--PFN1 116--empty--empty 167--empty--empty 
015--scramble--scramble 066--empty--empty 117--empty--empty 168--empty--empty 
016--219542--CDGAP 067--empty--empty 118--empty--empty 169--5366--CFL1 
017--empty--empty 068--empty--empty 119--empty--empty 170--empty--empty 
018--empty--empty 069--46535--TPM3 120--empty--empty 171--empty--empty 
019--empty--empty 070--13105--VASP 121--34278--ARHGAP9 172--empty--empty 
020--empty--empty 071--44902--GAPD 122--empty--empty 173--134050--PARVB 
021--empty--empty 072--empty--empty 123--empty--empty 174--22677--TENC1 
022--empty--empty 073--288568--ANXA2 124--empty--empty 175--8523--TPM1 
023--empty--empty 074--empty--empty 125--empty--empty 176--empty--empty 
024--empty--empty 075--empty--empty 126--empty--empty 177--empty--empty 
025--18602--RALBP1 076--empty--empty 127--empty--empty 178--empty--empty 
026--empty--empty 077--20312--PARVB 128--empty--empty 179--288634--TPM3 
027--empty--empty 078--136884--TENC1 129--empty--empty 180--103856--PPIA 
028--empty--empty 079--8333--TPM1 130--empty--empty 181--242566--DIAPH1 
029--empty--empty 080--empty--empty 131--empty--empty 182--26445--ENAH 
030--empty--empty 081--empty--empty 132--empty--empty 183--11862--PFN2 
031--empty--empty 082--empty--empty 133--29210--ARHGAP22 184--empty--empty 
032--empty--empty 083--43982--TPM3 134--288548--ABR 185--empty--empty 
033--empty--empty 084--13195--VASP 135--empty--empty 186--empty--empty 
034--empty--empty 085--8127--GSN 136--empty--empty 187--20220--PARVB 
035--empty--empty 086--32930--DIAPH3 137--empty--empty 188--136886--TENC1 
036--empty--empty 087--15713--PFN1 138--empty--empty 189--empty--empty 
037--26915--ARHGAP15 088--empty--empty 139--empty--empty 190--empty--empty 
038--29678--ABR 089--empty--empty 140--empty--empty 191--empty--empty 
039--empty--empty 090--empty--empty 141--empty--empty 192--empty--empty 
040--empty--empty 091--134049--PARVB 142--empty--empty 193--22649--CENTD1 
041--empty--empty 092--136885--TENC1 143--empty--empty 194--20189--RACGAP1 
042--empty--empty 093--42838--GAPD 144--empty--empty 195--26692--ARHGAP12 
043--empty--empty 094--empty--empty 145--35791--GIT2 196--empty--empty 
044--empty--empty 095--empty--empty 146--147285--ANXA2 197--empty--empty 
045--empty--empty 096--empty--empty 147--5455--CFL1 198--empty--empty 
046--empty--empty 097--128701--CENTD1 148--empty--empty 199--21983--RICS 
047--empty--empty 098--35819--SNX26 149--empty--empty 200--147331--BCR 
048--empty--empty 099--34374--ARHGAP9 150--empty--empty 201--empty--empty 
049--28431--INCENP 100--empty--empty 151--15997--DIAPH1 202--empty--empty 
050--138619--GIT2 101--empty--empty 152--132359--ENAH 203--empty--empty 
051--147286--ANXA2 102--empty--empty 153--118354--TPM1 204--empty--empty 
 
 
Table 5 | Structure of the siRNA microarray chip #160. Each table cell contains [number of 
the siRNA spot- -number of the siRNA oligonucleotide- -gene name]. siRNAs were designed 
and produced by Ambion Europe, Ltd. Empty spots did not contain any siRNA. 
135 
 
205--empty--empty 264--empty--empty 323--empty--empty 382--empty--empty 
206--empty--empty 265--24216--EVL 324--empty--empty 383--empty--empty 
207--22745--CENTD1 266--empty--empty 325--13799--IQGAP1 384--empty--empty 
208--20283--RACGAP1 267--empty--empty 326--1332--BCR 
209--empty--empty 268--empty--empty 327--empty--empty 
210--empty--empty 269--30149--TNS 328--empty--empty 
211--empty--empty 270--8429--TPM1 329--empty--empty 
212--empty--empty 271--13149--TPM2 330--empty--empty 
213--empty--empty 272--empty--empty 331--empty--empty 
214--empty--empty 273--empty--empty 332--empty--empty 
215--empty--empty 274--empty--empty 333--24546--COPB 
216--empty--empty 275--13059--TPM4 334--empty--empty 
217--128737--ARHGAP12 276--7523--PPIA 335--empty--empty 
218--empty--empty 277--18657--DIAPH2 336--empty--empty 
219--empty--empty 278--132358--ENAH 337--288631--M_014776 
220--empty--empty 279--11684--PFN2 338--scramble--scramble 
221--empty--empty 280--empty--empty 339--8031--GSN 
222--empty--empty 281--empty--empty 340--empty--empty 
223--empty--empty 282--empty--empty 341--empty--empty 
224--empty--empty 283--30244--TNS 342--empty--empty 
225--empty--empty 284--288545--TPM1 343--18467--DIAPH2 
226--empty--empty 285--empty--empty 344--37341--NEXN 
227--empty--empty 286--empty--empty 345--118375--TPM2 
228--empty--empty 287--empty--empty 346--empty--empty 
229--21792--RICS 288--empty--empty 347--empty--empty 
230--147330--BCR 289--29944--ARAP3 348--empty--empty 




233--empty--empty 292--empty--empty 351--288632--GIT2 
234--empty--empty 293--empty--empty 352--scramble--scramble 
235--empty--empty 294--empty--empty 353--26357--PARVA 
236--empty--empty 295--13894--IQGAP1 354--empty--empty 
237--empty--empty 296--1427--BCR 355--empty--empty 
238--empty--empty 297--empty--empty 356--empty--empty 
239--empty--empty 298--empty--empty 357--13013--VASP 
240--empty--empty 299--empty--empty 358--122515--PPIA 
241--138618--GIT2 300--empty--empty 359--empty--empty 
242--288566--ANXA2 301--empty--empty 360--empty--empty 
243--24121--EVL 302--empty--empty 361--8218--GSN 
244--empty--empty 303--30036--ARAP3 362--empty--empty 
245--empty--empty 304--scramble--scramble 363--empty--empty 
246--empty--empty 305--empty--empty 364--empty--empty 
247--146690--DIAPH2 306--empty--empty 365--22868--TENC1 
248--26351--ENAH 307--empty--empty 366--118352--TPM1 
249--12962--TPM2 308--empty--empty 367--13058--TPM2 
250--empty--empty 309--empty--empty 368--empty--empty 
251--empty--empty 310--empty--empty 369--empty--empty 
252--empty--empty 311--empty--empty 370--empty--empty 




255--138620--GIT2 314--empty--empty 373--146689--DIAPH2 
256--288567--ANXA2 315--empty--empty 374--37246--NEXN 
257--11776--PFN2 316--empty--empty 375--26545--PARVA 
258--empty--empty 317--empty--empty 376--empty--empty 
259--empty--empty 318--empty--empty 377--empty--empty 
260--empty--empty 319--empty--empty 378--empty--empty 








001--28431--INCENP 052--28431--INCENP 103--19755--RHOQ 154--22278--KIAA0672 
002--120602--RAC1 053--202491--ARHGAP8 104--21389--RND1 155--122574--PARG1 
003--43342--RAC2 054--138476--SRGAP2 105--15256--ARHGEF2 156--15718--PIK3R2 
004--28431--INCENP 055--129201--FGD4 106--258560--FLJ20220 157--20459--ARHGAP6 
005--145822--DOCK1 056--120493--RASGRF2 107--9553--ARHGDIG 158--121663--ARHGAP6 
006--21785--DOCK4 057--38124--ARHGEF7 108--10622--CHN1 159--133783--ITSN2 
007--242555--CDC42 058--27556--SH3BP1 109--2835--MCF2 160--27760--ARHGEF3 
008--36445--RHOV 059--108901--GMIP 110--136834--DNMBP 161--29582--ABR 
009--135247--NGEF 060--288635--PIK3R1 111--2808--RHOA 162--35378--ARHGAP18 
010--22765--DOCK9 061--20636--ARHGAP6 112--27408--RAC1 163--14477--ARHGAP1 
011--9552--ARHGDIB 062--121662--ARHGAP6 113--27796--RHOF 164--288609--SRGAP2 
012--146035--CHN1 063--scramble--scramble 114--217273--KIAA0720 165--22731--ARHGEF9 
013--119310--KIAA0861 064--16981--NET1 115--146562--DOCK2 166--4716--TIAM1 
014--25195--FLJ20184 065--21946--ARHGEF17 116--133245--DOCK6 167--13846--HAPIP 
015--scramble--scramble 066--288619--FLJ10312 117--43583--ARHGEF18 168--261264--KIAA1688 
016--242587--RAC1 067--213201--LOC553158 118--119417--ARHGEF11 169--22148--FARP2 
017--21613--RHOD 068--138477--SRGAP2 119--12546--ITSN1 170--31650--DLC1 
018--26070--ECT2 069--119317--ARHGEF4 120--288678--p190-A 171--288605--ARHGAP6 
019--145823--DOCK1 070--258555--TIAM2 121--41918--RAC3 172--20550--ARHGAP6 
020--21881--DOCK4 071--14029--HAPIP 122--288684--FLJ32854 173--28809--ALS2 
021--103506--AKAP13 072--135118--C5orf5 123--144005--MCF2 174--251364--OBSCN 
022--214646--ARHGEF11 073--138078--FARP1 124--136835--DNMBP 175--148850--CLG 
023--119420--ARHGEF1 074--scramble--scramble 125--44031--RHOBTB1 176--22182--KIAA0672 
024--147081--ARHGAP5 075--288604--ARHGAP6 126--122079--ARHGEF15 177--22105--KIAA0053 
025--43438--RAC2 076--288607--ARHGAP6 127--15160--ARHGEF2 178--128708--CENTD2 
026--scramble--scramble 077--110844--BCR 128--258559--FLJ20220 179--22826--ARHGEF9 
027--22402--KIAA0861 078--2839--VAV1 129--21847--ARHGAP11A 180--138877--TIAM1 
028--25387--FLJ20184 079--38295--ARHGEF7 130--131863--STARD13 181--14738--FGD1 
029--43848--RHOBTB1 080--27462--SH3BP1 131--43400--ARHGEF18 182--21727--ARHGEF10 
030--121751--SGEF 081--22201--KIAA0053 132--119418--ARHGEF11 183--147813--ABR 
031--135246--NGEF 082--34994--7h3 133--19665--RHOQ 184--128827--ARHGAP18 
032--22669--DOCK9 083--22774--ARHGEF4 134--21295--RND1 185--122573--PARG1 
033--140197--ARHGAP11A 084--20229--TIAM2 135--27700--RHOF 186--15906--PIK3R2 
034--202336--STARD13 085--129200--FGD4 136--217272--KIAA0720 187--133298--ALS2 
035--136052--AKAP13 086--120492--RASGRF2 137--9458--ARHGDIG 188--131675--OBSCN 
036--21848--ARHGEF11 087--21850--ARHGEF17 138--10528--CHN1 189--124683--HAPIP 
037--242554--CDC42 088--32847--FLJ10312 139--138465--RHOBTB1 190--288618--KIAA1688 
038--120713--RHOV 089--24794--GMIP 140--122080--ARHGEF15 191--288610--KIAA0053 
039--21520--RHOD 090--118085--PIK3R1 141--142608--ITSN1 192--22844--CENTD2 
040--146755--ECT2 091--1237--BCR 142--288677--p190-A 193--120361--RHOB 
041--9457--ARHGDIB 092--2933--VAV1 143--21943--ARHGAP11A 194--120600--RAC1 
042--146034--CHN1 093--137405--HAPIP 144--288666--M 052851 195--45990--RHOG 
043--138464--RHOBTB1 094--135119--C5orf5 145--17648--ITSN2 196--36435--GEFT 
044--22998--SGEF 095--22297--KIAA0053 146--135243--ARHGEF3 197--31982--DOCK5 
045--214561--ARHGEF1 096--125786--7h3 147--22052--FARP2 198--147974--DOCK7 
046--147082--ARHGAP5 097--120211--RHOA 148--31555--DLC1 199--28644--RHOJ 
047--140198--ARHGAP11A 098--45358--RAC1 149--14383--ARHGAP1 200--16082--ARHN 
048--288668--M 178007 099--42005--RAC3 150--22273--SRGAP2 201--103341--AKAP13 
049--28431--INCENP 100--288683--FLJ32854 151--14826--FGD1 202--129250--DOCK11 
050--16886--NET1 101--146561--DOCK2 152--138290--ARHGEF10 203--272051--ARHGAP23 
051--16818--FARP1 102--133244--DOCK6 153--148851--CLG 204--146298--CHN2 
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205--32098--MCF2L 256--16914--FARP1 307--146565--DOCK3 358--845--HAPIP
206--16561--SOS1 257--147815--ABR 308--149462--DOCK8 359--empty--empty
207--41889--RHOB 258--148782--ARHGAP20 309--119311--ARHGEF12 360--33369--ARHGAP24
208--120601--RAC1 259--10340--ARHGAP4 310--119422--ARHGEF1 361--41034--FGD2
209--5062--RHOH 260--148767--SRGAP1 311--empty--empty 362--213191--DLC1
210--288617--KIAA0720 261--39762--SPATA13 312--22398--ARHGAP26 363--scramble--scramble
211--130801--DOCK5 262--288681--FLJ00068 313--10324--CDC42 364--32759--FLJ10312
212--147975--DOCK7 263--849--TRIO 314--36623--GEFT 365--17378--VAV3 
213--288688--RGNEF 264--33188--ARHGAP24 315--scramble--scramble 366--38215--ARHGEF7
214--5491--ARHGEF1 265--26743--FLJ11183 316--143049--SOS2 367--22869--ARHGEF4
215--12452--ITSN1 266--202494--DLC1 317--42188--ARHGEF16 368--132262--ARHGAP17 
216--11646--OPHN1 267--288606--ARHGAP6 318--2841--ARHGEF5 369--18770--MYO9A
217--10243--RHOG 268--34874--ARHGAP19 319--136053--AKAP13 370--empty--empty 
218--141956--GEFT 269--13014--VAV2 320--119907--ARHGDIA 371--258556--TIAM2 
219--137007--MCF2L 270--119232--ARHGEF6 321--202362--STARD13 372--13939--HAPIP 
220--142883--SOS1 271--28779--PREX1 322--empty--empty 373--12181--RASGRF1 
221--136812--RHOBTB2 272--132261--ARHGAP17 323--22673--ARHGEF12 374--26377--FLJ10521 
222--121538--ARHGEF5 273--14116--MYO9B 324--5309--ARHGEF1 375--214833--BCR 
223--1569--AKAP13 274--128706--CENTD2 325--29108--RHOU 376--213040--LOC553158 
224--37496--DOCK11 275--129604--SPATA13 326--15891--ARHE 377--118086--PIK3R1 
225--21799--STARD8 276--288682--FLJ00068 327--43944--RHOBTB1 378--8189--OCRL
226--35407--STARD13 277--131558--FGD3 328--26321--FLJ10665 379--107954--VAV3 
227--288687--RGNEF 278--26281--FLJ10521 329--31229--ARHGAP10 380--119396--ARHGEF7 
228--119421--ARHGEF1 279--147814--ABR 330--9456--ARHGAP5 381--24546--COPB
229--28549--RHOJ 280--148781--ARHGAP20 331--42260--ARHGEF16 382--148941--ARHGAP24 
230--16252--ARHN 281--147474--HA-1 332--288577--ARHGEF5 383--18866--MYO9A 
231--120805--RHOH 282--104448--OCRL 333--24546--COPB 384--24546--COPB
232--123225--KIAA0720 283--138981--VAV2 334--22590--ARHGAP26 
 
233--272050--ARHGAP23 284--5326--ARHGEF6 335--35584--STARD13 
234--14167--CHN2 285--103343--TRIO 336--24546--COPB 
235--22631--RHOBTB2 286--148939--ARHGAP24 337--133782--ITSN2 
236--3027--ARHGEF5 287--14207--MYO9B 338--scramble--scramble 
237--12635--ITSN1 288--128707--CENTD2 339--40846--FGD2 
238--143673--OPHN1 289--44189--RHOC 340--46352--DLC1 
239--138366--STARD8 290--scramble--scramble 341--22081--SRGAP2 
240--35499--STARD13 291--10418--CDC42 342--261179--SRGAP2 
241--17743--ITSN2 292--36531--GEFT 343--120291--RASGRF1 
242--215120--FARP1 293--146564--DOCK3 344--123058--FLJ10521 
243--26648--FLJ11183 294--149461--DOCK8 345--119318--ARHGEF4 
244--17367--DLC1 295--29197--RHOU 346--26031--ARHGAP17 
245--10244--ARHGAP4 296--15798--ARHE 347--118087--PIK3R1 
246--148766--SRGAP1 297--1475--AKAP13 348--104450--M 001587 
247--131559--FGD3 298--14384--ARHGDIA 349--scramble--scramble 
248--123057--FLJ10521 299--127413--ARHGAP10 350--32666--FLJ10312 
249--121870--PREX1 300--9551--ARHGAP5 351--17834--ITSN2 
250--132263--ARHGAP17 301--scramble--scramble 352--scramble--scramble 
251--147475--HA-1 302--143048--SOS2 353--147329--BCR 
252--114042--OCRL 303--44091--RHOC 354--213042--LOC553158 
253--121664--ARHGAP6 304--scramble--scramble 355--138478--SRGAP2 
254--35051--ARHGAP19 305--138466--RHOBTB1 356--261180--SRGAP2 
255--133784--ITSN2 306--140527--FLJ10665 357--258554--TIAM2 
 




001--28431--INCENP 052--28431--INCENP 103--15501--KIF5A 154--empty--empty 
002--14762--KIF2 053--empty--empty 104--118514--LOC374654 155--empty--empty 
003--118447--KIF3A 054--empty--empty 105--24036--MPHOSPH1 156--empty--empty 
004--28431--INCENP 055--261145--CLASP2 106--288671--MYH 157--13539--DNCL1 
005--11788--MYH3 056--258848--MACF1 107--288685--MYO5B 158--215817--D2LIC 
006--11604--MYH8 057--empty--empty 108--263744--MYO7B 159--142517--RSN 
007--288680--KIF4B 058--empty--empty 109--22516--MAPK8IP3 160--146318--DCTN1 
008--37893--C6orf102 059--empty--empty 110--118410--MYO1C 161--empty--empty 
009--16618--KIF20A 060--empty--empty 111--14392--KIF1A 162--empty--empty 
010--13674--MYH13 061--118342--DNCL2B 112--34309--LOC84643 163--empty--empty 
011--8174--MYO5A 062--288696--DYNC2H1 113--36707--KIF12 164--empty--empty 
012--8175--MYO7A 063--scramble--scramble 114--221472--MYO1G 165--empty--empty 
013--20076--MAPK8IP2 064--43533--CYLN2 115--24994--MYH4 166--empty--empty 
014--148408--MYO1B 065--42410--MLPH 116--11701--MYH9 167--empty--empty 
015--scramble--scramble 066--empty--empty 117--118501--KIF23 168--empty--empty 
016--14669--KIF2 067--empty--empty 118--288689--KIF26B 169--20987--MAPRE2 
017--14765--KIF11 068--empty--empty 119--118504--KIFC2 170--17983--TCTEL1 
018--19899--MYO1F 069--empty--empty 120--118400--MYO15A 171--118315--DNCL1 
019--11602--MYH3 070--empty--empty 121--15207--KIF3B 172--124933--D2LIC 
020--11700--MYH8 071---empty--empty 122--22364--KIFAP3 173--empty--empty 
021--118450--KIF22 072--empty--empty 123--136770--MAPK8IP3 174--empty--empty 
022--263710--KIF26A 073--3708--MAPRE1 124--35347--MYO1C 175--empty--empty 
023--43827--KIFC1 074--scramble--scramble 125--118474--KNSL7 176--empty--empty 
024--19898--MYO10 075--36233--DNCL2B 126--118492--KIF18A 177--empty--empty 
025--19038--KIF3A 076--288695--DYNC2H1 127--118465--MPHOSPH1 178--empty--empty 
026--scramble--scramble 077--empty--empty 128--288673--MYH 179--empty--empty 
027--19889--MAPK8IP2 078--empty--empty 129--118407--MYO18B 180--empty--empty 
028--148409--MYO1B 079--empty--empty 130--24008--DNCLI1 181--8383--PAFAH1B1 
029--22099--KIF14 080--empty--empty 131--36749--KIF23 182--258847--MACF1 
030--118477--KIF17 081--empty--empty 132--288690--KIF26B 183--empty--empty 
031--288582--KIF20A 082--empty--empty 133--118435--KIF5A 184--empty--empty 
032--13581--MYH13 083--empty--empty 134--118513--LOC374654 185--empty--empty 
033--147986--MYO18A 084--empty--empty 135--118498--KIF12 186--empty--empty 
034--9741--DNCI2 085--261144--CLASP2 136--221471--MYO1G 187--empty--empty 
035--19353--KIF22 086--258846--MACF1 137--288686--MYO5B 188--empty--empty 
036--263711--KIF26A 087--42493--MLPH 138--263743--MYO7B 189--empty--empty 
037--288679--KIF4B 088--empty--empty 139--28246--KNSL7 190--empty--empty 
038--37797--C6orf102 089--empty--empty 140--32973--KIF18A 191--empty--empty 
039--14672--KIF11 090--empty--empty 141--38128--KIFC2 192--empty--empty 
040--118394--MYO1F 091--empty--empty 142--24065--MYO15A 193--22400--KIF1B 
041--8081--MYO5A 092--empty--empty 143--34346--MYO18B 194--18738--KIF2C 
042--8082--MYO7A 093--empty--empty 144--23822--DNCLI1 195--118421--KIF3C 
043--22195--KIF14 094--empty--empty 145--142516--RSN 196--9431--AP1B1 
044--118478--KIF17 095--empty--empty 146--242560--DCTN1 197--11603--MYH6 
045--43923--KIFC1 096--empty--empty 147--136574--MAPRE2 198--147398--MYH10 
046--19992--MYO10 097--147322--KIF1A 148--139625--TCTEL1 199--14763--KIF5B 
047--147987--MYO18A 098--118495--LOC84643 149--empty--empty 200--30070--KIF9 
048--9836--DNCI2 099--118432--KIF3B 150--empty--empty 201--118472--KIF21A 
049--28431--INCENP 100--118456--KIFAP3 151)--8478--PAFAH1B1 202--1486--MYO3A 
050--43346--CYLN2 101--24899--MYH4 152--288620--MACF1 203--27397--MYO5C 
051--3891--MAPRE1 102--11605--MYH9 153--empty--empty 204--144275--MYO9A 
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205--144012--MYO1A 256--14081--DCTN1 307--8172--MYH7 358--empty--empty
206--251683--MYO1D 257--empty--empty 308--43338--MYH11 359--empty--empty
207--118460--KIF1B 258--empty--empty 309--118490--KIF25 360--empty--empty
208--18553--KIF2C 259--empty--empty 310--271492--LOC441930 361--136867--CLASP1
209--29745--KIF13A 260--empty--empty 311--empty--empty 362--279207--DNCL2A
210--17208--MYH1 261--empty--empty 312--288670--MYO16 363--scramble--scramble
211--11699--MYH6 262--empty--empty 313--288675--KIF4A 364--empty--empty
212--147399--MYH10 263--empty--empty 314--16356--MAPK8IP1 365--empty--empty
213--26777--KIF24 264--empty--empty 315--scramble--scramble 366--empty--empty
214--118468--KIF27 265--19890--MAPRE3 316--15509--MYO1E 367--empty--empty
215--118438--KIFC3 266--18077--TCTE1L 317--288694--KIF16B 368--empty--empty
216--251256--MYO15B 267--35969--Dlc2 318--39789--FLJ37300 369--empty--empty
217--11118--KIF3C 268--288672--MYH 319--288692--KIF21B 370--empty--empty
218--9527--AP1B1 269--empty--empty 320--1137--MYO3B 371--empty--empty
219--16050--MYO1A 270--empty--empty 321--14712--DNCI1 372--empty--empty
220--222682--MYO1D 271--empty--empty 322--empty--empty 373--16896--APC2
221--251250--STARD9 272--empty--empty 323--32833--KIF25 374--122703--ch-TOG
222--251223--LOC146909 273--empty--empty 324--271493--LOC441930 375--empty--empty
223--118471--KIF21A 274--empty--empty 325--14850--KIF5C 376--empty--empty
224--131930--MYO3A 275--empty--empty 326--121337--CENPE 377--empty--empty
225--118309--DNCH1 276--empty--empty 327--22848--KIF13B 378--empty--empty
226--118326--DNCLI2 277--42812--APC 328--118403--MYH2 379--empty--empty
227--26683--KIF24 278--21827--ch-TOG 329--15510--MYO6 380--empty--empty
228--118469--KIF27 279--empty--empty 330--14293--MYO9B 381--24546--COPB
229--14670--KIF5B 280--empty--empty 331--288693--KIF16B 382--empty--empty
230--118509--KIF9 281--empty--empty 332--39883--FLJ37300 383--empty--empty
231--29651--KIF13A 282--empty--empty 333--24546--COPB 384--24546--COPB
232--17114--MYH1 283--empty--empty 334--288669--MYO16 
233--118404--MYO5C 284--empty--empty 335--14617--DNCI1 
234--18960--MYO9A 285--empty--empty 336--24546--COPB 
235--251251--STARD9 286--empty--empty 337--139011--CYLN2 
236--251224--LOC146909 287--empty--empty 338--scramble--scramble 
237--16324--KIFC3 288--empty--empty 339--136866--CLASP1 
238--251257--MYO15B 289--18210--KIF1C 340--279206--DNCL2A 
239--118310--DNCH1 290--scramble--scramble 341--empty--empty 
240--17395--DNCLI2 291--288676--KIF4A 342--empty--empty 
241--12224--RSN 292--16261--MAPK8IP1 343--16991--APC2 
242--146317--DCTN1 293--8079--MYH7 344--22017--ch-TOG 
243--136502--MAPRE3 294--118370--MYH11 345--empty--empty 
244--17984--TCTE1L 295--14764--KIF5C 346--empty--empty 
245--empty--empty 296--10520--CENPE 347--empty--empty 
246--empty--empty 297---288691--KIF21B 348--empty--empty 
247--44755--APC 298--1138--MYO3B 349--scramble--scramble 
248--21923--ch-TOG 299--15603--MYO6 350--empty--empty 
249--empty--empty 300--143862--MYO9B 351--43442--CYLN2 
250--empty--empty 301--scramble--scramble 352--scramble--scramble 
251--empty--empty 302--15693--MYO1E 353--empty--empty 
252--empty--empty 303--18304--KIF1C 354--empty--empty 
253--118341--Dlc2 304--scramble--scramble 355--empty--empty 
254--288674--MYH 305--22657--KIF13B 356--empty--empty 
255--12317--RSN 306--24900--MYH2 357--empty--empty 
 




001--28431--INCENP 052--28431--INCENP 103--9041--ITGB6 154--4366--PTPRF 
002--109878--ITGB1 053--11974--PIK3CG 104--12768--TM4SF6 155--114285--PTPRA 
003--106001--ITGB3 054--136520--PIP5K1C 105--21093--ITGB3BP 156--10475--CAPNS1 
004--28431--INCENP 055--12193--RDX 106--1442--FYN 157--288585--PAK4 
005--16824--SCAM-1 056--23307--TES 107--142304--MAPK3 158--42854--PRKCA 
006--146413--CSK 057--288576--GRB7 108--145116--ILK 159--288641--NF2 
007--11108--ITGB5 058--104588--PTPRF 109--107195--PPFIA1 160--108962--FBLP-1 
008--14501--CD81 059--4363--PTPRA 110--16651--SDCBP 161--10297--CAV1 
009--17808--CIB1 060--105571--CAPNS1 111--109879--ITGB1 162--110865--ROCK2 
010--144829--FYN 061--288584--PAK4 112--288621--ITGB1 163--288639--PIK3R1 
011--691--YES1 062--288587--PAK4 113--288558--TM4SF7 164--45927--PTEN 
012--288570--ILK 063--scramble--scramble 114--288581--SDCBP 165--215169--NCK2 
013--13394--PPFIA1 064--136120--PLEKHC1 115--147447--ABL1 166--12157--PXN 
014--34040--SDOS 065--13145--ZYX 116--103698--PTK2 167--22801--SORBS1 
015--scramble--scramble 066--142844--ROCK1 117--42217--K-ALPHA-1 168--10333--ARF1 
016--288625--ITGB1 067--11879--PIK3CG 118--15476--ACTN4 169--11593--MSN 
017--288557--TM4SF7 068--136521--PIP5K1C 119--9965--FLNC 170--110779--PAK2 
018--288580--SDCBP 069--17402--NCK1 120--1653--LIMK2 171--288591--PAK4 
019--16920--SCAM-1 070--21515--BCAR1 121--288542--ITGB4 172--300--PRKCA 
020--146414--CSK 071--136917--SORBS1 122--288599--SORBS1 173--146745--CRK 
021--9415--ACTB 072--10237--ARF1 123--13311--PPFIA1 174--144866--GRB2 
022--9416--ACTN1 073--288615--FBLP-1 124--121551--SDCBP 175--23481--TGFB1I1 
023--9964--FLNB 074--scramble--scramble 125--12434--SDC4 176--4454--PTPRF 
024--143455--LIMK1 075--288590--PAK4 126--14494--CALR 177--14711--DNM1 
025--8055--ITGB3 076--288593--PAK4 127--21001--ITGB3BP 178--146559--DNM2 
026--scramble--scramble 077--2827--CBL 128--144828--FYN 179--13296--NCK2 
027--13472--PPFIA1 078--14079--CSRP1 129--103376--MYLK 180--12253--PXN 
028--34136--SDOS 079--2834--GRB7 130--288626--MYLK 181--5379--TLN1 
029--288554--TM4SF7 080--4274--PTPRF 131--42130--K-ALPHA-1 182--108453--VCL 
030--112326--PTPNS1 081--14616--DNM1 132--15570--ACTN4 183--145951--CAV1 
031--17715--CIB1 082--146560--DNM2 133--8947--inbeta6 184--595--ROCK2 
032--144827--FYN 083--17498--NCK1 134--138892--TM4SF6 185--104566--PTPRA 
033--263692--MAP3K1 084--21608--BCAR1 135--12769--TM4SF7 186--10388--CAPNS1 
034--103460--MYLK 085--142472--RDX 136--121550--SDCBP 187--6472--CRK 
035--9511--ACTB 086--134609--TES 137--214749--MAPK3 188--4292--GRB2 
036--9512--ACTN1 087--13054--ZYX 138--1556--ILK 189--288597--SORBS1 
037--11289--ITGB5 088--681--ROCK1 139--12529--SDC4 190--288550--ARF1 
038--14407--CD81 089--4271--PTPRA 140--14400--CALR 191--146449--DNM1 
039--138896--TM4SF7 090--10293--CAPNS1 141--10060--FLNC 192--288574--DNM2 
040--16742--SDCBP 091--2921--CBL 142--144048--LIMK2 193--112291--ITGB1 
041--690--YES1 092--14172--CSRP1 143--288627--MYLK 194--35488--ITGB1 
042--145117--ILK 093--288596--SORBS1 144--288628--MYLK 195--2981--ITGB4 
043--288561--TM4SF7 094--10426--ARF1 145--202368--NF2 196--136919--SORBS1 
044--43659--PTPNS1 095--14804--DNM1 146--279294--FBLP-1 197--147450--ABL2 
045--10059--FLNB 096--288573--DNM2 147--143572--MSN 198--103649--PTK2 
046--143456--LIMK1 097--109877--ITGB1 148--110776--PAK2 199--288629--CD151 
047--263693--MAP3K1 098--35575--ITGB1 149--288636--PIK3R1 200--288555--TM4SF7 
048--1510--MYLK 099--2888--ITGB4 150--142044--PTEN 201--137693--ITGB1BP1 
049--28431--INCENP 100--22895--SORBS1 151--5467--TLN1 202--103417--SRC 
050--136119--PLEKHC1 101--1241--ABL1 152--20570--VCL 203--1449--MAPK1 
051--288613--FBLP-1 102--103596--PTK2 153--23577--TGFB1I1 204--145118--ILK 
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205--3664--GNB2L1 256--288614--FBLP-1 307--103430--ABL2 358--22706--SORBS1 
206--121549--SDCBP 257--9575--CAV2 308--1627--FYN 359--empty--empty 
207--112292--ITGB1 258--2960--PIK3CA 309--13019--VIM 360--43082--DDEF1
208--288622--ITGB1 259--288640--PIK3R1 310--144674--FLNA 361--23784--KIAA0992 
209--288559--TM4SF7 260--4264--PTPN1 311--empty--empty 362--288589--PAK4 
210--12968--TRIP6 261--13379--NCK2 312--144049--LIMK2 363--scramble--scramble
211--103346--ABL2 262--15503--LIMS1 313--288544--ITGB4 364--103397--PRKCM 
212--142859--PTK2 263--136918--SORBS1 314--288601--SORBS1 365--2828--CRKL 
213--120764--OK-SW- 264--214733--ARF1 315--scramble--scramble 366--2928--GRB7 
214--13018--VIL2 265--20179--MYLIP 316--288579--SDCBP 367--132221--LIMS2 
215--202366--NF2 266--288588--PAK4 317--111141--LRP1 368--104563--PTPRA 
216--144050--LIMK2 267--288592--PAK4 318--10385--CANX 369--15581--DNM2 
217--288543--ITGB4 268--679--PRKCE 319--137692--ITGB1BP1 370--empty--empty 
218--288600--SORBS1 269--146743--CRK 320--103333--SRC 371--288564--NCK2 
219--3757--GNB2L1 270--4196--GRB2 321--144402--MYLK 372--288595--SORBS1
220--288578--SDCBP 271--17398--LASP1 322--empty--empty 373--23211--TES 
221--1490--TRPM7 272--4361--PTPN11 323--13111--VIM 374--115435--ZYX
222--10290--CANX 273--15488--DNM2 324--9963--FLNA 375--145680--CAV2
223--44218--ITGB1BP1 274--20586--GIT1 325--43538--CD151 376--144253--PIK3CB 
224--142855--SRC 275--288563--NCK2 326--138895--TM4SF7 377--10292--CAPN2
225--144403--MYLK 276--15596--LIMS1 327--288553--TM4SF7 378--147188--ARF1
226--143703--PAK1 277--5622--TLN2 328--17014--SCAM-1 379--2922--CRKL
227--120844--OK-SW- 278--108454--VCL 329--1544--MAPK1 380--3020--GRB7
228--13110--VIL2 279--9481--CAV2 330--1318--LIMK1 381--24546--COPB
229--43352--CD151 280--144250--PIK3CA 331--11342--LRP1 382--42901--DDEF1
230--46050--TM4SF7 281--15805--CAPN1 332--145945--CANX 383--288572--DNM2
231--12860--TM4SF7 282--46173--RNF5 333--24546--COPB 384--24546--COPB
232--13155--TRIP6 283--146744--CRK 334--1469--LIMK2 
 
233--142301--MAPK1 284--106680--GRB2 335--1692--MYLK 
234--1461--ILK 285--288598--SORBS1 336--24546--COPB 
235--212797--TRPM7 286--288551--ARF1 337--202367--NF2 
236--10472--CANX 287--15673--DNM2 338--scramble--scramble 
237--8090--NF2 288--20497--GIT1 339--23879--KIAA0992 
238--1563--LIMK2 289--35396--ITGB1 340--733--PAK4
239--144401--MYLK 290--scramble--scramble 341--288638--PIK3R1 
240--249--PAK1 291--2793--ITGB4 342--142400--PTPN12 
241--8183--NF2 292--288594--SORBS1 343--134610--TES 
242--279293--FBLP-1 293--1478--ABL2 344--139068--ZYX 
243--118397--MYLIP 294--1537--FYN 345--25885--LIMS2 
244--732--PAK4 295--43447--CD151 346--104569--PTPRA 
245--288637--PIK3R1 296--288556--TM4SF7 347--10387--CAPN2 
246--104533--PTPN1 297--44998--ITGB1BP1 348--147189--ARF1 
247--5717--TLN2 298--288644--SRC 349--scramble--scramble 
248--20480--VCL 299--1634--MAPK1 350--103310--PRKCM 
249--17494--LASP1 300--1413--LIMK1 351--288642--NF2 
250--4449--PTPN11 301--scramble--scramble 352--scramble--scramble 
251--15898--CAPN1 302--16556--SDCBP 353--145681--CAV2 
252--18776--RNF5 303--112293--ITGB1 354--17439--PIK3CB 
253--288586--PAK4 304--scramble--scramble 355--203811--M_181524 
254--677--epsilon 305--288560--TM4SF7 356--4270--PTPN12 
255--8273--NF2 306--126654--SCAM-1 357--13457--NCK2 
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Plate Position Gene ENSEMBL ID
305 1 incenp
305 2 aadat ENSG00000109576
305 3 aak1 ENSG00000115977
305 4 abat ENSG00000183044
305 5 abca1 ENSG00000165029
305 6 abca13 ENSG00000179869
305 7 abcc10 ENSG00000124574
305 8 abcc6 ENSG00000091262
305 9 abhd1 ENSG00000143994
305 10 abhd13 ENSG00000139826
305 11 abhd5 ENSG00000011198
305 12 incenp
305 13 ablim1 ENSG00000099204
305 14 copb
305 15 ablim2 ENSG00000163995
305 16 acaa2 ENSG00000167315
305 17 acat2 ENSG00000120437
305 18 acbd6 ENSG00000135847
305 19 ache ENSG00000087085
305 20 scrambled
305 21 acox2 ENSG00000168306
305 22 acoxl ENSG00000153093
305 23 actl6b ENSG00000077080
305 24 actr3 ENSG00000115091
305 25 acvr1b ENSG00000135503
305 26 acvr2b ENSG00000114739
305 27 acvrl1 ENSG00000139567
305 28 adam11 ENSG00000073670
305 29 adam12 ENSG00000148848
305 30 gosr1
305 31 adam20 ENSG00000134007
305 32 adam21 ENSG00000139985
305 33 adam30 ENSG00000134249
305 34 adamts14 ENSG00000138316
305 35 adamts7 ENSG00000136378
305 36 adamts9 ENSG00000163638
305 37 adar ENSG00000160710
305 38 adfp ENSG00000147872
305 39 scrambled
305 40 adk ENSG00000156110
305 41 adora1 ENSG00000163485
305 42 adora2a ENSG00000128271
305 43 adra2a ENSG00000150594
305 44 aebp1 ENSG00000106624
305 45 agpat2 ENSG00000169692
305 46 rab1a
305 47 agpat4 ENSG00000026652
305 48 agtrap ENSG00000177674
305 49 agxt2l2 ENSG00000175309
305 50 aim1l ENSG00000176092
Plate Position Gene ENSEMBL ID
305 51 akap3 ENSG00000111254
305 52 akap5 ENSG00000179841
305 53 akap9 ENSG00000127914
305 54 akr1cl1 ENSG00000196326
305 55 akt1 ENSG00000142208
305 56 aldh16a1 ENSG00000161618
305 57 aldh1a1 ENSG00000165092
305 58 aldh1a2 ENSG00000128918
305 59 aldh9a1 ENSG00000143149
305 60 alpk2 ENSG00000198796
305 61 alpp ENSG00000163283
305 62 als2cl ENSG00000178038
305 63 rab1a
305 64 ambp ENSG00000106927
305 65 ank1 ENSG00000029534
305 66 ankfn1 ENSG00000153930
305 67 ankh ENSG00000154122
305 68 ankrd11 ENSG00000167522
305 69 ankrd35 ENSG00000198483
305 70 scrambled
305 71 ankrd5 ENSG00000132623
305 72 ankrd9 ENSG00000156381
305 73 anks6 ENSG00000165138
305 74 anpep ENSG00000166825
305 75 ap2s1 ENSG00000042753
305 76 cpeb1 ENSG00000103723
305 77 ap3s1 ENSG00000177879
305 78 ap4s1 ENSG00000100478
305 79 copb
305 80 apbb1ip ENSG00000077420
305 81 apoa5 ENSG00000110243
305 82 apobec3b ENSG00000179750
305 83 ar ENSG00000169083
305 84 arcn1 ENSG00000095139
305 85 arf3 ENSG00000134287
305 86 arfip1 ENSG00000164144
305 87 arhgap12 ENSG00000165322
305 88 scrambled
305 89 arhgap24 ENSG00000138639
305 90 arhgef18 ENSG00000104880
305 91 arid1a ENSG00000117713
305 92 arih1 ENSG00000166233
305 93 arl14 ENSG00000179674
305 94 arl5a ENSG00000162980
305 95 gosr1
305 96 arpc1b ENSG00000130429
305 97 arrdc1 ENSG00000197070
305 98 ars2 ENSG00000087087
305 99 arsf ENSG00000062096
305 100 art4 ENSG00000111339
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Plate Position Gene ENSEMBL ID
305 101 asah3l ENSG00000177076
305 102 asb12 ENSG00000198881
305 103 asb15 ENSG00000146809
305 104 asb18 ENSG00000182177
305 105 ascc2 ENSG00000100325
305 106 asf1a ENSG00000111875
305 107 astn2 ENSG00000148219
305 108 atp2c2 ENSG00000064270
305 109 atad3a ENSG00000197785
305 110 gosr1
305 111 atf7ip ENSG00000171681
305 112 atg4a ENSG00000101844
305 113 atg4b ENSG00000168397
305 114 atg5 ENSG00000057663
305 115 atg9b ENSG00000181652
305 116 scrambled
305 117 atp6v1b2 ENSG00000147416
305 118 atp6v1d ENSG00000100554
305 119 atrx ENSG00000085224
305 120 avpi1 ENSG00000119986
305 121 axl ENSG00000167601
305 122 b3gat2 ENSG00000112309
305 123 b3gat3 ENSG00000149541
305 124 b4galt5 ENSG00000158470
305 125 b4galt6 ENSG00000118276
305 126 rab1a
305 127 baiap2l1 ENSG00000006453
305 128 bccip ENSG00000107949
305 129 bcl11b ENSG00000127152
305 130 bcor ENSG00000183337
305 131 bcr ENSG00000186716
305 132 kiaa1446 ENSG00000183092
305 133 pmf1 ENSG00000160783
305 134 bhlhb9 ENSG00000198908
305 135 scrambled
305 136 birc8 ENSG00000180152
305 137 bmp3 ENSG00000152785
305 138 brd1 ENSG00000100425
305 139 brd4 ENSG00000141867
305 140 brd7 ENSG00000166164
305 141 btbd14a ENSG00000148411
305 142 copb
305 143 btbd7 ENSG00000011114
305 144 btn3a1 ENSG00000026950
305 145 bub1b ENSG00000156970
305 146 bub3 ENSG00000154473
305 147 bud31 ENSG00000106245
305 148 bxdc5 ENSG00000117133
305 149 loc151579 ENSG00000082153
305 150 c10orf137 ENSG00000107938
Plate Position Gene ENSEMBL ID
305 151 c10orf33 ENSG00000119943
305 152 c10orf61 ENSG00000119977
305 153 c10orf73 ENSG00000172538
305 154 c10orf79 ENSG00000197748
305 155 c10orf9 ENSG00000108100
305 156 c10orf99 ENSG00000188373
305 157 c11orf55 ENSG00000196559
305 158 bc024479 ENSG00000120458
305 159 copb
305 160 c11orf64 ENSG00000181995
305 161 c11orf71 ENSG00000180425
305 162 c12orf34 ENSG00000139438
305 163 c12orf44 ENSG00000123395
305 164 c13orf18 ENSG00000102445
305 165 1200003c05rik ENSG00000050130
305 166 scrambled
305 167 c14orf102 ENSG00000119720
305 168 c14orf126 ENSG00000129480
305 169 c14orf162 ENSG00000181492
305 170 c14orf178 ENSG00000197734
305 171 c17orf56 ENSG00000167302
305 172 c17orf76 ENSG00000181350
305 173 c17orf85 ENSG00000074356
305 174 c19orf10 ENSG00000074842
305 175 gosr1
305 176 c19orf35 ENSG00000188305
305 177 c19orf4 ENSG00000105696
305 178 2310036o22rik ENSG00000123144
305 179 c19orf57 ENSG00000132016
305 180 c19orf7 ENSG00000130749
305 181 c1orf109 ENSG00000116922
305 182 c1orf151 ENSG00000173436
305 183 c1orf157 ENSG00000176754
305 184 scrambled
305 185 c1orf191 ENSG00000198711
305 186 c1orf201 ENSG00000001460
305 187 c1orf32 ENSG00000143195
305 188 rd3 ENSG00000198570
305 189 c1orf42 ENSG00000169509
305 190 c1orf50 ENSG00000164008
305 191 rab1a
305 192 c1orf54 ENSG00000118292
305 193 c1orf85 ENSG00000198715
305 194 c1qa ENSG00000173372
305 195 c1s ENSG00000182326
305 196 c20orf133 ENSG00000172264
305 197 c20orf175 ENSG00000042062
305 198 c22orf34 ENSG00000188511
305 199 c2orf32 ENSG00000119865
305 200 c2orf43 ENSG00000118961
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Plate Position Gene ENSEMBL ID
305 201 c2orf47 ENSG00000162972
305 202 c3orf18 ENSG00000088543
305 203 c3orf26 ENSG00000184220
305 204 c3orf32 ENSG00000125046
305 205 c3orf38 ENSG00000179021
305 206 rab1a
305 207 c3orf52 ENSG00000114529
305 208 c3orf60 ENSG00000178057
305 209 c4orf14 ENSG00000084092
305 210 c4orf17 ENSG00000138813
305 211 c5orf24 ENSG00000181904
305 212 scrambled
305 213 c6 ENSG00000039537
305 214 c6orf115 ENSG00000146386
305 215 c6orf167 ENSG00000146263
305 216 c6orf170 ENSG00000146350
305 217 c6orf190 ENSG00000172673
305 218 c6orf81 ENSG00000157343
305 219 c6orf96 ENSG00000155906
305 220 c7orf25 ENSG00000136197
305 221 c8b ENSG00000021852
305 222 copb
305 223 c8orf40 ENSG00000176209
305 224 c8orf51 ENSG00000183610
305 225 c8orf54 ENSG00000181171
305 226 c9orf103 ENSG00000148057
305 227 c9orf105 ENSG00000175768
305 228 c9orf116 ENSG00000160345
305 229 c9orf19 ENSG00000122694
305 230 c9orf25 ENSG00000164970
305 231 scrambled
305 232 c9orf46 ENSG00000107020
305 233 c9orf48 ENSG00000186638
305 234 c9orf58 ENSG00000126878
305 235 c9orf80 ENSG00000148153
305 236 c9orf98 ENSG00000165695
305 237 cabc1 ENSG00000163050
305 238 gosr1
305 239 cacna1a ENSG00000141837
305 240 cacna2d3 ENSG00000157445
305 241 calm3 ENSG00000160014
305 242 calm1 ENSG00000198668
305 243 calm2 ENSG00000143933
305 244 camk2n1 ENSG00000162545
305 245 camta2 ENSG00000108509
305 246 casc1 ENSG00000118307
305 247 casz1 ENSG00000130940
305 248 cblb ENSG00000114423
305 249 cbln4 ENSG00000054803
305 250 cbx6 ENSG00000183741
Plate Position Gene ENSEMBL ID
305 251 ccbl1 ENSG00000171097
305 252 ccdc107 ENSG00000159884
305 253 ccdc112 ENSG00000164221
305 254 ccdc124 ENSG00000007080
305 255 gosr1
305 256 ccdc126 ENSG00000169193
305 257 ccdc16 ENSG00000198783
305 258 ccdc43 ENSG00000180329
305 259 ccdc46 ENSG00000154240
305 260 ccdc51 ENSG00000164051
305 261 ccdc68 ENSG00000166510
305 262 scrambled
305 263 ccdc93 ENSG00000125633
305 264 ccnk ENSG00000090061
305 265 ccr4 ENSG00000183813
305 266 ccr5 ENSG00000160791
305 267 fgfr1op ENSG00000112486
305 268 cct8 ENSG00000156261
305 269 cd300lg ENSG00000161649
305 270 cd40 ENSG00000101017
305 271 rab1a
305 272 cd40lg ENSG00000102245
305 273 cdc37 ENSG00000105401
305 274 cdc42bpb ENSG00000198752
305 275 cdc42ep1 ENSG00000128283
305 276 cdh24 ENSG00000139880
305 277 cdh26 ENSG00000124215
305 278 cdk5r1 ENSG00000176749
305 279 cdkn2c ENSG00000123080
305 280 scrambled
305 281 cdkn2d ENSG00000129355
305 282 cdkn3 ENSG00000100526
305 283 cecr5 ENSG00000069998
305 284 cenpi ENSG00000102384
305 285 cenpm ENSG00000100162
305 286 centa1 ENSG00000105963
305 287 copb
305 288 cflar ENSG00000003402
305 289 cftr ENSG00000001626
305 290 cgrrf1 ENSG00000100532
305 291 chchd1 ENSG00000172586
305 292 chchd3 ENSG00000106554
305 293 chchd6 ENSG00000159685
305 294 chi3l1 ENSG00000133048
305 295 chid1 ENSG00000177830
305 296 chmp2b ENSG00000083937
305 297 chrna4 ENSG00000101204
305 298 chrnb4 ENSG00000117971
305 299 chrnd ENSG00000135902
305 300 chst6 ENSG00000183196
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Plate Position Gene ENSEMBL ID
305 301 cirbp ENSG00000099622
305 302 copb
305 303 cirh1a ENSG00000141076
305 304 tbcb ENSG00000105254
305 305 ckap2 ENSG00000136108
305 306 clca2 ENSG00000137975
305 307 clcn4 ENSG00000073464
305 308 scrambled
305 309 cldn22 ENSG00000177300
305 310 clec2a ENSG00000188393
305 311 clic2 ENSG00000155962
305 312 clic4 ENSG00000169504
305 313 clk1 ENSG00000013441
305 314 clk3 ENSG00000179335
305 315 clpb ENSG00000162129
305 316 clstn3 ENSG00000139182
305 317 clu ENSG00000120885
305 318 gosr1
305 319 cmtm4 ENSG00000183723
305 320 ngdn ENSG00000129460
305 321 cndp1 ENSG00000150656
305 322 cnksr1 ENSG00000142675
305 323 cnnm1 ENSG00000119946
305 324 cnr2 ENSG00000188822
305 325 cntfr ENSG00000122756
305 326 col11a1 ENSG00000060718
305 327 scrambled
305 328 commd4 ENSG00000140365
305 329 copb2 ENSG00000184432
305 330 copg ENSG00000181789
305 331 cova1 ENSG00000165675
305 332 cox5a ENSG00000178741
305 333 cpeb3 ENSG00000107864
305 334 rab1a
305 335 cpm ENSG00000135678
305 336 cpne8 ENSG00000139117
305 337 cpsf3l ENSG00000127054
305 338 cpxm1 ENSG00000088882
305 339 creb5 ENSG00000146592
305 340 crmp1 ENSG00000072832
305 341 crtc3 ENSG00000140577
305 342 crygn ENSG00000127377
305 343 csad ENSG00000139631
305 344 csmd1 ENSG00000183117
305 345 cst9 ENSG00000173335
305 346 cstb ENSG00000160213
305 347 ctgf ENSG00000118523
305 348 ctsg ENSG00000100448
305 349 cul4a ENSG00000139842
305 350 cutc ENSG00000119929
Plate Position Gene ENSEMBL ID
































311 383 gosr1 ENSG00000108587
311 384 incenp ENSG00000149503
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Plate Position Gene ENSEMBL ID
306 1 incenp
306 2 dera ENSG00000023697
306 3 dgkd ENSG00000077044
306 4 dgke ENSG00000153933
306 5 dgkq ENSG00000145214
306 6 dguok ENSG00000114956
306 7 dhx35 ENSG00000101452
306 8 dhx37 ENSG00000150990
306 9 dicer1 ENSG00000100697
306 10 diras1 ENSG00000176490
306 11 dkk3 ENSG00000050165
306 12 incenp
306 13 dlgap3 ENSG00000116544
306 14 copb
306 15 dmbt1 ENSG00000187908
306 16 dnajc15 ENSG00000120675
306 17 dnal1 ENSG00000119661
306 18 dnase1l1 ENSG00000013563
306 19 dnase1l3 ENSG00000163687
306 20 scrambled
306 21 dnd1 ENSG00000183403
306 22 dnhd1 ENSG00000132283
306 23 dnm1 ENSG00000106976
306 24 dok3 ENSG00000146094
306 25 dok5 ENSG00000101134
306 26 dpep1 ENSG00000015413
306 27 bbs1 ENSG00000174483
306 28 dpp9 ENSG00000142002
306 29 dppa4 ENSG00000121570
306 30 gosr1
306 31 dqx1 ENSG00000144045
306 32 dr1 ENSG00000117505
306 33 drd2 ENSG00000149295
306 34 drg1 ENSG00000185721
306 35 dsp ENSG00000096696
306 36 dst ENSG00000151914
306 37 dusp13 ENSG00000079393
306 38 dusp15 ENSG00000149599
306 39 scrambled
306 40 dydc1 ENSG00000170788
306 41 dyrk3 ENSG00000143479
306 42 ebi3 ENSG00000105246
306 43 ecd ENSG00000122882
306 44 ecel1 ENSG00000171551
306 45 ecgf1 ENSG00000025708
306 46 rab1a
306 47 echdc2 ENSG00000121310
306 48 edc3 ENSG00000179151
306 49 edf1 ENSG00000107223
306 50 ednra ENSG00000151617
Plate Position Gene ENSEMBL ID
306 51 eed ENSG00000074266
306 52 eef1a2 ENSG00000101210
306 53 eef2k ENSG00000103319
306 54 efna3 ENSG00000143590
306 55 egfl6 ENSG00000198759
306 56 egln2 ENSG00000171570
306 57 egr2 ENSG00000122877
306 58 eif1ax ENSG00000173674
306 59 eif2b1 ENSG00000111361
306 60 eif2s2 ENSG00000125977
306 61 eif3s3 ENSG00000147677
306 62 eif5b ENSG00000158417
306 63 rab1a
306 64 elac1 ENSG00000141642
306 65 elavl2 ENSG00000107105
306 66 elovl1 ENSG00000066322
306 67 elovl5 ENSG00000012660
306 68 emilin1 ENSG00000138080
306 69 emilin2 ENSG00000132205
306 70 scrambled
306 71 enpp3 ENSG00000154269
306 72 enpp6 ENSG00000164303
306 73 loc644511 ENSG00000148713
306 74 loc730167 ENSG00000172760
306 75 loc729662 ENSG00000173609
306 76 fsip2 ENSG00000180922
306 77 loc440585 ENSG00000186973
306 78 loc644334 ENSG00000188179
306 79 copb
306 80 loc285193 ENSG00000188542
306 81 mgc59937 ENSG00000197191
306 82 loc652708 ENSG00000198848
306 83 epb41l4b ENSG00000095203
306 84 epdr1 ENSG00000086289
306 85 epha3 ENSG00000044524
306 86 ephb3 ENSG00000182580
306 87 eps8l3 ENSG00000198758
306 88 scrambled
306 89 erc2 ENSG00000187672
306 90 ercc3 ENSG00000163161
306 91 ergic3 ENSG00000125991
306 92 ervwe1 ENSG00000197604
306 93 etnk1 ENSG00000139163
306 94 ets2 ENSG00000157557
306 95 gosr1
306 96 ext1 ENSG00000182197
306 97 extl1 ENSG00000158008
306 98 extl2 ENSG00000162694
306 99 f2r ENSG00000181104
306 100 f5 ENSG00000198734
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Plate Position Gene ENSEMBL ID
306 101 f7 ENSG00000057593
306 102 fabp4 ENSG00000170323
306 103 fam101b ENSG00000183688
306 104 fam109b ENSG00000177096
306 105 c030004a17rik ENSG00000197798
306 106 fam3d ENSG00000198643
306 107 fam43b ENSG00000183114
306 108 fam55a ENSG00000095110
306 109 fam63a ENSG00000143409
306 110 gosr1
306 111 fam63b ENSG00000128923
306 112 fam81b ENSG00000153347
306 113 fam98a ENSG00000119812
306 114 fam9b ENSG00000177138
306 115 fastkd3 ENSG00000124279
306 116 scrambled
306 117 fbln2 ENSG00000163520
306 118 fbln5 ENSG00000140092
306 119 fbxl8 ENSG00000135722
306 120 fbxo45 ENSG00000174013
306 121 fbxw5 ENSG00000159069
306 122 fbxw9 ENSG00000132004
306 123 fcer2 ENSG00000104921
306 124 fcgr1a ENSG00000150337
306 125 fcgrt ENSG00000104870
306 126 rab1a
306 127 fcmd ENSG00000106692
306 128 fech ENSG00000066926
306 129 fer ENSG00000151422
306 130 ffar2 ENSG00000126262
306 131 fgf19 ENSG00000162344
306 132 fgr ENSG00000000938
306 133 fhl1 ENSG00000022267
306 134 flt3lg ENSG00000090554
306 135 scrambled
306 136 flt4 ENSG00000037280
306 137 flywch1 ENSG00000059122
306 138 foxr1 ENSG00000176302
306 139 fprl2 ENSG00000187474
306 140 frmpd3 ENSG00000147234
306 141 fscn2 ENSG00000186765
306 142 copb
306 143 fsd1l ENSG00000106701
306 144 fst ENSG00000134363
306 145 fuk ENSG00000157353
306 146 fut7 ENSG00000180549
306 147 fuz ENSG00000010361
306 148 fxyd5 ENSG00000089327
306 149 gabarapl2 ENSG00000034713
306 150 gabra5 ENSG00000186297
Plate Position Gene ENSEMBL ID
306 151 gabra6 ENSG00000145863
306 152 gabrr1 ENSG00000146276
306 153 galr3 ENSG00000128310
306 154 ganab ENSG00000089597
306 155 gapdhs ENSG00000105679
306 156 gbp2 ENSG00000162645
306 157 gcnt4 ENSG00000176928
306 158 gdf6 ENSG00000156466
306 159 copb
306 160 gdf8 ENSG00000138379
306 161 gfra1 ENSG00000151892
306 162 gimap2 ENSG00000106560
306 163 gimap6 ENSG00000133561
306 164 git1 ENSG00000108262
306 165 glra1 ENSG00000145888
306 166 scrambled
306 167 glrb ENSG00000109738
306 168 glrx2 ENSG00000023572
306 169 gmfb ENSG00000197045
306 170 gmppa ENSG00000144591
306 171 gnai3 ENSG00000065135
306 172 gnb2 ENSG00000172354
306 173 gng10 ENSG00000059769
306 174 gng13 ENSG00000127588
306 175 gosr1
306 176 gng2 ENSG00000186469
306 177 gng8 ENSG00000167414
306 178 golga ENSG00000140478
306 179 gon4l ENSG00000116580
306 180 gosr1 ENSG00000108587
306 181 gosr2 ENSG00000108433
306 182 gp5 ENSG00000178732
306 183 gpatc2 ENSG00000092978
306 184 scrambled
306 185 gpatc3 ENSG00000198746
306 186 gpbp1 ENSG00000062194
306 187 gpc2 ENSG00000197093
306 188 gpc3 ENSG00000147257
306 189 gpnmb ENSG00000136235
306 190 tmem181 ENSG00000146433
306 191 rab1a
306 192 gpr31 ENSG00000120436
306 193 gpr35 ENSG00000178623
306 194 gpr37 ENSG00000170775
306 195 gpr45 ENSG00000135973
306 196 gpr50 ENSG00000102195
306 197 gps2 ENSG00000132522
306 198 gpt ENSG00000167701
306 199 grb14 ENSG00000115290
306 200 grb7 ENSG00000141738
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306 201 grem1 ENSG00000166923
306 202 grik2 ENSG00000164418
306 203 grik5 ENSG00000105737
306 204 grin1 ENSG00000176884
306 205 grin2b ENSG00000150086
306 206 rab1a
306 207 grin2c ENSG00000161509
306 208 grin3a ENSG00000198785
306 209 grina ENSG00000178719
306 210 grk5 ENSG00000198873
306 211 gsg2 ENSG00000177602
306 212 scrambled
306 213 gstcd ENSG00000138780
306 214 gstp1 ENSG00000084207
306 215 gtf2h3 ENSG00000111358
306 216 gtf2ird1 ENSG00000006704
306 217 gtpbp5 ENSG00000101181
306 218 gucy2d ENSG00000132518
306 219 gyg1 ENSG00000163754
306 220 gys2 ENSG00000111713
306 221 gzma ENSG00000145649
306 222 copb
306 223 h1fnt ENSG00000187166
306 224 hadha ENSG00000084754
306 225 haghl ENSG00000103253
306 226 has3 ENSG00000103044
306 227 hcfc2 ENSG00000111727
306 228 hcn3 ENSG00000143630
306 229 hdgfl1 ENSG00000112273
306 230 hebp1 ENSG00000013583
306 231 scrambled
306 232 herc6 ENSG00000138642
306 233 hexa ENSG00000140488
306 234 hgd ENSG00000113924
306 235 hif1a ENSG00000100644
306 236 hif3a ENSG00000124440
306 237 hipk1 ENSG00000163349
306 238 gosr1
306 239 hisppd1 ENSG00000145725
306 240 hist1h2ac ENSG00000180573
306 241 hist1h2ae ENSG00000168274
306 242 hmbox1 ENSG00000147421
306 243 hnrpa1 ENSG00000135486
306 244 hnrpa2b1 ENSG00000122566
306 245 hoxc9 ENSG00000180806
306 246 hoxd11 ENSG00000128713
306 247 hp ENSG00000197711
306 248 hpgd ENSG00000164120
306 249 hpn ENSG00000105707
306 250 hs6st2 ENSG00000171004
Plate Position Gene ENSEMBL ID
306 251 hsd17b1 ENSG00000108786
306 252 hsd17b4 ENSG00000133835
306 253 hsd17b6 ENSG00000025423
306 254 hsd3b2 ENSG00000203859
306 255 gosr1
306 256 hsf5 ENSG00000176160
306 257 hsp90b1 ENSG00000166598
306 258 hspa4 ENSG00000170606
306 259 hspb8 ENSG00000152137
306 260 htr3c ENSG00000178084
306 261 htr3e ENSG00000186038
306 262 scrambled
306 263 htr6 ENSG00000158748
306 264 htra2 ENSG00000115317
306 265 hyal4 ENSG00000106302
306 266 ifih1 ENSG00000115267
306 267 ifnar1 ENSG00000142166
306 268 ift88 ENSG00000032742
306 269 igf1r ENSG00000140443
306 270 igfbp2 ENSG00000115457
306 271 rab1a
306 272 ihpk3 ENSG00000161896
306 273 il15ra ENSG00000134470
306 274 il17rd ENSG00000144730
306 275 il18r1 ENSG00000115604
306 276 il1f5 ENSG00000136695
306 277 il1rap ENSG00000196083
306 278 il20ra ENSG00000016402
306 279 il21 ENSG00000138684
306 280 scrambled
306 281 il23r ENSG00000162594
306 282 il2rb ENSG00000100385
306 283 il9r ENSG00000124334
306 284 impdh2 ENSG00000178035
306 285 inadl ENSG00000132849
306 286 loc727773 ENSG00000168395
306 287 copb
306 288 insl6 ENSG00000120210
306 289 ipo8 ENSG00000133704
306 290 iqce ENSG00000106012
306 291 iqcf1 ENSG00000173389
306 292 iqgap3 ENSG00000183856
306 293 iqsec1 ENSG00000144711
306 294 itgav ENSG00000138448
306 295 itgb5 ENSG00000082781
306 296 itgb6 ENSG00000115221
306 297 itih1 ENSG00000055957
306 298 itpa ENSG00000125877
306 299 itpr2 ENSG00000123104
306 300 ivd ENSG00000128928
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306 301 jag1 ENSG00000101384
306 302 copb
306 303 jak2 ENSG00000096968
306 304 jazf1 ENSG00000153814
306 305 jmjd1b ENSG00000120733
306 306 josd2 ENSG00000161677
306 307 visa ENSG00000088888
306 308 scrambled
306 309 kcnmb2 ENSG00000197584
306 310 kcnn4 ENSG00000104783
306 311 kcnq2 ENSG00000075043
306 312 kcnq4 ENSG00000117013
306 313 kctd4 ENSG00000180332
306 314 khk ENSG00000138030
306 315 kiaa0133 ENSG00000135763
306 316 kiaa0240 ENSG00000112624
306 317 kiaa0372 ENSG00000198677
306 318 gosr1
306 319 kiaa0423 ENSG00000198718
306 320 kiaa0907 ENSG00000132680
306 321 kiaa1018 ENSG00000198690
306 322 kiaa1161 ENSG00000164976
306 323 kiaa1840 ENSG00000104133
306 324 kif15 ENSG00000163808
306 325 kif19 ENSG00000196169
306 326 kif1c ENSG00000129250
306 327 scrambled
306 328 kif23 ENSG00000137807
306 329 kif26a ENSG00000066735
306 330 kif2c ENSG00000142945
306 331 kifap3 ENSG00000075945
306 332 kir2dl4 ENSG00000189013
306 333 kirrel ENSG00000183853
306 334 rab1a
306 335 kit ENSG00000157404
306 336 kl ENSG00000133116
306 337 klhl17 ENSG00000187961
306 338 klhl21 ENSG00000162413
306 339 phospho2 ENSG00000144362
306 340 klhl4 ENSG00000102271
306 341 klk2 ENSG00000167751
306 342 kng1 ENSG00000113889
306 343 kpna6 ENSG00000025800
306 344 kremen1 ENSG00000183762
306 345 smarce1 ENSG00000073584
306 346 krt6b ENSG00000185479
306 347 krt8 ENSG00000170421
306 348 l1cam ENSG00000198910
306 349 lair1 ENSG00000167613
306 350 lamp3 ENSG00000078081
Plate Position Gene ENSEMBL ID
306 351 rab1a
306 352 larp5 ENSG00000107929
306 353 lcn6 ENSG00000204003
306 354 ldb2 ENSG00000169744
306 355 ldhb ENSG00000111716
306 356 leng4 ENSG00000125505
306 357 leo1 ENSG00000166477
306 358 scrambled
306 359 letm1 ENSG00000168924
306 360 lgals14 ENSG00000006659
306 361 lgicz1 ENSG00000186919
306 362 lhfpl5 ENSG00000197753
306 363 lhx9 ENSG00000143355
306 364 lipc ENSG00000166035
306 365 lmo3 ENSG00000048540
306 366 lnx2 ENSG00000139517
306 367 copb
306 368 lrfn3 ENSG00000126243
306 369 lrp4 ENSG00000134569
306 370 lrrc21 ENSG00000148602
306 371 lrrc23 ENSG00000010626
306 372 lrrc27 ENSG00000148814
306 373 incenp
306 374 lrrc31 ENSG00000114248
306 375 lrrc39 ENSG00000122477
306 376 scrambled
306 377 lrrc3b ENSG00000179796
306 378 lrrc46 ENSG00000141294
306 379 lsm14a ENSG00000105216
306 380 lsr ENSG00000105699
306 381 ltbp1 ENSG00000049323
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307 1 incenp
307 2 luzp1 ENSG00000169641
307 3 ly75 ENSG00000054219
307 4 lyn ENSG00000147507
307 5 lypla3 ENSG00000103066
307 6 lyplal1 ENSG00000143353
307 7 lyst ENSG00000143669
307 8 lztr2 ENSG00000120341
307 9 madd ENSG00000110514
307 10 mafg ENSG00000197063
307 11 magea4 ENSG00000147381
307 12 incenp
307 13 mageb10 ENSG00000177689
307 14 copb
307 15 magi3 ENSG00000081026
307 16 mansc1 ENSG00000111261
307 17 map3k15 ENSG00000180815
307 18 mapk11 ENSG00000185386
307 19 mapk12 ENSG00000188130
307 20 scrambled
307 21 mapk15 ENSG00000181085
307 22 mapkap1 ENSG00000119487
307 23 mapkapk2 ENSG00000162889
307 24 mapkbp1 ENSG00000137802
307 25 mark2 ENSG00000072518
307 26 mast2 ENSG00000086015
307 27 mast3 ENSG00000099308
307 28 matr3 ENSG00000015479
307 29 maz ENSG00000103495
307 30 gosr1
307 31 mbl2 ENSG00000165471
307 32 jtv1 ENSG00000106305
307 33 mchr1 ENSG00000128285
307 34 mcm10 ENSG00000065328
307 35 mcm7 ENSG00000166508
307 36 mdn1 ENSG00000112159
307 37 med28 ENSG00000118579
307 38 mrg1 ENSG00000134138
307 39 scrambled
307 40 mesdc2 ENSG00000117899
307 41 metrnl ENSG00000176845
307 42 mettl3 ENSG00000165819
307 43 mettl4 ENSG00000101574
307 44 mfap3l ENSG00000198948
307 45 mfge8 ENSG00000140545
307 46 rab1a
307 47 mfng ENSG00000100060
307 48 mfsd5 ENSG00000182544
307 49 mga ENSG00000174197
307 50 mgat4b ENSG00000161013
Plate Position Gene ENSEMBL ID
307 51 mgst1 ENSG00000008394
307 52 mid2 ENSG00000080561
307 53 minpp1 ENSG00000107789
307 54 mlf1ip ENSG00000151725
307 55 mlh1 ENSG00000076242
307 56 mll ENSG00000118058
307 57 mlph ENSG00000115648
307 58 mlstd2 ENSG00000197601
307 59 mlxipl ENSG00000009950
307 60 mme ENSG00000196549
307 61 mmp14 ENSG00000157227
307 62 mmp16 ENSG00000156103
307 63 rab1a
307 64 mmp2 ENSG00000087245
307 65 mmp21 ENSG00000154485
307 66 mmp28 ENSG00000129270
307 67 mnd1 ENSG00000121211
307 68 mnt ENSG00000070444
307 69 mosc2 ENSG00000117791
307 70 scrambled
307 71 mpv17 ENSG00000115204
307 72 mrgpre ENSG00000184350
307 73 mrpl41 ENSG00000182154
307 74 mrps2 ENSG00000122140
307 75 mrps33 ENSG00000090263
307 76 mrps35 ENSG00000061794
307 77 mrps5 ENSG00000144029
307 78 ms4a6a ENSG00000110077
307 79 copb
307 80 msr1 ENSG00000038945
307 81 mtfmt ENSG00000103707
307 82 mtnr1b ENSG00000134640
307 83 muc2 ENSG00000198788
307 84 mutyh ENSG00000132781
307 85 mxd4 ENSG00000123933
307 86 myb ENSG00000118513
307 87 mybpc1 ENSG00000196091
307 88 scrambled
307 89 mybph ENSG00000133055
307 90 myh10 ENSG00000133026
307 91 myh7 ENSG00000092054
307 92 myl1 ENSG00000168530
307 93 myoc ENSG00000034971
307 94 myom2 ENSG00000036448
307 95 gosr1
307 96 myot ENSG00000120729
307 97 myoz3 ENSG00000164591
307 98 nalp14 ENSG00000158077
307 99 nat13 ENSG00000121579
307 100 nat8 ENSG00000144035
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307 101 nav3 ENSG00000067798
307 102 ndnl2 ENSG00000185115
307 103 ndst2 ENSG00000166507
307 104 ndufa12l ENSG00000164182
307 105 ndufs2 ENSG00000158864
307 106 nedd4 ENSG00000069869
307 107 nek2 ENSG00000117650
307 108 neurog1 ENSG00000181965
307 109 nfatc4 ENSG00000100968
307 110 gosr1
307 111 nfkbie ENSG00000146232
307 112 nfkbil2 ENSG00000160949
307 113 nfyb ENSG00000120837
307 114 nhp2l1 ENSG00000100138
307 115 nipbl ENSG00000164190
307 116 scrambled
307 117 nle1 ENSG00000073536
307 118 eg238564 ENSG00000145949
307 119 nmral1 ENSG00000153406
307 120 nmu ENSG00000109255
307 121 nol12 ENSG00000100101
307 122 nol3 ENSG00000140939
307 123 nol4 ENSG00000101746
307 124 nolc1 ENSG00000166197
307 125 nono ENSG00000147140
307 126 rab1a
307 127 notch2nl ENSG00000163386
307 128 notum ENSG00000185269
307 129 nox4 ENSG00000086991
307 130 spink5l2 ENSG00000196800
307 131 ttmb ENSG00000187975
307 132 flj90757 ENSG00000175901
307 133 flj40194 ENSG00000177369
307 134 loc136242 ENSG00000165076
307 135 scrambled
307 136 loc348180 ENSG00000174177
307 137 loc388965 ENSG00000182814
307 138 np_001013713.1 ENSG00000197332
307 139 loc51149 ENSG00000161010
307 140 loc286076 ENSG00000181097
307 141 c1d ENSG00000197223
307 142 copb
307 143 hspc159 ENSG00000119862
307 144 rics ENSG00000134909
307 145 kiaa0738 ENSG00000198420
307 146 kiaa0672 ENSG00000006740
307 147 kiaa0523 ENSG00000179314
307 148 cgi-09 ENSG00000089195
307 149 crop ENSG00000108848
307 150 loc51252 ENSG00000168754
Plate Position Gene ENSEMBL ID
307 151 larp7 ENSG00000174720
307 152 tug1 ENSG00000182457
307 153 flj20628 ENSG00000171103
307 154 mreg ENSG00000118242
307 155 np_060529.2 ENSG00000157927
307 156 flj10490 ENSG00000104865
307 157 flj10781 ENSG00000182013
307 158 mettl2b ENSG00000165055
307 159 copb
307 160 bc021381 ENSG00000146067
307 161 kiaa1505 ENSG00000135205
307 162 kiaa1530 ENSG00000163945
307 163 9430057o19rik ENSG00000084693
307 164 p53aip1 ENSG00000120471
307 165 flj21865 ENSG00000167280
307 166 scrambled
307 167 ccdc134 ENSG00000100147
307 168 flj14154 ENSG00000122390
307 169 flj21687 ENSG00000017621
307 170 flj22374 ENSG00000106121
307 171 flj23356 ENSG00000185900
307 172 kiaa1729 ENSG00000178163
307 173 loc653383 ENSG00000187713
307 174 hel308 ENSG00000163312
307 175 gosr1
307 176 xtp7 ENSG00000130201
307 177 slc25a46 ENSG00000164209
307 178 loc113386 ENSG00000166718
307 179 mgc29891 ENSG00000143458
307 180 dact3 ENSG00000197380
307 181 flj38663 ENSG00000130921
307 182 mgc45438 ENSG00000153446
307 183 flj36004 ENSG00000152936
307 184 scrambled
307 185 flj31196 ENSG00000180638
307 186 flj39501 ENSG00000171954
307 187 flj25791 ENSG00000177214
307 188 glb1l3 ENSG00000166105
307 189 flj40288 ENSG00000183470
307 190 flj90650 ENSG00000172901
307 191 rab1a
307 192 flj12949 ENSG00000129347
307 193 dnhd2 ENSG00000163669
307 194 agbl3 ENSG00000146856
307 195 ostbeta ENSG00000186198
307 196 aasdh ENSG00000157426
307 197 gddr ENSG00000183607
307 198 np_919270.1 ENSG00000188676
307 199 hspc268 ENSG00000164898
307 200 loc196264 ENSG00000160588
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307 201 mgc12965 ENSG00000198048
307 202 loc284361 ENSG00000161671
307 203 loc150763 ENSG00000186281
307 204 np_997271.1 ENSG00000167934
307 205 flj45244 ENSG00000198411
307 206 rab1a
307 207 flj45256 ENSG00000197672
307 208 mgc48628 ENSG00000184305
307 209 ai593442 ENSG00000185742
307 210 npc1l1 ENSG00000015520
307 211 npepps ENSG00000141279
307 212 scrambled
307 213 npm1 ENSG00000181163
307 214 npw ENSG00000183971
307 215 nr1i3 ENSG00000143257
307 216 nr2c1 ENSG00000120798
307 217 nr2f6 ENSG00000160113
307 218 nr4a2 ENSG00000153234
307 219 nr6a1 ENSG00000148200
307 220 csde1 ENSG00000009307
307 221 nrip1 ENSG00000180530
307 222 copb
307 223 nrip2 ENSG00000053702
307 224 nt5c ENSG00000125458
307 225 nt5c2 ENSG00000076685
307 226 nt5c3 ENSG00000122643
307 227 nudt16 ENSG00000198585
307 228 nudt4 ENSG00000173598
307 229 nudt9 ENSG00000170502
307 230 nup188 ENSG00000095319
307 231 scrambled
307 232 nup35 ENSG00000163002
307 233 nxn ENSG00000167693
307 234 kiaa0363 ENSG00000136274
307 235 ocel1 ENSG00000099330
307 236 odz3 ENSG00000109716
307 237 ogfr ENSG00000060491
307 238 gosr1
307 239 ogg1 ENSG00000114026
307 240 olfml3 ENSG00000116774
307 241 oma1 ENSG00000162600
307 242 omg ENSG00000126861
307 243 oprl1 ENSG00000125510
307 244 or10a4 ENSG00000170782
307 245 or10a7 ENSG00000179919
307 246 or10ag1 ENSG00000174970
307 247 or10j5 ENSG00000184155
307 248 or11h4 ENSG00000176198
307 249 or13c3 ENSG00000204246
307 250 or13f1 ENSG00000186881
Plate Position Gene ENSEMBL ID
307 251 or4p4 ENSG00000181927
307 252 or51a7 ENSG00000176895
307 253 or51e1 ENSG00000180785
307 254 or51f2 ENSG00000176925
307 255 gosr1
307 256 or51m1 ENSG00000184698
307 257 or51s1 ENSG00000176922
307 258 or52e4 ENSG00000180974
307 259 or52k2 ENSG00000181963
307 260 or5a2 ENSG00000172324
307 261 or5as1 ENSG00000181785
307 262 scrambled
307 263 or5au1 ENSG00000169327
307 264 or5b2 ENSG00000172365
307 265 or5bf1 ENSG00000177174
307 266 or5t3 ENSG00000172489
307 267 or6c2 ENSG00000179695
307 268 or6c70 ENSG00000184954
307 269 or6k6 ENSG00000180433
307 270 or7a10 ENSG00000127515
307 271 rab1a
307 272 or7g1 ENSG00000161807
307 273 osbp ENSG00000110048
307 274 otud7a ENSG00000169918
307 275 ovch1 ENSG00000187950
307 276 oxct1 ENSG00000083720
307 277 oxsr1 ENSG00000172939
307 278 oxtr ENSG00000180914
307 279 p2rx7 ENSG00000089041
307 280 scrambled
307 281 pacrg ENSG00000112530
307 282 pacs1 ENSG00000175115
307 283 paep ENSG00000122133
307 284 pag1 ENSG00000076641
307 285 pak7 ENSG00000101349
307 286 palm ENSG00000099864
307 287 copb
307 288 pank2_predicted ENSG00000125779
307 289 paqr4 ENSG00000162073
307 290 parvg ENSG00000138964
307 291 pax4 ENSG00000106331
307 292 paxip1 ENSG00000157212
307 293 pbxip1 ENSG00000163346
307 294 pcbd2 ENSG00000132570
307 295 pcdhb10 ENSG00000120324
307 296 pcdhb12 ENSG00000120328
307 297 pcdhb18 ENSG00000146001
307 298 pcnxl2 ENSG00000135749
307 299 pcsk4 ENSG00000115257
307 300 pdcd10 ENSG00000114209
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307 301 pdgfa ENSG00000197461
307 302 copb
307 303 pdp2 ENSG00000172840
307 304 pdxk ENSG00000160209
307 305 intu ENSG00000164066
307 306 pea15 ENSG00000162734
307 307 pecam1 ENSG00000198802
307 308 scrambled
307 309 pfkfb4 ENSG00000114268
307 310 pgam5 ENSG00000176894
307 311 ercc6 ENSG00000032514
307 312 pgc ENSG00000096088
307 313 pglyrp1 ENSG00000008438
307 314 pgm5 ENSG00000154330
307 315 phf11 ENSG00000136147
307 316 phf2 ENSG00000197724
307 317 phf7 ENSG00000010318
307 318 gosr1
307 319 phkg2 ENSG00000156873
307 320 phlpp ENSG00000081913
307 321 phlppl ENSG00000040199
307 322 phtf1 ENSG00000116793
307 323 pib5pa ENSG00000185133
307 324 picalm ENSG00000073921
307 325 pigb ENSG00000069943
307 326 pigh ENSG00000100564
307 327 scrambled
307 328 pigr ENSG00000162896
307 329 pik3r4 ENSG00000196455
307 330 pilra ENSG00000085514
307 331 pitx3 ENSG00000107859
307 332 piwil4 ENSG00000134627
307 333 pkp1 ENSG00000081277
307 334 rab1a
307 335 pla2g12b ENSG00000138308
307 336 pla2g4c ENSG00000105499
307 337 plcb2 ENSG00000137841
307 338 plch1 ENSG00000114805
307 339 plcz1 ENSG00000139151
307 340 tnfrsf25 ENSG00000171680
307 341 plekhm2 ENSG00000116786
307 342 plscr4 ENSG00000114698
307 343 plunc ENSG00000198183
307 344 pmaip1 ENSG00000141682
307 345 pml ENSG00000140464
307 346 pms2 ENSG00000122512
307 347 pnldc1 ENSG00000146453
307 348 pnliprp2 ENSG00000165862
307 349 pnma2 ENSG00000171362
307 350 pnma5 ENSG00000198883
Plate Position Gene ENSEMBL ID
307 351 rab1a
307 352 polh ENSG00000170734
307 353 polr3f ENSG00000132664
307 354 polr3g ENSG00000113356
307 355 polr3gl ENSG00000121851
307 356 pou6f1 ENSG00000184271
307 357 ppapdc1 ENSG00000147535
307 358 scrambled
307 359 ppfia1 ENSG00000131626
307 360 ppie ENSG00000084072
307 361 ppox ENSG00000143224
307 362 ppp1r14c ENSG00000198729
307 363 ppp1r16a ENSG00000160972
307 364 ppp2cb ENSG00000104695
307 365 dock5 ENSG00000147459
307 366 ppp2r2d ENSG00000175470
307 367 copb
307 368 ppp4r1 ENSG00000154845
307 369 ppp4r2 ENSG00000163605
307 370 pric285 ENSG00000130589
307 371 prdm5 ENSG00000138738
307 372 prdx3 ENSG00000165672
307 373 incenp
307 374 prep ENSG00000085377
307 375 prg1 ENSG00000122862
307 376 scrambled
307 377 prg3 ENSG00000156575
307 378 prkab2 ENSG00000131791
307 379 prkcd ENSG00000163932
307 380 proc ENSG00000115718
307 381 prpf8 ENSG00000174231
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308 1 incenp
308 2 prrc1 ENSG00000164244
308 3 prrg2 ENSG00000126460
308 4 prrt3 ENSG00000163704
308 5 prss22 ENSG00000005001
308 6 prtn3 ENSG00000196415
308 7 psat1 ENSG00000135069
308 8 pscd2 ENSG00000105443
308 9 psd ENSG00000059915
308 10 psg7 ENSG00000124435
308 11 pskh2 ENSG00000147613
308 12 incenp
308 13 psmb1 ENSG00000008018
308 14 copb
308 15 psmc3ip ENSG00000131470
308 16 psmc4 ENSG00000013275
308 17 pstpip1 ENSG00000140368
308 18 ptafr ENSG00000169403
308 19 ptbp1 ENSG00000011304
308 20 scrambled
308 21 ptcd3 ENSG00000132300
308 22 ptdsr ENSG00000070495
308 23 ptdss1 ENSG00000156471
308 24 ptdss2 ENSG00000174915
308 25 ptov1 ENSG00000104960
308 26 ptpn12 ENSG00000127947
308 27 ptpn21 ENSG00000070778
308 28 ptpn22 ENSG00000134242
308 29 ptpn9 ENSG00000169410
308 30 gosr1
308 31 ptprn ENSG00000054356
308 32 pus3 ENSG00000110060
308 33 pvalb ENSG00000100362
308 34 pvr ENSG00000073008
308 35 pycr2 ENSG00000143811
308 36 pzp ENSG00000126838
308 37 q5jss6_human ENSG00000197889
308 38 mgc10334 ENSG00000187488
308 39 scrambled
308 40 plch2 ENSG00000149527
308 41 ovos2 ENSG00000177359
308 42 q6p462_human ENSG00000189316
308 43 loc401565 ENSG00000188163
308 44 flj38596 ENSG00000176753
308 45 flj35880 ENSG00000172752
308 46 rab1a
308 47 flj34651 ENSG00000178803
308 48 loc283507 ENSG00000168852
308 49 loc113230 ENSG00000141854
308 50 ubqlnl ENSG00000175518
Plate Position Gene ENSEMBL ID
308 51 flj31033 ENSG00000181381
308 52 loc90113 ENSG00000145198
308 53 loc152217 ENSG00000179823
308 54 q9h052_human ENSG00000184405
308 55 loc642452 ENSG00000182794
308 56 flj13305 ENSG00000170264
308 57 dkfzp434i0714 ENSG00000170009
308 58 loc388554 ENSG00000104983
308 59 qrich1 ENSG00000198218
308 60 dnm2 ENSG00000079805
308 61 rab11a ENSG00000103769
308 62 rab11b ENSG00000185236
308 63 rab1a
308 64 rab18 ENSG00000099246
308 65 rab8b ENSG00000166128
308 66 rabac1 ENSG00000105404
308 67 ramp3 ENSG00000122679
308 68 ranbp6 ENSG00000137040
308 69 rap1gds1 ENSG00000138698
308 70 scrambled
308 71 rasl11b ENSG00000128045
308 72 rassf2 ENSG00000101265
308 73 rbbp6 ENSG00000122257
308 74 rbbp9 ENSG00000089050
308 75 rbm15b ENSG00000179837
308 76 rbm41 ENSG00000089682
308 77 rbm5 ENSG00000003756
308 78 rbp4 ENSG00000138207
308 79 copb
308 80 rbpsuhl ENSG00000124232
308 81 rccd1 ENSG00000166965
308 82 rdh12 ENSG00000139988
308 83 rdh16 ENSG00000139547
308 84 rdm1 ENSG00000187456
308 85 reep3 ENSG00000165476
308 86 reep6 ENSG00000115255
308 87 reg4 ENSG00000134193
308 88 scrambled
308 89 rela ENSG00000173039
308 90 rerg ENSG00000134533
308 91 rev1 ENSG00000135945
308 92 rftn2 ENSG00000162944
308 93 rfx3 ENSG00000080298
308 94 rfx5 ENSG00000143390
308 95 gosr1
308 96 rfxap ENSG00000133111
308 97 rgn ENSG00000130988
308 98 rgs19 ENSG00000171700
308 99 rhbdl1 ENSG00000103269
308 100 rhoc ENSG00000155366
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308 101 rhof ENSG00000139725
308 102 rhoj ENSG00000126785
308 103 rhot1 ENSG00000126858
308 104 rhou ENSG00000116574
308 105 ribc1 ENSG00000158423
308 106 riok3 ENSG00000101782
308 107 rln2 ENSG00000107014
308 108 rnase2 ENSG00000169385
308 109 rnf11 ENSG00000123091
308 110 gosr1
308 111 rnf130 ENSG00000113269
308 112 rnf133 ENSG00000188050
308 113 rnf207 ENSG00000189429
308 114 rrp9 ENSG00000114767
308 115 robo3 ENSG00000154134
308 116 scrambled
308 117 ros1 ENSG00000047936
308 118 rpgrip1 ENSG00000092200
308 119 rpl32 ENSG00000144713
308 120 rpl35a ENSG00000182899
308 121 rplp2 ENSG00000177600
308 122 rpp14 ENSG00000163684
308 123 rpp40 ENSG00000124787
308 124 rprc1 ENSG00000116871
308 125 rps26 ENSG00000197728
308 126 rab1a
308 127 rps27l ENSG00000185088
308 128 rrad ENSG00000166592
308 129 rtn4r ENSG00000040608
308 130 rufy3 ENSG00000018189
308 131 runx1t1 ENSG00000079102
308 132 rusc1 ENSG00000160753
308 133 ruvbl1 ENSG00000175792
308 134 rxra ENSG00000186350
308 135 scrambled
308 136 rxrg ENSG00000143171
308 137 ryr1 ENSG00000196218
308 138 s100a10 ENSG00000197747
308 139 samd3 ENSG00000164483
308 140 samd4a ENSG00000020577
308 141 scgb2a2 ENSG00000110484
308 142 copb
308 143 scgb3a1 ENSG00000161055
308 144 scn3b ENSG00000166257
308 145 scn5a ENSG00000183873
308 146 scn7a ENSG00000136546
308 147 scyl1 ENSG00000142186
308 148 sele ENSG00000007908
308 149 sema4b ENSG00000185033
308 150 sema4f ENSG00000135622
Plate Position Gene ENSEMBL ID
308 151 sepp1 ENSG00000211446
308 152 sepx1 ENSG00000198736
308 153 serpinf2 ENSG00000167711
308 154 sez6l2 ENSG00000174938
308 155 sf3b4 ENSG00000143368
308 156 sfmbt1 ENSG00000163935
308 157 sfrs1 ENSG00000136450
308 158 sfrs6 ENSG00000124193
308 159 copb
308 160 sfxn4 ENSG00000183605
308 161 sgcg ENSG00000102683
308 162 sgk ENSG00000118515
308 163 sh2b1 ENSG00000178188
308 164 sh3glb2 ENSG00000148341
308 165 shank3 ENSG00000099882
308 166 scrambled
308 167 shb ENSG00000107338
308 168 sipa1 ENSG00000173442
308 169 sirt2 ENSG00000068903
308 170 six2 ENSG00000170577
308 171 ski ENSG00000157933
308 172 skiv2l2 ENSG00000039123
308 173 loc681062 ENSG00000163950
308 174 slc12a8 ENSG00000163848
308 175 gosr1
308 176 slc20a1 ENSG00000144136
308 177 slc25a30 ENSG00000174032
308 178 slc25a4 ENSG00000151729
308 179 slc35b1 ENSG00000121073
308 180 slc36a2 ENSG00000186335
308 181 slc36a3 ENSG00000186334
308 182 slc39a6 ENSG00000141424
308 183 slc3a2 ENSG00000168003
308 184 scrambled
308 185 slc5a1 ENSG00000100170
308 186 slc6a14 ENSG00000087916
308 187 slc6a3 ENSG00000142319
308 188 slit1 ENSG00000187122
308 189 slk ENSG00000065613
308 190 hltf ENSG00000071794
308 191 rab1a
308 192 smarcd1 ENSG00000066117
308 193 sms ENSG00000102172
308 194 smyd2 ENSG00000143499
308 195 snap29 ENSG00000099940
308 196 sncaip ENSG00000064692
308 197 snx13 ENSG00000071189
308 198 snx19 ENSG00000120451
308 199 soat1 ENSG00000057252
308 200 sorbs3 ENSG00000120896
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308 201 sorcs1 ENSG00000108018
308 202 sos2 ENSG00000100485
308 203 sox9 ENSG00000125398
308 204 spag6 ENSG00000077327
308 205 spata5 ENSG00000145375
308 206 rab1a
308 207 spata5l1 ENSG00000171763
308 208 spcs3 ENSG00000129128
308 209 spdya ENSG00000163806
308 210 sphk1 ENSG00000176170
308 211 spry3 ENSG00000168939
308 212 scrambled
308 213 spryd4 ENSG00000176422
308 214 spnb2 ENSG00000115306
308 215 srms ENSG00000125508
308 216 ssbp1 ENSG00000106028
308 217 sssca1 ENSG00000173465
308 218 sst ENSG00000157005
308 219 st3gal5 ENSG00000115525
308 220 st5 ENSG00000166444
308 221 st6gal1 ENSG00000073849
308 222 copb
308 223 st8sia1 ENSG00000111728
308 224 st8sia2 ENSG00000140557
308 225 stac2 ENSG00000141750
308 226 stam2 ENSG00000115145
308 227 brdg1 ENSG00000035720
308 228 stard3nl ENSG00000010270
308 229 stc1 ENSG00000159167
308 230 stk40 ENSG00000196182
308 231 scrambled
308 232 stox2 ENSG00000173320
308 233 stt3b ENSG00000163527
308 234 stx17 ENSG00000136874
308 235 stx19 ENSG00000178750
308 236 stx1b2 ENSG00000099365
308 237 suhw2 ENSG00000198477
308 238 gosr1
308 239 suox ENSG00000139531
308 240 sybl1 ENSG00000124333
308 241 syk ENSG00000165025
308 242 dbndd2 ENSG00000198641
308 243 syt1 ENSG00000067715
308 244 syt6 ENSG00000134207
308 245 syt7 ENSG00000011347
308 246 syt9 ENSG00000170743
308 247 sytl5 ENSG00000147041
308 248 tacc1 ENSG00000147526
308 249 tada2l ENSG00000108264
308 250 taf7l ENSG00000102387
Plate Position Gene ENSEMBL ID
308 251 taldo1 ENSG00000177156
308 252 tanc1 ENSG00000115183
308 253 tanc2 ENSG00000170921
308 254 tbc1d17 ENSG00000104946
308 255 gosr1
308 256 tbc1d8b ENSG00000133138
308 257 tbca ENSG00000171530
308 258 tbx2 ENSG00000121068
308 259 tbx6 ENSG00000149922
308 260 tcp11 ENSG00000124678
308 261 tead1 ENSG00000187079
308 262 scrambled
308 263 tead3 ENSG00000007866
308 264 tecta ENSG00000109927
308 265 tgfbr3 ENSG00000069702
308 266 tgm7 ENSG00000159495
308 267 thap4 ENSG00000176946
308 268 thap7 ENSG00000184436
308 269 thop1 ENSG00000172009
308 270 thpo ENSG00000090534
308 271 rab1a
308 272 thumpd1 ENSG00000066654
308 273 tigd5 ENSG00000179886
308 274 timeless ENSG00000111602
308 275 timm9 ENSG00000100575
308 276 tktl1 ENSG00000007350
308 277 tle4 ENSG00000106829
308 278 tlr3 ENSG00000164342
308 279 tlr5 ENSG00000187554
308 280 scrambled
308 281 tlr7 ENSG00000196664
308 282 mgc33212 ENSG00000145107
308 283 tmcc3 ENSG00000057704
308 284 tmco4 ENSG00000162542
308 285 tmem1 ENSG00000160218
308 286 tmem116 ENSG00000198270
308 287 copb
308 288 tmem119 ENSG00000183160
308 289 tmem135 ENSG00000166575
308 290 tmem15 ENSG00000175283
308 291 tmem166 ENSG00000115363
308 292 tmem169 ENSG00000163449
308 293 tmem16a ENSG00000131620
308 294 tmem176b ENSG00000106565
308 295 tmem38b ENSG00000095209
308 296 tmem46 ENSG00000180730
308 297 tmem5 ENSG00000118600
308 298 tmem53 ENSG00000126106
308 299 tmem61 ENSG00000143001
308 300 tmem64 ENSG00000180694
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308 301 tmprss2 ENSG00000184012
308 302 copb
308 303 tmtc1 ENSG00000133687
308 304 tnfrsf10d ENSG00000173530
308 305 tnfrsf19 ENSG00000127863
308 306 tnfrsf8 ENSG00000120949
308 307 tnfrsf9 ENSG00000049249
308 308 scrambled
308 309 tnfsf11 ENSG00000120659
308 310 tnks ENSG00000173273
308 311 tnnt2 ENSG00000118194
308 312 tnrc5 ENSG00000137161
308 313 tomm20 ENSG00000173726
308 314 tor1a ENSG00000136827
308 315 tp73l ENSG00000073282
308 316 tram2 ENSG00000065308
308 317 trappc4 ENSG00000196655
308 318 gosr1
308 319 trappc5 ENSG00000181029
308 320 treml3 ENSG00000184106
308 321 trim29 ENSG00000137699
308 322 trim41 ENSG00000146063
308 323 trim72 ENSG00000177238
308 324 trip10 ENSG00000125733
308 325 trip13 ENSG00000071539
308 326 trpc5 ENSG00000072315
308 327 scrambled
308 328 trpt1 ENSG00000149743
308 329 tsc1 ENSG00000165699
308 330 tshz2 ENSG00000182463
308 331 tspan1 ENSG00000117472
308 332 tspan2 ENSG00000134198
308 333 tspan32 ENSG00000064201
308 334 rab1a
308 335 ttbk1 ENSG00000146216
308 336 ttc12 ENSG00000149292
308 337 ttf1 ENSG00000125482
308 338 ttf2 ENSG00000116830
308 339 ttll1 ENSG00000100271
308 340 tulp2 ENSG00000104804
308 341 tusc3 ENSG00000104723
308 342 twist1 ENSG00000122691
308 343 txnl6 ENSG00000171773
308 344 tyms ENSG00000176890
308 345 tyro3 ENSG00000092445
308 346 tyrobp ENSG00000011600
308 347 loc51035 ENSG00000162191
308 348 uaca ENSG00000137831
308 349 triad3 ENSG00000011275
308 350 ube2a ENSG00000077721
Plate Position Gene ENSEMBL ID
308 351 rab1a
308 352 ube2d3 ENSG00000109332
308 353 ube2d2 ENSG00000131508
308 354 ube2e1 ENSG00000170142
308 355 ube2m ENSG00000130725
308 356 ube2q2 ENSG00000140367
308 357 ube2t ENSG00000077152
308 358 scrambled
308 359 ube2u ENSG00000177414
308 360 ube2v2 ENSG00000169139
308 361 ubl5 ENSG00000198258
308 362 ufc1 ENSG00000143222
308 363 ufm1 ENSG00000120686
308 364 ugp2 ENSG00000169764
308 365 uqcrq ENSG00000164405
308 366 urod ENSG00000126088
308 367 copb
308 368 mds032 ENSG00000053501
308 369 usp1 ENSG00000162607
308 370 usp12 ENSG00000152484
308 371 usp19 ENSG00000172046
308 372 usp34 ENSG00000115464
308 373 incenp
308 374 usp35 ENSG00000118369
308 375 usp5 ENSG00000111667
308 376 scrambled
308 377 ust ENSG00000111962
308 378 utp18 ENSG00000011260
308 379 uts2r ENSG00000181408
308 380 vipr1 ENSG00000114812
308 381 best2 ENSG00000039987
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309 1 incenp
309 2 vps37b ENSG00000139722
309 3 vps72 ENSG00000163159
309 4 vsig1 ENSG00000101842
309 5 wbp2 ENSG00000132471
309 6 wbscr22 ENSG00000071462
309 7 wdr27 ENSG00000184465
309 8 wdr40a ENSG00000198876
309 9 wdr49 ENSG00000174776
309 10 wdr52 ENSG00000206530
309 11 wdr75 ENSG00000115368
309 12 incenp
309 13 wfikkn1 ENSG00000127578
309 14 copb
309 15 wnk3 ENSG00000196632
309 16 xg ENSG00000124343
309 17 loc127099 ENSG00000174092
309 18 loc730647 ENSG00000173568
309 19 loc646643 ENSG00000187550
309 20 scrambled
309 21 rps6p1 ENSG00000173322
309 22 xpo5 ENSG00000124571
309 23 xylb ENSG00000093217
309 24 kiaa0143 ENSG00000132294
309 25 y0574_human ENSG00000104059
309 26 yipf7 ENSG00000177752
309 27 cted ENSG00000090238
309 28 ythdf2 ENSG00000198492
309 29 yy2 ENSG00000198767
309 30 gosr1
309 31 zadh1 ENSG00000140043
309 32 zbed4 ENSG00000100426
309 33 zbed5 ENSG00000129586
309 34 zbtb25 ENSG00000089775
309 35 zbtb8 ENSG00000160062
309 36 zc3h8 ENSG00000144161
309 37 zcchc17 ENSG00000121766
309 38 zcd2 ENSG00000145354
309 39 scrambled
309 40 zcwpw1 ENSG00000078487
309 41 loc649917 ENSG00000188818
309 42 zdhhc13 ENSG00000177054
309 43 hszfp36 ENSG00000197933
309 44 zfhx1b ENSG00000169554
309 45 zfp14 ENSG00000142065
309 46 rab1a
309 47 zfp36 ENSG00000128016
309 48 zfpl1 ENSG00000162300
309 49 zfyve20 ENSG00000131381
309 50 zhx2 ENSG00000178764
Plate Position Gene ENSEMBL ID
309 51 zic2 ENSG00000043355
309 52 znf10 ENSG00000090612
309 53 znf100 ENSG00000197020
309 54 znf133 ENSG00000125846
309 55 znf167 ENSG00000196345
309 56 znf185 ENSG00000147394
309 57 znf205 ENSG00000122386
309 58 znf207 ENSG00000010244
309 59 znf222 ENSG00000159885
309 60 znf287 ENSG00000141040
309 61 znf306 ENSG00000189298
309 62 znf32 ENSG00000169740
309 63 rab1a
309 64 znf334 ENSG00000198185
309 65 znf350 ENSG00000171032
309 66 znf407 ENSG00000166540
309 67 znf446 ENSG00000083838
309 68 znf447 ENSG00000121413
309 69 znf451 ENSG00000112200
309 70 scrambled
309 71 znf473 ENSG00000142528
309 72 znf485 ENSG00000198298
309 73 znf503 ENSG00000165655
309 74 znf512 ENSG00000198522
309 75 znf607 ENSG00000198182
309 76 znf649 ENSG00000198093
309 77 znf684 ENSG00000117010
309 78 znf705a ENSG00000196946
309 79 copb
309 80 znf71 ENSG00000197951
309 81 znf799 ENSG00000196466
309 82 znf800 ENSG00000048405
309 83 znf85 ENSG00000105750
309 84 znhit1 ENSG00000106400
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310 51 q5t7b9_human ENSG00000170590
310 52 q6kf84_human ENSG00000180574
310 53 q6p575_human ENSG00000169325
310 54 q7z4h1_human ENSG00000198676
310 55 q7z4v3_human ENSG00000189054
310 56 q8izm0_human ENSG00000182992
310 57 q8n0t1_human ENSG00000176731
310 58 q8n1g8_human ENSG00000181508
310 59 q8n214_human ENSG00000182109
310 60 q8n2a4_human ENSG00000180156
310 61 q8n507_human ENSG00000180769
310 62 q8n666_human ENSG00000168913
310 63 rab1a
310 64 q8n675_human ENSG00000180840
310 65 q8n6v7_human ENSG00000177112
310 66 q8n779_human ENSG00000175789
310 67 q8n7f4_human ENSG00000177527
310 68 q8n7s0_human ENSG00000176833
310 69 q8n8b3_human ENSG00000180935
310 70 scrambled
310 71 q8n8e8_human ENSG00000196888
310 72 q8n8z0_human ENSG00000181558
310 73 q8naj1_human ENSG00000180642
310 74 q8nam3_human ENSG00000180838
310 75 q8nan4_human ENSG00000176078
310 76 q8nas9_human ENSG00000177797
310 77 q8nat4_human ENSG00000175892
310 78 q8nbe0_human ENSG00000178193
310 79 copb
310 80 q8ne65_human ENSG00000172687
310 81 q8nej6_human ENSG00000186756
310 82 q8nf02_human ENSG00000185136
310 83 q8ngm6_human ENSG00000180909
310 84 q8tch9_human ENSG00000182424
310 85 q8te90_human ENSG00000182335
310 86 q8wuc7_human ENSG00000184091
310 87 q8wus3_human ENSG00000198596
310 88 scrambled
310 89 q8wvj8_human ENSG00000170807
310 90 q8wyg7_human ENSG00000177107
310 91 q8wyw9_human ENSG00000177221
310 92 q8wz02_human ENSG00000185370
310 93 q969h1_human ENSG00000182136
310 94 q96fp4_human ENSG00000184474
310 95 gosr1
310 96 q96hg9_human ENSG00000198672
310 97 q96kt8_human ENSG00000178223
310 98 q96lv3_human ENSG00000177806
310 99 q96mt0_human ENSG00000182418
310 100 q96nc1_human ENSG00000182341
Plate Position Gene ENSEMBL ID
310 1 incenp
310 2 ad13_human ENSG00000196097
310 3 bcorl2 ENSG00000197840
310 4 c17orf59 ENSG00000196892
310 5 centg2 ENSG00000157985
310 6 cox1_human ENSG00000198804
310 7 ctage1 ENSG00000184546
310 8 cu122_human ENSG00000183821
310 9 dnajc4 ENSG00000110011
310 10 eml3 ENSG00000149499
310 11 ensg00000125881 ENSG00000125881
310 12 incenp
310 13 ensg00000172666 ENSG00000172666
310 14 copb
310 15 ensg00000176243 ENSG00000176243
310 16 ensg00000177083 ENSG00000177083
310 17 ensg00000177835 ENSG00000177835
310 18 ensg00000185036 ENSG00000185036
310 19 ensg00000186459 ENSG00000186459
310 20 scrambled
310 21 ensg00000187175 ENSG00000187175
310 22 ensg00000197502 ENSG00000197502
310 23 ensg00000197559 ENSG00000197559
310 24 eps15l2 ENSG00000176657
310 25 id2b ENSG00000182801
310 26 ighg3 ENSG00000130076
310 27 lpp ENSG00000145012
310 28 lv1g_human ENSG00000182843
310 29 ncbp2l ENSG00000170935
310 30 gosr1
310 31 neil1 ENSG00000140398
310 32 np_001004355.1 ENSG00000197152
310 33 np_001013687.1 ENSG00000188185
310 34 np_001013691.1 ENSG00000177596
310 35 np_001020362.1 ENSG00000172764
310 36 np_113604.1 ENSG00000132204
310 37 np_775772.1 ENSG00000185716
310 38 np_775946.1 ENSG00000175753
310 39 scrambled
310 40 np_852607.2 ENSG00000186105
310 41 np_997351.1 ENSG00000197520
310 42 np_997353.1 ENSG00000197886
310 43 nu4lm_human ENSG00000198868
310 44 o15421_human ENSG00000132075
310 45 o94914_human ENSG00000175483
310 46 rab1a
310 47 or4fe_human ENSG00000198615
310 48 p1768_human ENSG00000140031
310 49 q16370_human ENSG00000177962
310 50 q562t6_human ENSG00000204443
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310 101 q9bsl4_human ENSG00000177620
310 102 q9bsy8_human ENSG00000176120
310 103 q9btr0_human ENSG00000198664
310 104 q9bvq6_human ENSG00000180924
310 105 q9h1s0_human ENSG00000171738
310 106 q9h669_human ENSG00000182505
310 107 q9h752_human ENSG00000128345
310 108 q9ha39_human ENSG00000185517
310 109 q9hbf5_human ENSG00000180953
310 110 gosr1
310 111 q9npd2_human ENSG00000188362
310 112 q9nps2_human ENSG00000176173
310 113 q9ntt1_human ENSG00000149345
310 114 q9p132_human ENSG00000197791
310 115 q9p146_human ENSG00000196232
310 116 scrambled
310 117 q9p1l9_human ENSG00000180639
310 118 q9ud07_human ENSG00000198857
310 119 q9uhu7_human ENSG00000180441
310 120 q9uhz5_human ENSG00000177320
310 121 rbm27 ENSG00000091009
310 122 tp53ap1 ENSG00000182165
310 123 tva2_human ENSG00000129563
310 124 unc84a ENSG00000164828
310 125 vdac4 ENSG00000198696
310 126 rab1a
310 127 xp_370634.2 ENSG00000173727
310 128 xp_371480.1 ENSG00000198639
310 129 xp_372632.3 ENSG00000205454
310 130 yg02_human ENSG00000196813
310 131 znf283 ENSG00000176232
310 132 znf29 ENSG00000108452
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311 1 incenp ENSG00000149503
311 2 aadat ENSG00000109576
311 3 aadat ENSG00000109576
311 4 aadat ENSG00000109576
311 5 ap2s1 ENSG00000042753
311 6 ap2s1 ENSG00000042753
311 7 axl ENSG00000167601
311 8 axl ENSG00000167601
311 9 bcorl2 ENSG00000197840
311 10 bcorl2 ENSG00000197840
311 11 c10orf33 ENSG00000119943
311 12 incenp ENSG00000149503
311 13 c10orf33 ENSG00000119943
311 14 copb ENSG00000129083
311 15 c9orf19 ENSG00000122694
311 16 c9orf19 ENSG00000122694
311 17 c9orf55 ENSG00000137145
311 18 c9orf55 ENSG00000137145
311 19 cbln4 ENSG00000054803
311 20 scramble
311 21 cbln4 ENSG00000054803
311 22 cflar ENSG00000003402
311 23 cflar ENSG00000003402
311 24 chrnb4 ENSG00000117971
311 25 chrnb4 ENSG00000117971
311 26 ctgf ENSG00000118523
311 27 ctgf ENSG00000118523
311 28 dgkd ENSG00000077044
311 29 dgkd ENSG00000077044
311 30 gosr1 ENSG00000108587
311 31 diras1 ENSG00000176490
311 32 diras1 ENSG00000176490
311 33 dkfzp434g072 ENSG00000138813
311 34 dkfzp434g072 ENSG00000138813
311 35 dkfzp761c169 ENSG00000062194
311 36 dkfzp761c169 ENSG00000062194
311 37 dnm2 ENSG00000079805
311 38 dnm2 ENSG00000079805
311 39 scramble
311 40 dqx1 ENSG00000144045
311 41 dqx1 ENSG00000144045
311 42 eef2k ENSG00000103319
311 43 eef2k ENSG00000103319
311 44 egfl6 ENSG00000198759
311 45 egfl6 ENSG00000198759
311 46 rab1a ENSG00000138069
311 47 ensg00000099308 ENSG00000099308
311 48 ensg00000099308 ENSG00000099308
311 49 ensg00000118369 ENSG00000118369
311 50 ensg00000118369 ENSG00000118369
Plate Position Gene ENSEMBL ID
311 51 ensg00000125458 ENSG00000125458
311 52 ensg00000125458 ENSG00000125458
311 53 ensg00000133704 ENSG00000133704
311 54 ensg00000133704 ENSG00000133704
311 55 ensg00000145107 ENSG00000145107
311 56 ensg00000145107 ENSG00000145107
311 57 ensg00000148814 ENSG00000148814
311 58 ensg00000148814 ENSG00000148814
311 59 ensg00000157005 ENSG00000157005
311 60 ensg00000157005 ENSG00000157005
311 61 ensg00000163935 ENSG00000163935
311 62 ensg00000163935 ENSG00000163935
311 63 rab1a ENSG00000138069
311 64 ensg00000166508 ENSG00000166508
311 65 ensg00000166508 ENSG00000166508
311 66 ensg00000168274 ENSG00000168274
311 67 ensg00000168274 ENSG00000168274
311 68 ensg00000168913 ENSG00000168913
311 69 ensg00000168913 ENSG00000168913
311 70 scramble
311 71 ensg00000173598 ENSG00000173598
311 72 ensg00000173598 ENSG00000173598
311 73 ensg00000176833 ENSG00000176833
311 74 ensg00000176833 ENSG00000176833
311 75 ensg00000177752 ENSG00000177752
311 76 ensg00000177752 ENSG00000177752
311 77 ensg00000177797 ENSG00000177797
311 78 ensg00000177797 ENSG00000177797
311 79 copb ENSG00000129083
311 80 ensg00000181789 ENSG00000181789
311 81 ensg00000181789 ENSG00000181789
311 82 ensg00000181995 ENSG00000181995
311 83 ensg00000181995 ENSG00000181995
311 84 ensg00000182335 ENSG00000182335
311 85 ensg00000182335 ENSG00000182335
311 86 ensg00000182418 ENSG00000182418
311 87 ensg00000182418 ENSG00000182418
311 88 scramble
311 89 ensg00000183971 ENSG00000183971
311 90 ensg00000183971 ENSG00000183971
311 91 ensg00000185136 ENSG00000185136
311 92 ensg00000185136 ENSG00000185136
311 93 flj10324 ENSG00000157927
311 94 flj10324 ENSG00000157927
311 95 gosr1 ENSG00000108587
311 96 flj10781 ENSG00000182013
311 97 flj10781 ENSG00000182013
311 98 flj12644 ENSG00000198093
311 99 flj12644 ENSG00000198093
311 100 flj12949 ENSG00000129347
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311 101 flj12949 ENSG00000129347
311 102 flj23221 ENSG00000118292
311 103 flj23221 ENSG00000118292
311 104 flj23259 ENSG00000114248
311 105 flj23259 ENSG00000114248
311 106 flj25333 ENSG00000153347
311 107 flj25333 ENSG00000153347
311 108 flj45244 ENSG00000198411
311 109 flj45244 ENSG00000198411
311 110 gosr1 ENSG00000108587
311 111 flj90650 ENSG00000172901
311 112 flj90650 ENSG00000172901
311 113 flt4 ENSG00000037280
311 114 flt4 ENSG00000037280
311 115 glra1 ENSG00000145888
311 116 scramble
311 117 glra1 ENSG00000145888
311 118 grin2b ENSG00000150086
311 119 grin2b ENSG00000150086
311 120 gstp1 ENSG00000084207
311 121 gstp1 ENSG00000084207
311 122 gzma ENSG00000145649
311 123 gzma ENSG00000145649
311 124 hscarg ENSG00000153406
311 125 hscarg ENSG00000153406
311 126 rab1a ENSG00000138069
311 127 htpap ENSG00000147535
311 128 htpap ENSG00000147535
311 129 ifih1 ENSG00000115267
311 130 ifih1 ENSG00000115267
311 131 iqsec1 ENSG00000144711
311 132 iqsec1 ENSG00000144711
311 133 khk ENSG00000138030
311 134 khk ENSG00000138030
311 135 scramble
311 136 kiaa0052 ENSG00000039123
311 137 kiaa0052 ENSG00000039123
311 138 kiaa0626 ENSG00000198948
311 139 kiaa0626 ENSG00000198948
311 140 kiaa0672 ENSG00000006740
311 141 kiaa0672 ENSG00000006740
311 142 copb ENSG00000129083
311 143 kiaa0703 ENSG00000064270
311 144 kiaa0703 ENSG00000064270
311 145 kiaa1145 ENSG00000057704
311 146 kiaa1145 ENSG00000057704
311 147 loc51035 ENSG00000162191
311 148 loc51035 ENSG00000162191
311 149 loc58486 ENSG00000129586
311 150 loc58486 ENSG00000129586
Plate Position Gene ENSEMBL ID
311 151 loc90529 ENSG00000001460
311 152 loc90529 ENSG00000001460
311 153 ly75 ENSG00000054219
311 154 ly75 ENSG00000054219
311 155 mgc20398 ENSG00000198783
311 156 mgc20398 ENSG00000198783
311 157 minpp1 ENSG00000107789
311 158 minpp1 ENSG00000107789
311 159 copb ENSG00000129083
311 160 mmp14 ENSG00000157227
311 161 mmp14 ENSG00000157227
311 162 mrps5 ENSG00000144029
311 163 mrps5 ENSG00000144029
311 164 ms4a6a ENSG00000110077
311 165 ms4a6a ENSG00000110077
311 166 scramble
311 167 mxd4 ENSG00000123933
311 168 mxd4 ENSG00000123933
311 169 myb ENSG00000118513
311 170 myb ENSG00000118513
311 171 ndnl2 ENSG00000185115
311 172 ndnl2 ENSG00000185115
311 173 ndufs2 ENSG00000158864
311 174 ndufs2 ENSG00000158864
311 175 gosr1 ENSG00000108587
311 176 oa48-18 ENSG00000108848
311 177 oa48-18 ENSG00000108848
311 178 or10a4 ENSG00000170782
311 179 or10a4 ENSG00000170782
311 180 pecam1 ENSG00000198802
311 181 pecam1 ENSG00000198802
311 182 pib5pa ENSG00000185133
311 183 pib5pa ENSG00000185133
311 184 scramble
311 185 pml ENSG00000140464
311 186 pml ENSG00000140464
311 187 pms2 ENSG00000122512
311 188 pms2 ENSG00000122512
311 189 polr3f ENSG00000132664
311 190 polr3f ENSG00000132664
311 191 rab1a ENSG00000138069
311 192 proc ENSG00000115718
311 193 proc ENSG00000115718
311 194 rap1gds1 ENSG00000138698
311 195 rap1gds1 ENSG00000138698
311 196 rhof ENSG00000139725
311 197 rhof ENSG00000139725
311 198 rhou ENSG00000116574
311 199 rhou ENSG00000116574
311 200 rics ENSG00000134909
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311 201 rics ENSG00000134909
311 202 rxra ENSG00000186350
311 203 rxra ENSG00000196940
311 204 sema4f ENSG00000135622
311 205 sema4f ENSG00000135622
311 206 rab1a ENSG00000138069
311 207 sepp1 ENSG00000198865
311 208 sepp1 ENSG00000198865
311 209 sirt2 ENSG00000068903
311 210 sirt2 ENSG00000068903
311 211 skd3 ENSG00000162129
311 212 scramble
311 213 skd3 ENSG00000162129
311 214 smarcd1 ENSG00000066117
311 215 smarcd1 ENSG00000066117
311 216 stx1b2 ENSG00000099365
311 217 stx1b2 ENSG00000099365
311 218 syt7 ENSG00000011347
311 219 syt7 ENSG00000011347
311 220 tbx2 ENSG00000121068
311 221 tbx2 ENSG00000121068
311 222 copb ENSG00000129083
311 223 ttid ENSG00000120729
311 224 ttid ENSG00000120729
311 225 tyrobp ENSG00000011600
311 226 tyrobp ENSG00000011600
311 227 yy2 ENSG00000198767
311 228 yy2 ENSG00000198767
311 229 znf167 ENSG00000196345
311 230 znf167 ENSG00000196345
311 231 scramble
311 232 znf334 ENSG00000198185
311 233 znf334 ENSG00000198185
311 234 znf71 ENSG00000197951
311 235 znf71 ENSG00000197951
311 236 empty
311 237 empty
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311 383 gosr1 ENSG00000108587
311 384 incenp ENSG00000149503
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